

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Strategies for Enhancing Cholesterol Lowering Medication Use Among Patients at High Cardiovascular Disease Risk: Patient and General Practitioners' Perspectives on a Facilitated Relay Intervention

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-038469
Article Type:	Original research
Date Submitted by the Author:	12-Mar-2020
Complete List of Authors:	Campbell, David; University of Calgary Cumming School of Medicine, Department of Medicine Lee, Rachelle; University of Ottawa McBrien, Kerry; University of Calgary, Family Medicine Anderson, Todd; University of Calgary Cumming School of Medicine, Department of Cardiac Sciences Quan, Hude; University of Calgary, Community Health Sciences Leung, Alexander; University of Calgary Cumming School of Medicine, Department of Medicine Chen, Guanmin Lu, Mingshan ; University of Calgary, Economics Naugler, Christopher; University of Calgary, Pathology and Laboratory Medicine; Calgary Laboratory Services, Butalia, Sonia; University of Calgary Cumming School of Medicine, Department of Medicine
Keywords:	QUALITATIVE RESEARCH, GENERAL MEDICINE (see Internal Medicine), Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Cardiology < INTERNAL MEDICINE, PREVENTIVE MEDICINE

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reziez onz

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2	
3	Strategies for Enhancing Cholesterol Lowering Medication Use Among Patients at High Cardiovascular
4	Disease Risk: Patient and General Practitioners' Perspectives on a Facilitated Relay Intervention
5	Discuse hisk i dicine and General Practicioners i erspectives on a Pacificated heavy intervention
6	
7	David J.T. Campbell, MD PhD FRCPC ^{1,2,3}
8	Rachelle C.W. Lee, MSc ⁴
9	Kerry A. McBrien, MD MPH CCFP ^{2,5}
10	Todd J. Anderson, MD PhD FRCPC ³
11	Hude Quan, MD PhD ²
12	Alexander A.C. Leung, MD MPH FRCPC ^{1,2,3}
13	Guanmin Chen, MD PhD ²
14	
15	Mingshan Lu, PhD ^{2,6}
16	Christopher Naugler, MD FRCPC ^{2,7}
17	Sonia Butalia, MD MSc FRCPC ^{1,2}
18	
19	1 – Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
20	2 – Department of Community Health Sciences, Cumming School of Medicine, University of Calgary,
21	
22	Calgary, AB, Canada
23	3 – Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB,
24	Canada
25	4 – Department of Innovation in Medical Education, Faculty of Medicine, University of Ottawa, Ottawa,
26	ON, Canada
27	5 – Department of Family Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB,
28	Canada
29	6 – Department of Economics, Faculty of Arts, University of Calgary, Calgary, AB, Canada
30	7 – Department of Pathology & Laboratory Medicine, Cumming School of Medicine, University of
31	
32	Calgary, Calgary, AB, Canada
33	
34	Correspondence:
35	Dr. David J.T. Campbell
36	TRW 3E33, 3280 Hospital Dr NW
30	Calgary, AB, Canada T2N 4Z6
38	dcampbel@ucalgary.ca
39 40	403-210-9511
40 41	
41 42 1	Word count: Main text (3926 words), abstract (272 words), 3 tables, 3 appendices
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2		
3		ABSTRACT
4	2	ABSTRACT
5	2	Objective: The objective of our study was to explore the perspectives of patients and general
6	4	practitioners (GPs) regarding interventions to increase cholesterol lowering medication (or statin) use,
7	5	including a proposed laboratory-based facilitated relay intervention.
8 9	6	including a proposed laboratory-based lacintated relay intervention.
9 10	7	Design: Qualitative descriptive study using interviews and focus groups for data collection, and thematic
11	8	analysis for data analysis.
12	9	
13	10	Setting: Primary care providers and patients in Calgary, Alberta, Canada.
14	11	Setting. I findary care providers and patients in calgary, Alberta, canada.
15	12	Participants: 17 General Practitioners with primarily community-based, non-academic practices with at
16	13	least 1 year of practice experience participated in semi-structured interviews. 14 patients at high risk of
17 18	14	cardiovascular disease participated in focus groups.
19	15	
20	16	Main outcome measures: Exploration of strategies that might be used to enhance the prescription of,
21	17	and adherence to statin therapy for patients with statin-indicated conditions.
22	18	
23	19	Results: GPs proposed a variety of interventions to improve statin use, including electronic record audit
24	20	solutions, GP directed education and patient-oriented campaigns. Patients expressed that they may
25 26	21	benefit from being provided access to their laboratory test results, as well as targeted education. Both
20	22	parties provided positive feedback on the proposed laboratory-based facilitated relay intervention,
28	23	while pointing out areas for improvement. Notably, GPs were concerned that the patient-directed
29	24	component of the intervention might jeopardize their therapeutic relationship, and patients were
30	25	concerned about accidental disclosure of their personal information. Important considerations for the
31	26	design of facilitated relay messaging should include brevity, simplicity and the provision of contact
32	27	information for questions.
33 34	28	
35	29	Conclusions: GPs and patients described several suggestions for increasing statin use and welcomed the
36	30	proposal of a laboratory-based facilitated relay strategy. These findings support further testing of this
37	31	intervention which may enhance GPs' ability to successfully engage patients in cardiovascular risk
38	32	reduction through statin therapy.
39	33	
40 41	34	Keywords: focus groups, qualitative research, interviews, statins, facilitated relay
42		
43		
44		
45		
46		
47 48		
40 49		
50		
51		
52		
53		
54 55		
55 56		
57		
58		2
59		Ear poor rovious only better //besieven besi com/cite/shevet/evidelines shered
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3	
4 5 6	
7 8	
9 10 11	
12 13 14	
15 16 17	
18 19	
20 21 22	
23 24 25	
26 27 28	
29 30	
31 32 33	
34 35 36	
37 38 39	
40 41 42	
43 44	
45 46 47	
48 49 50	
51 52 53	
54 55 56	
57 58	
59 60	

Strengths & Limitations of this Study

- This is a qualitative study, with relatively few participants therefore we cannot say definitively • if the views represented here represent those of all patients and prescribers.
- We sampled physician participants to the point of saturation, which means that we are • confident the views represented here span the breadth of those held by physicians.
- The patient sample we recruited may not be representative of the broader population, as many • of them had previously stated an interest in quality improvement and research.
 - Given the context-dependent nature of qualitative data, the applicability of these findings to • other settings is not certain.
 - One of the major strengths of this study is the depth and richness of the qualitative data that • were collected. By asking questions in an open-ended manner, we were able to record detailed accounts and opinions.

INTRODUCTION

35

36 37

38

39

40

41

42

43

44

45

46

47

48 49 50

51

61

52 High cholesterol (or dyslipidemia) affects one-third of the general population and is a major risk factor 53 for heart attacks and strokes(1-3). Several high quality randomized controlled trials show that people at 54 high risk for cardiovascular disease (i.e. have a history of heart attack, stroke, diabetes, or chronic kidney 55 disease) lower their risk of heart attack and death by reducing their cholesterol with a class of 56 medications called statins. Despite over 30 years of clinical use, efficacy, safety and cost-effectiveness 57 data (4, 5), only 23% to 55% of individuals who would benefit take this medication and fewer than half 58 of individuals are treated to target cholesterol levels(4, 6-8). There is substantial unwanted variability in 59 dyslipidemia management and health system intervention is required to promote equitable treatment 60 (9, 10).

62 Evidence related to the management of other common cardiovascular risk factors, such as hypertension, 63 provides insight into how this care gap may be closed (11-13). Integrated quality improvement strategies 64 that target both patients and healthcare providers are more likely to achieve quality indicators than 65 strategies which only target one aspect in isolation(12). One such strategy is facilitated relay. Facilitated 66 relay is a quality improvement strategy whereby information about individual patients is sent directly to 67 healthcare providers through a means other than the usual clinical encounter (14). This strategy has 68 been shown to be effective in improving cardiovascular risk factors (12, 15), but it remains to be 69 explored in the management of dyslipidemia. Despite this evidence, and the implementation of a 70 number of quality improvement strategies for chronic disease management in our setting, facilitated 71 relay remains among the least commonly used (16).

72

73 We therefore drew from behaviour change theory to develop a proposed facilitated relay intervention 74 to increase statin uptake(17-19). Our proposed intervention uses our province's single laboratory 75 system to identify individuals who have had their cholesterol levels measured, who are at high risk for 76 cardiovascular disease and who are not filling statin prescriptions (i.e. identifying these individuals using 77 validated algorithms). The general practitioner (GP) ordering the cholesterol levels and the patient, will 78 then each receive a letter outlining the indication for treatment and the potential to benefit from statin 79 therapy. The patient letter will encourage them to speak to their GP, and the GP letter will encourage 80 them to make an appointment to discuss directly with the patient - both with the objective to initiate or 81 renew statin prescriptions.

1	
2	
3 4	83
5	84
6	85
7	86
7 8	87
9	88
10	89
11 12	90
12 13	91
14	92
15	93
16	94
17	95
18	96
19	97
20	98
21	99
22 23	100
23 24 25	101
25	102
26 27	103
27	104
28	105
29	106
30 31	107
32	108
33	109
34	110
35	111
36	112
37	113
38	114
39 40	115
40 41	116
42	117
43	118
44	119
45	120
46	121
47	122
48 49	123
49 50	124
50	125
52	126
53	127
54	128
55	129
56	
57	

3 For an intervention to have the potential to maximum impact, it is important to have the input of key 4 stakeholders prior to the application of any intervention with a qualitative study being suited to do

5 so(20). This allows for the development of a higher quality intervention, rather than one that relies on

- 6 physician feedback alone (21). As such, the objective of our study was to explore the perspectives of
- 7 patients GPs regarding interventions to increase cholesterol lowering medication (or statin) use,
- 8 including a proposed laboratory-based facilitated relay intervention.

0 **METHODS:**

2 **Study Design**

4 We conducted a qualitative descriptive study(20) to explore patients' and general practitioners' 5 perspectives on interventions to increase cholesterol lowering medication (or statin) use . Specifically, 6 we sought directed feedback and perceptions on the acceptability of the proposed facilitated relay 7 intervention from both patients and GPs(22). We used the consolidated criteria for reporting qualitative 8 research (COREQ) as the reporting framework for this study(23).

0 **Participant Selection**

2 General Practitioners: We recruited general practitioners to participate in individual interviews, using a 3 snowball sampling approach. First, we asked key stakeholders in areas of primary care, endocrinology, 4 nephrology and cardiology affiliated with the university medical centre, to recommend community-5 based (non-academic) GPs to participate in the study. Individuals were then contacted by telephone and 6 email with a formal invitation to participate. GPs who met the following criteria were enrolled: (1) 7 currently practicing in community general practice settings; and, (2) have at least one year of experience 8 as a GP. We sampled participants purposively based on several key demographic characteristics in order 9 to achieve representation across a range of ages, genders and practice types.

1 Patients: We recruited patients who may potentially be recipients of the intervention (i.e. those at high 2 risk of cardiovascular disease). Using a convenience sampling approach, we invited patients who were

3 part of an established advisory panel and previously agreed to be contacted about research

4 opportunities for study participation(24, 25). In addition, patients were recruited using poster

5 advertisements placed throughout the academic health sciences centre and in various clinical care areas 6 where care is provided to patients with diabetes, heart disease and kidney disease.

8 **Data Collection**

9 0 We developed an open-ended semi-structured interview guide (Appendix A) and focus group guide 1 (Appendix B) based on a review of the literature and discussion with the research team. Sensitive and 2 personal disclosures are more likely to occur with focus groups and as such we used this methodology 3 with patient participants(26). However, we purposely used different data collection methods to offset 4 low recruitment of community based GPs due to their competing clinical demands and importantly 5 wanted to recruit from both urban and rural locales.

7 Interview and focus group guides were designed so that they initially asked study participants what they 8 thought would be effective strategies or interventions to improve statin use (i.e. prescribing, patient use 9 and adherence). After they had given their unprompted views, participants were then given a brief

explanation of facilitated relay, the proposed intervention, and shown a copy of the proposed intervention letter (Appendix C) and asked for their feedback.

All interviews were conducted in-person (in clinician offices) or via telephone, by a female trained research assistant (RCWL) with oversight by experienced study team members. None of the study team were acquainted with or involved in the clinical care of the participants. Physician interviews were continued until the point of theoretical saturation when no new information emerged from the interviews (27). Because the research objective was relatively focused, interviews were brief and lasted approximately 30 to 45 minutes. We convened two small focus groups of patients in our academic medical centre which each lasted approximately 90 minutes. No one but researchers (including 1 facilitator and 2 field-note takers) and participants were present. Data was collected from September 2018 to November 2018.

Interviews and focus group proceedings were digitally audio-recorded and transcribed verbatim by a professional transcriptionist. Field notes were taken to inform data analysis. All data were anonymized and stored securely. Signed informed consent was received from each study participant. Gift cards were provided to all participants. Ethics approval was granted from the University's Health Research Ethics Board.

Data Analysis

Analysis was completed using conventional qualitative content analysis(28), a method of interpreting interview data with the goal of describing the phenomenon of interest. Transcripts for the initial three interviews were reviewed by three team members (DC, RL and SB), with the objective of inductively establishing a preliminary coding template that was used for subsequent data analysis. All transcripts were then analyzed by two reviewers (DC and RL). Codes were generated from the interview data and systematically applied to identify themes and patterns. The process was iterative, reflexive, and interactive as continual data collection and analysis shaped each other⁴. For example, code titles or definitions identified based on earlier interviews were modified according to the data collected during subsequent interviews. The team met together to review the coding to elicit discussion about the coding strategy and attempted to achieve consensus to resolve coding discrepancies. NVivo 12 (Doncaster, Australia) qualitative data analysis software was used to facilitate the coding process.

Patient and public involvement

Patient partners and family members from the Libin Cardiovascular Institute's established patient and family member advisory group voiced that *prevention* was one of their top research priorities for cardiovascular health. This work is related to prevention of cardiovascular disease. Patients were included in focus groups.

RESULTS

We reached saturation after having completed 17 individual interviews with GPs (Table 1a). 4 physicians declined participation in the interview. The majority were women (88%) with 65% having graduated from medical school within the last ten years. All GPs spent more than 50% of their time in clinical practice, at urban centers within Primary Care Networks (PCNs). PCNs are networks of GPs that share interdisciplinary resources to enhance the delivery of primary care within geographical regions (29); they are associated with improved chronic disease care and outcomes(30).

1			
2 3	178		
4	178	Table 1a. Descriptive statistics for Primary Care Provider	rs (n = 17).
5 6	-	Physician characteristics	Total (%)
7		Age (years)	
8		< 40	13 (76)
9		40 - 60	4 (24)
10		Gender	
11		Man	2 (12)
12		Woman	15 (88)
13 14		Years of primary care practice	
15		< 10	14 (83)
16		10 – 20	3 (18)
17		Years since medical school graduation	
18		< 10	11 (65)
19		≥10	6 (35)
20		Primary Care Network membership	
21		Yes	15 (88)
22		No	2 (12)
23 24		Location of primary care practice	
24 25		Urban	13 (76)
26		Rural	4 (24)
27		Focused practice interest	
28		Yes*	9 (53)
29		No	8 (47)
30			
31		Clinical practice last 12 months	
32		Estimated number of patients at high CVD risk	
33		< 20	1 (6)
34 35		20 to 99	7 (41)
36		≥100	9 (53)
37		Use of endocrinology consultation services	
38		Yes	5 (29)
39		No	12 (71)
40		Use of cardiology consultation services	
41		Yes	10 (59)
42		No	7 (41)
43		Use of nephrology consultation services	- ()
44 45		Yes	3 (18)
46		No	14 (82)
47	180	* Focused practice, or special interest types: care of the	
48	181	urgent care (n = 1), refugee medicine (n = 1), obstetrics	
49	182	1).	
50		_,.	
51			
52			
53 54			
55			
56			
57			
58		6	
59		For peer review only - http://bmjopen.bm	i.com/site/about/quidelines.vhtml
60		i or peer review only - http://binjopen.bin	J.com, site, about, guidennes.xittini

2		
3	183	
4	184	
5 6	185	We hosted two focus groups for patients – one with 8 and another with 6 participants (Table 1b). There
7	186	were no dominant members and all participants got equal opportunity to voice their opinions. There
8	187	was a range of ages represented, with a similar distribution of men and women. Nearly all had a general
9	188	practitioner and were also followed by medical specialist(s). The conditions represented in our patient
10	189	group were diabetes, history of myocardial infarction and elevated cholesterol level; none reported a
11	190	history of stroke, chronic kidney disease, or peripheral arterial disease.
12	191	

Table 1b. Descriptive statistics for patient participants (n = 13).

192	Table 1b. Descriptive statistics for patient participants (n = 1	.3).
	Patient characteristics	Total (%)
	Age (years)	
	< 40	2 (15)
	40 - 60	5 (39)
	> 60	6 (46)
	Gender	
	Men	6 (46)
	Women	7 (54)
	Chronic condition qualifying as "high CVD risk"	
	None/High cholesterol only	3 (23)
	Diabetes only	6 (46)
	Myocardial infarct (MI) only	1 (8)
	Diabetes & MI	3 (23)
	Has a primary care provider	
	Yes	12 (92)
	No	1 (8)
	Followed by a medical specialist	
	Yes	10 (77)
	No	3 (23)
	Self-reported awareness of high cholesterol levels	
	Yes	11 (85)
	No	2 (15)
	Current use of statin medication	
	Yes	6 (46)
	If not, had spoken with physicians about statins	3 (23)
	If not, had not spoken with physicians about statins	4 (31)
	*Note one participant did not complete a demographic	
	questionnaire	
193		
194		
195	General suggestions for potential interventions	
196		
197	Several themes arose regarding interventions to improve sta	
198	the interviews (Table 2). General practitioner participants de	
199	(1) enhancing aspects of physician education to promote ap	
200	implementation of support tools to help physicians in decision	-
201	whom statins are indicated. In addition, patients suggested t	U U
202	results may enable them to be more effective self-advocates	5.

Providers	Treatment of	Patients with chronic kidney disease:
	specific Sub-	"I struggle with the GFRs [glomerular filtration rate] – knowing when it
	populations	would be safe, when it wouldn't be safe. I do get confused as to the
		dosing based on GFR.
		Patients who previously experienced side effects with statin(s): <i>"I have one strategy but if somebody is still like 'no, it's completely not tolerable for me' then I don't know what the next step is after that."</i>
		Elderly patients:
		"getting some better understanding about the elderly. Are there any
		contraindications to starting on statin therapy? Is there one statin that
		may be more beneficial than another?"
		Patients with hypertriglyceridemia:
		<i>"I always find it hard to know what to do with triglycerides more</i>
		education around how to manage those [patients]."
	Treatment to	"Most people in my office are confused about what we are doing in
	Targets	terms of treating to the target of 2 mmol/L, because the cardiologist is
		still sending consults about that, but then we have these family medicine evidence-based groups saying that targets don't matter".
		<i>"I know the TOP [Towards Optimized Practice] guidelines don't</i>
		necessarily correlate with CCS [Canadian Cardiovascular Society]
		guidelines, so there are several schools of thought"
		"There's no real way to unify the guidelines, but to have an education
		session on why they're different and how to approach it so maybe
		you'll break down patient populations that fit better with one guideline
		versus another".
	Preferred	"we have a lot of drug reps [representatives] coming to town, so it
	modality of	would be great to have more [education] that was not pharma,
	Education	absolutely".
	EMR-based	"One thing that would be helpful for me is if there was some automatic
	tools	flag that came when I saw a patient that would alert to the fact that their treatment is not optimized for their conditions".
Patients	Laboratory	<i>"I would like to get a copy, in addition to the doctor. I can do with it</i>
	Results	what I want"
		<i>"It gets you questioning things so that you can come back to your doctor and say 'I saw these numbers, what does that mean? What do need to do?"</i>
	Enhanced	"What if somebody was going regularly to a lab, and a clinician sort of
	education	goes: 'How are you doing on this?".

EMR: electronic medical record

to beet eview only

2		
3	205	
4	205	1) Concret exectition of vertices
5	206	1) General practitioner <i>education:</i>
6	207	Nearly all CDs highlighted that there are general areas of knowledge that could be belatered in order to
7	208	Nearly all GPs highlighted that there are general areas of knowledge that could be bolstered in order to
8	209	enhance statin use. One of the main content areas in which they sought enhanced education related to
9	210	the treatment of specific patient sub-populations, in particular those with chronic kidney disease, prior
10	211	statin side effects, elderly patients, and those with other concurrent lipid disorders (i.e.
11 12	212	hypertriglyceridemia).
13	213	
14	214	Whether providers should be treating patients to a specific cholesterol level was a major source of
15	215	confusion. They frequently referenced receiving conflicting advice, including a contradiction in clinical
16	216	practice guidelines(31), some of which advocate for a 'fire and forget' approach(5, 32), while
17	217	Canadian(4) and European(33) specialist guidelines recommend a 'treat-to-target' approach(4).
18	218	
19	219	Regarding the modality of education sessions, most preferred in-person education sessions delivered at
20	220	their clinics and delivered by someone who did not have clear conflicts of interest with pharmaceutical
21 22	221	companies. Many GPs also suggested the use of handouts, tools or algorithms to simplify their decision-
22	222	making process.
24	223	
25	224	2) General practitioner <i>tools</i>
26	225	
27	226	In addition to education, several GPs suggested that the use of automated tools would facilitate their
28	227	prescribing of statins. Most felt that they would benefit from optimizing the use of their electronic
29	228	medical records (EMR) to 'flag' individuals who were at high cardiovascular risk or had elevated
30 31	229	cholesterol levels. Other GPs spoke of wishing for a 'running list' of eligible patients, while some
32	230	mentioned using an employee or contractor designated as a panel manager to perform these tasks.
33	231	
34	232	3) Patient results and information
35	233	
36	234	Many patients independently indicated that they would like to have access to their lipid test results,
37	235	without needing to rely on this being conveyed to them by their general practitioner. Some patients also
38	236	suggested that providing them with their own results might reduce the frequency of unnecessary follow-
39 40	237	up visits; and as a result, alleviate related financial burden on the healthcare system. Doing so was also
40 41	238	thought to help foster patient engagement with their GP. Patients also felt that having greater access to
42	239	information about cholesterol and treatment might facilitate more patients being on statin therapy.
43	240	Suggestions were made to deliver this through enhanced patient-facing materials (i.e. brochures), as
44	241	well as pharmacists or lab technicians who were able to discuss results and treatment options.
45	242	
46	243	Feedback on the proposed facilitated relay intervention
47	244	
48	245	After briefing participants on the principles and practices of facilitated relay and showing them our
49 50	246	preliminary documents for the intervention, we asked for feedback. Emerging themes were organized
50	247	into four major categories: (1) general feedback and impression; (2) suggested changes; (3) intervention
52	248	details; and, (4) workflow processing considerations.
53	249	
54	250	1) General feedback and impression
55	251	
56		
57		
58 59		10
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
50		

General practitioners responded with strongly positive feedback (Table 3), which included that they found the information to be helpful and direct. They generally felt that the letter was written in a clear fashion and with a respectful tone. Several mentioned that the information provided them with reassurance and credibility in making recommendations to their patients. GPs also voiced some questions and potential concerns after hearing about our proposed intervention. These concerns included whether the introduction of a facilitated relay intervention might increase their workload, lead to possible disclosure to patients of new diagnoses of conditions that qualified them as high risk (i.e. diabetes), and pose a threat to their therapeutic relationships with patients. In addition, logistical issues around how the letter will be best delivered to ordering providers and patients were raised as concerns. Patients generally felt that bringing their facilitated relay letter to a scheduled appointment would be positive in their relationship by providing structure to the follow-up encounter, holding GPs to account, and enhancing patient-provider communication. Even though most were generally positive, some patients expressed concern about the facilitated relay intervention, including the possibility for privacy breaches and increasing patient anxieties. 2) Suggested information to remove or add We asked GPs specifically what they would like to see changed in the preliminary materials shown. Almost unanimously, they suggested that the letter would be more appreciated if it were shortened to fit on one page. Several participants suggested removing the references, mention of clinical studies, and guideline citations to make it more reader-friendly. There was also a preference voiced for revising the introductory paragraphs to have direct relevance to individual patient(s): "I'm going to read it for sure, but then when you start to read it, people might put it down and say 'oh this is a study intervention', [but] if you have the first thing at the very top: 'you know this person has been identified as being at risk' – then it's about the patient rather than being about the studies". A few GPs voiced opinions that specific additions could be made to improve the letter's utility. These suggestions included adding: information about health behavior change ("the whole picture, as opposed to just medication"); adding contact information for a specialist; and details about how/why a particular individual was flagged as eligible for the facilitated relay intervention: "It would be helpful if I got a name, condition and then the statin-indicated condition, and where the condition was pulled from". Patient feedback was notable for also suggesting that the intervention provide contact information, in case they have further questions about interpreting their results: "back that up with a helpline for somebody that doesn't know what the [results] mean". Similar to physicians, patients expressed a strong preference for brevity: "If I have to go through 14 pages of information to figure out what that means, I'm sorry, I don't have time for that". However, numerous patients also stressed the importance of not only providing results or diagnoses, but also giving some basic education and an action plan to follow. 3) Intervention details For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2		
3	300	
4 5	301	In addition to general feedback, we also explicitly asked GPs whether they would prefer to receive
6	302	information about their patient in the form of facilitated relay (individual letter for each patient
7	303	identified) or 'audit and feedback' (summary report including a group of their patient panel). A summary
8	304	list or report (audit and feedback) was preferred by roughly 2/3 of the general practitioners interviewed.
9	305	Regarding receiving letters for each patient, participants stated:
10	306	
11 12	307	"this is going to get tiresome very quickly"
13	308	
14	309	"Am I going to get this letter 20 times? I'm probably just going to read it once";
15	310	"[a list would] doors not build an approach the shares of it patting micelessed"
16	311	"[a list would] decrease paper burden, decrease the chance of it getting misplaced".
17	312	While the faudit and feedback' approach was more pepular, some CDs were clearly in favor of facilitated
18	313 314	While the 'audit and feedback' approach was more popular, some GPs were clearly in favor of facilitated relay: "I can't even think of the amount of work it would take to do it patient-specific. I'd love it. Sure go
19 20	314 315	for it, if you have the means to do it, then why not?"
20	315	Jor It, if you have the means to do it, then why not?
22	317	We also asked pointedly about how providers would feel about receiving a follow-up reminder from the
23	318	study team, if patients' had not filled the prescription as recommended in the initial letter. The response
24	319	was split with roughly half of the general practitioners stating that a reminder would not be necessary.
25	320	was spirt with roughly han of the general practitioners stating that a reminder would not be necessary.
26 27	321	Those who felt a reminder would be acceptable generally agreed that a 6 month window should be
27	322	sufficient to ascertain whether or not the patient would have started on therapy: "There are people that
29	323	have a three-month wait list time, you may have to pick an interval more like six-months to appeal to the
30	324	masses".
31	325	
32	326	Most patients felt that they would benefit from receiving a follow-up reminder. After considerable
33	327	discussion amongst the groups, consensus was achieved that follow-up should not happen prior to four
34 35	328	months, and possibly even as long as six months after the initial contact. One participant stated: "close
35 36	329	enough that I vaguely remember that I meant to do something with that, but not a few weeks later, [so]
37	330	it's not irritating".
38	331	
39	332	We also asked patients if they had a preference for who had signed the letter. Most felt that having
40	333	letters come from a local specialist in cardiology or endocrinology would be preferable to having them
41	334	signed by another GP.
42 43	335	
44	336	4) Workflow processing considerations (General practitioners only)
45	337	
46	338	To each GP we asked specific details about how our intervention letter would be received in their offices
47	339	and what would happen upon receipt. The majority stated that such a letter would be opened and
48	340	processed by their front-desk staff. One participant clarified that the information on the envelope would
49 50	341	determine who opened it: "if it's addressed to me then it will come to me, if it has a patient name for
51	342	me, then it goes through our document people [who file it]".
52	343	Once the letter has been enough difference office and a state of the state of the
53	344 245	Once the letter has been opened, different offices employed a variety of different processes. In many
54	345	practices, it would be given directly to the GP; while in others it would be scanned directly into a
55	346	patient's file in an electronic medical record, yet in others, the hardcopy would be filed in a patient's
56 57	347	chart.
57 58		12
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2		
3	348	
4		
5	349	In terms of the preferred delivery modality, most GPs felt that electronic delivery directly via the EMR
6	350	platform would be the preferred method of receiving the intervention. However, a number still felt that
0	351	conventional delivery via paper mail or fax would be preferable. Even those who expressed a preference
/		
8	352	for conventional delivery, many elaborated that such letters would often be scanned into a patient's
9	353	electronic file: "if it was to come by mail or fax, then they have to scan it onto the computer". A few GPs
10	354	described systems which can do this process automatically: "our office works with a new web system, so
11	355	everything that comes in via the fax actually goes directly into the computer and they then allocate to
12		
	356	the patient".
13	357	
	207	

Table 3. Positive and negative feedback on facilitated relay intervention from general practitioners and patients

(General Practitioners		Patients
	Po	sitive	
Composition	"Overall I thought it was worded quite well and was very clear" "I think it's appropriate, it didn't take me very long to get through"	Provides structure to interaction	"My doctor would be okay with that It gives them a little checklist of things to talk about"
Tone	"it's written in a way that doesn't make you feel stupid, I guess" "it's good because [it's] not telling you to do this [start statin therapy], but telling you to have a conversation]."	Enhances communication	"I think that's good 'cause these doctors, some guys don't communicate."
Credibility	"it gives family physicians more confidence to do those things and know the specialists are behind them in that recommendation" "there's so much information for people to sift through if you can get valid information that's corroborated and consistent, that's helpful"	Increases doctor accountability	"I think it keeps them [doctors] honest as well. They should actually be proactive in terms of having that information already, but that's not always the case. So I don't have a problem with a patient having all their information at their disposal"
Direct	"it's a good idea it tells you what to do, which is great. You don't have to look up the guideline every time" "it's just one of those extra little reminders that takes the brain power out of the work you have to do day-to-day"	Increases patient accountability	"If [patients] are encouraged to wor with their doctor to monitor your numbers, you have a bit of control a well as the doctor like working together"
Information	"[side effects] are what people hear about in the news a lot, so it's very	Provides peace of mind	"It gives me a little peace of mind in that we've talked about all of the

		helpful to have some numbers		things that are important and that
		around it, and strategies to address		should be covered that we haven't
		that"		left anything out"
		"All the suggestions that you made		
		are excellent. I'm reading through		
		this and I'm like ' oh yeah, I didn't		
		realize this' and ' this is something I		
-		can do for some of my patients'"		
		Neg	ative	
F	Increased	"I would caution against anything	Privacy	"You know what, my doctor isn't
	workload	that causes more documents or	concerns	going to send it out to me, anyway.
		more paperwork there's already		It's going to go on to a receptionist,
		so much"		who might pass it on to somebody
				else in the office, so there's no
				guarantee of privacy there"
		P C C		
				"Privacy is always an issue. I mean it
				like, the less information that's out
				there about you, the better off you
-				are, period. I don't care what it is"
	Disclosing new	"my concern is that they get this	Difficulty	"Some people might know all the
	diagnoses	information from a letter my	interpreting	numbers and everything else, I don't
		preference would be that it came	results	You give me a bunch of numbers, it
		straight to me"		means nothing to me. So unless the
				doctor explained it to me I'd rather talk to my doctor"
F	Therapeutic	"If the patient gets a letter that's	Provoking	"There are people who are coming
	relationship	like 'you need to be on a statin' and	Anxieties	down with every disease known to
	•	we already had a conversation that		man, so for someone like that, that
		they didn't need a statin. That		kind of information would just send
		could cause some issues in the		them off the deep-end, right?"
		therapeutic relationship."		
	Logistical	"What if a person gets a check from	Lack of	"You mentioned mail outs and thing
	concerns	a walk-in clinic? My concern is then	engagement	like that have they proven to be
		is that walk-in clinic docs are just		effective, though, 'cause how many
		going to ignore this letter"		people read them? How many peopl
				understand them? I don't think there
		"If it goes to the patient,		would be a lot of point in it, 'cause I
		sometimes you get lots of mail and		don't think people pay that much
		they may just discard it"		attention"
			Sense of	"Some will [say] 'I can't talk to my
			intimidation	doctor like that'. There will be some
				people who might be intimidated to
				initiate that conversation"
358				Initiate that conversation"
358				Initiate that conversation"
358]	14	Ļ	Initiate that conversation"

DISCUSSION

In this study, both GPs and patients acknowledged that there is the potential to improve the prescription and use of statin therapy among those at high risk for cardiovascular disease. In unprompted questions, GPs acknowledged that there was a need for improved education on this topic, and that tools to help identify and track patients would be helpful. Patients also suggested that providing themselves with laboratory test results and information on treatment options may result in better medical care. When shown the proposed intervention, both groups were strongly supportive of the facilitated relay intervention. While there were clear benefits to the intervention, some potential downsides were raised from both GPs and patient perspectives. In general, all recipients would prefer letters to be succinct, yet contain high yield information and provide contact information where clarification could be sought.

Several strategies have been used to encourage GPs to be more engaged in ensuring that patients are started on statins appropriately(34). An educational audit and feedback intervention regarding dyslipidemia treatment in Italian primary care practices was shown to increase adherence to statins by approximately 10%(35). Improved communication and shared decision making, which are explicit goals of facilitated relay interventions, can improve patient adherence (36). While these and other studies have reviewed the clinical efficacy of quality improvement strategies (12), few have used detailed qualitative methods as we have done. One large qualitative study interviewed audit and feedback experts to generate hypotheses about the various factors that may contribute to the efficacy of such interventions(37). Others have used qualitative methods to highlight the barriers physicians face in encouraging adherence(38), but ours is unique in using such methods to design and develop an intervention to address these challenges.

The fact that participants suggested elements of our facilitated relay intervention in the unprompted portion of the interviews lends credibility and face validity to the proposed intervention. However, it is notable that while general practitioner felt they would benefit from having internal systems to monitor patients' records, none independently suggested a strategy mediated by an independent third party (such as facilitated relay or audit and feedback), as we have proposed. Investigators who wish to implement facilitated relay interventions to enhance adherence to medical therapies can use the findings of this study to help develop interventions that are more likely to be acceptable to both GPs and patients. One of the main findings is to ensure that any such information is brief and high yield, containing patient identifiers early to capture general practitioner's attention. Such interventions can be strengthened by incorporating education on controversial or little-known topics. Patients strongly preferred any correspondence to also contain direct suggestions or an action plan. Workflow and processing of these letters needs to be considered and interventions designed to be as minimally disruptive to clinical practice as possible – with most physicians preferring that it be embedded directly within the EMR; yet in healthcare settings (like ours) where there is marked heterogeneity in the use and type of EMRs, this may not be possible.

There are limitations to this study. Firstly, as in most qualitative studies, the number of participants was relatively small. This limitation is mitigated by the fact that physician interviews proceeded until the point of saturation. Patient data were not collected in this manner, and these themes may not be fully saturated and appreciate this as a limitation. Furthermore, the patient sample we recruited may not be representative of the broader population, as many of them had previously stated an interest in quality improvement and research. Secondly, given the context-dependent nature of qualitative data, the

60

BMJ Open

1		
2		
3	407	applicability of these findings to other settings is not certain. Yet physicians face similar problems (i.e.
4	408	time constraints, patient complexity and comorbidities and patient resistance to medical therapies) in
5	409	numerous facets of medical care; therefore, it is conceivable that the findings of this study would apply
6		
7	410	to interactions between patients and GPs in other clinical settings. Due to time constraints of
8	411	participants and researchers, member checking was not undertaken in this study. Finally, it is important
9	412	to note that feedback was sought specifically about the proposed intervention. However, given the
10	413	details reported, we feel that these findings are likely to be helpful to others proposing similar quality
11	414	improvement interventions. One of the major strengths of this study is the depth and richness of the
12	415	qualitative data that were collected. By asking questions in an open-ended manner, we were able to
13	416	record detailed accounts and opinions. Another strength of this work is the fact that we also sought
14	417	patient input into the development of this intervention, rather than relying on physician feedback alone.
15	418	
16		Statin therapy has been demonstrated to effectively lower chalacterial and reduce the rick of
17	419	Statin therapy has been demonstrated to effectively lower cholesterol and reduce the risk of
18	420	cardiovascular events and death in individuals at high risk of cardiovascular disease. Despite this, they
19	421	remain underused. There are patient, provider and system factors that contribute to the underuse of
20	422	statins. Facilitated relay interventions hold promise as a potential method to address this important care
21	423	gap. Our study sought perspectives of both healthcare providers and patients, which will be
22	424	incorporated into intervention design to maximize acceptability. Insights gained from qualitative data
23	425	will be used to improve the likelihood of success and achieve the desired clinical impact.
24	426	
25	427	Contributions
26	428	All study team members contribute to the development of the research question. The study design was
27	429	conceived by DJTC and SB. DJTC wrote the first draft of the study protocol. Data collection and analysis
28		
29	430	was completed by DJTC, RCWL and SB. All study team members contribute to the interpretation and
30 31	431	contextualization of study findings. The first draft of the manuscript was written by DJTC. All study team
32	432	members contributed substantively to further revisions of the manuscript and have consented to the
33	433	publication of this version.
34	434	
35	435	Data Sharing
36	436	No additional data available
37	437	
38	438	
39	150	
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		16
59		

2		
3	439	References
4	440	hererences
5		
6	441	1. Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin
7	442	therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised
8 9	443	trials. The Lancet. 2012;380(9841):581-90.
10	444	2. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable
11	445	risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control
12	446	study. The Lancet. 2004;364(9438):937-52.
13	447	3. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic
14	448	and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.
15	449 450	The Lancet. 2010;376(9735):112-23.
16 17	450 451	4. Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian
18	451 452	Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2016;32(11):1263-82.
19	452 453	5. Grundy SM, Stone NJ. 2018 American Heart Association/American College of
20	455 454	Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention.
21	454 455	JAMA Cardiol. 2019;4(6):589-91.
22	455 456	6. Butalia S, Lewin A, Simpson S, Dasgupta K, Khan N, Pilote L, et al. Sex-based disparities in
23	450 457	cardioprotective medication use in adults with diabetes. Diabetol Metab Syndr. 2014;5(6):117.
24 25	458	7. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R, et al. 2012 Update of
25 26	459	the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the
27	460	Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2013;29(2):151-67.
28	400 461	8. Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular Risk and Statin Use in
29	462	the United States. The Annals of Family Medicine. 2014;12(3):215-23.
30	463	9. Gamble JM, Butalia S. Medical Practice Variations in Diabetes Mellitus. In: Johnson A, Stukel T,
31	464	editors. Medical Practice Variations. Health Services Research: Springer US; 2015. p. 1-40.
32	465	10. Tu JV, Chu A, Maclagan L, Austin PC, Johnston S, Ko DT, et al. Regional variations in ambulatory
33 34	466	care and incidence of cardiovascular events. Canadian Medical Association Journal. 2017;189(13):E494-
35	467	E501.
36	468	11. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in
37	469	primary care: a systematic review. CMAJ. 1997;156(12):1705-12.
38	470	12. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality
39	471	improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet.
40	472	2012;379(9833):2252-61.
41 42	473	13. Rash JA, Campbell DJ, Tonelli M, Campbell TS. A systematic review of interventions to improve
42 43	474	adherence to statin medication: What do we know about what works? Prev Med. 2016;90:155-69.
44	475	14. Walsh J, McDonald KM, Shojania KG, Sundaram V, Nayak S, Davies S, et al. Closing the Quality
45	476	Gap: A Critical Analysis of Quality Improvement Strategies (Vol 3: Hypertension Care). AHRQ Technical
46	477	Reviews. Rockville (MD)2005.
47	478	15. Walsh JM, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, et al. Quality
48	479	improvement strategies for hypertension management: a systematic review. Med Care. 2006;44(7):646-
49 50	480	57.
50 51	481	16. Campbell DJ, Sargious P, Lewanczuk R, McBrien K, Tonelli M, Hemmelgarn B, et al. Use of
52	482	chronic disease management programs for diabetes: in Alberta's primary care networks. Can Fam
53	483	Physician. 2013;59(2):e86-92.
54	484	17. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for
55	485	characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.
56		
57		17
58 59		17
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
50		

1		
2		
3	486	18. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in
4	487	behaviour change and implementation research. Implement Sci. 2012;7:37.
5	488	19. Michie S, Johnston M, Francis J, Hardeman W, Eccles M. From Theory to Intervention: Mapping
6	489	Theoretically Derived Behavioural Determinants to Behaviour Change Techniques. Applied Psychology.
7	490	2008;57(4):660-80.
8		
9	491	20. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):7.
10	492	21. Pope C, van Royen P, Baker R. Qualitative methods in research on healthcare quality. Qual Saf
11	493	Health Care. 2002;11(2):148-52.
12	494	22. Ayala GX, Elder JP. Qualitative methods to ensure acceptability of behavioral and social
13 14	495	interventions to the target population. J Public Health Dent. 2011;71 Suppl 1:S69-79.
14 15	496	23. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a
15 16	497	32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-57.
17	498	24. Santana M, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Working Together with
18	499	Patients and Clinician Researchers to Improve Cardiovascular Health. 2018 SPOR Summit; Ottawa, ON.
19	500	25. Santana M, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Working Together: Co-
20	501	designing Priorities for Patient-Oriented Cardiovascular Research by Patients, Clinicians, and
21	501	Researchers. Canadian Association for Health Services and Policy Research (CAHSPR); Halifax, NS2019.
22		
23	503	26. Guest G, Namey E, Taylor J, Eley N, McKenna K. Comparing focus groups and individual
24	504	interviews: findings from a randomized study. <i>Int J Soc Res Methodol</i> . 2017;20(6):693-708.
25	505	27. Walker JL. The use of saturation in qualitative research. Can J Cardiovasc Nurs. 2012;22(2):37-
26	506	46.
27	507	28. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res.
28	508	2005;15(9):1277-88.
29	509	29. Drew P, Jones B, Norton D. Team effectiveness in primary care networks in Alberta. Healthc Q.
30	510	2010;13(3):33-8.
31	511	30. Manns BJ, Tonelli M, Zhang J, Campbell DJT, Sargious P, Ayyalasomayajula B, et al. Enrolment in
32	512	primary care networks: impact on outcomes and processes of care for patients with diabetes. Canadian
33	513	Medical Association Journal. 2012;184(2):E144-E52.
34	514	31. Tibrewala A, Jivan A, Oetgen WJ, Stone NJ. A Comparative Analysis of Current Lipid Treatment
35	515	Guidelines: Nothing Stands Still. J Am Coll Cardiol. 2018;71(7):794-9.
36		•
37	516	32. Toward Optimized Practice (TOP) Cardiovascular Disease Risk Working Group. Prevention and
38	517	management of cardiovascular disease risk in primary care clinical practice
39 40	518	guideline 2015 [Available from:
40 41	519	
41		http://www.topalbertadoctors.org/download/1655/Lipid%20Pathway%20CPG.pdf?_20150916105016.
43	520	33. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS
44	521	Guidelines for the Management of Dyslipidaemias. Rev Esp Cardiol (Engl Ed). 2017;70(2):115.
45	522	34. Kaya H, Beton O, Yilmaz M. How to increase level of patients' awareness regarding the
46	523	importance of statins despite the influence of the media? International Journal of Cardiology.
47	524	2016;207:164.
48	525	35. Casula M, Tragni E, Piccinelli R, Zambon A, De Fendi L, Scotti L, et al. A simple informative
49	526	intervention in primary care increases statin adherence. Eur J Clin Pharmacol. 2016;72(2):227-34.
50	527	36. Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, et al. Shared treatment decision
51	528	making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med.
52	529	2010;181(6):566-77.
53	530	37. Colquhoun HL, Carroll K, Eva KW, Grimshaw JM, Ivers N, Michie S, et al. Advancing the literature
54	530	on designing audit and feedback interventions: identifying theory-informed hypotheses. Implement Sci.
55		
56	532	2017;12(1):117.
57		
58		18
59		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60		ror peer review only intep//onljopen.onlj.com/site/about/guidelines.xitum

1 2	
3 533 4 534	38. Kvarnström K, Airaksinen M, Liira H. Barriers and facilitators to medication adherence: a qualitative study with general practitioners. BMJ Open. 2018;8(1):e015332.
4 534 5 535 7 536 9 10 10 11 12 13 14 15 16 17 18 19 20 21 23 24 25 26	
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	
49 50 51 52 53 54 55 56 57	
58	19
59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Appendix A: Interview Guide for health care professional

Thank you for agreeing to participate in our interview today. We wish to discuss your experience in managing dyslipidemia (or high cholesterol) in order to better understand how we might help family physicians treat dyslipidemia (or high cholesterol). We have a proposed intervention and would like your assistance in how to enrich it.

1. Experience managing dyslipidemia

Please describe any challenges or difficulties that you experience in identifying and managing patients with dyslipidemia?

- Do you use any resources to guide you in the management of these patients?
 - Canadian Cardiovascular Society Guidelines
 - Diabetes Canada Guidelines
 - TOP guidelines

In addition to measuring a patient's lipids, what are some other parameters that you consider when assessing a patient for dyslipidemia, and how to optimally manage this condition?

2. Dyslipidemia-related practices

In your practice, do you find it helpful to quantify a patient's LDL-cholesterol or get a lipid panel?

If yes,

- Are there certain populations in whom you find this test most helpful?
- What is your chosen method/diagnostic test to do so?
 - Fasting or random lipid profile
 - Total cholesterol
 - HDL-cholesterol
 - LDL-cholesterol
 - ApoB
- How does this information change your clinical practice?
- How often do you repeat cholesterol testing for patients with with conditions that puts them at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease)?

If no,

- Why is it not particularly helpful?
 - Don't know which test to do
 - Don't know how to order it
 - Don't know in whom it is indicated

Don't know what to do with the results

In thinking about your practice, what proportion of your patients with conditions that put them at high risk for cardiovascular disease (i.e. previous myocardial infarction, stroke, diabetes, and/or chronic kidney disease) have had their lipid profile assessed in the past 12 months?

What are some of the reasons this does not happen (in your practice and in others')?

- Didn't think it was indicated/for whom it is indicated
- Too many things to attend to
- Not perceived to be an important issue amongst all other disease/conditions that FPs manage
- Patient factors (doesn't go for test)

3. Intervention

If we wanted to increase the use of statins among people at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease), what might be done? What tools, resources, prompts may help facilitate increased treatment of dyslipidemia?

In your opinion, what type of educational intervention is most effective in disseminating clinical practice guidelines to family physicians? (i.e. conferences, local lectures, treatment recommendations on lab results).

We are considering the use of a facilitated relay strategy, where patient's information from Calgary Laboratory Services is used to identify those who have indications for statin therapy. Those who are not currently filling statin prescriptions at the pharmacy would receive a letter from the lab indicating that they may benefit from statins. They will be encouraged to bring this letter in to discuss this with you.

How would family physicians respond to receiving a letter from the lab prompting them to consider starting their patient on statin treatment?

- What would be the characteristics of such a letter that would make it more likely to succeed?
 - Short/Pictorial/Colorful

Would it be more helpful to have this information specific about one named patient, or rather have an audit of your entire practice that would indicate what proportion of eligible patients with statin-indicated conditions are currently being treated with statins? (i.e. Audit and Feedback)

How should such an intervention either on a specific patient or about your entire practice be received?

• Mail/Fax/EMR/combo

How would such an intervention be processed in your office?

- Who would open the envelope?
- What would they do with it? (give it to you, put it in the patient's chart)
- How likely would you be to see this information?

Who should this letter be coming from in order to have it received in the most positive way possible?

- A non-clinical academic researcher (Dr. XXXX)
- Head of the Calgary Laboratory Services (Dr. Christopher Naugler)
- A lipid specialist (Dr. Sonia Butalia, Alex Leung)
- An academic family doctor (Dr. Kerry McBrien)
- A respected community family doctor
- The lead of Dyslipidemia Guidelines (Dr. Todd Anderson)
- Dr. Cello Tonelli, Associate Vice-President (Research) at the University of Calgary
- Dr. Richard Lewanczuk, Senior Medical Director for Primary Care, Chronic Disease Management, Community and Rural for Alberta Health Services
- Someone else

Would it be helpful to receive a reminder or follow-up letter?

• How much later should this be sent, so as to be useful and not annoying?

If the intervention provided you with patient-oriented material about this subject, and asked you to share it with your patients, how would you feel about doing so?

- What content should be included in this patient-oriented material to enhance statin use?
- What format should this material be in? Electronic, hard-copy? How should it be delivered? Mail, email?
- Would you share it in a clinical setting?
- Would you be willing to mail it to patients directly?

Do you have any additional comments or suggestions for developing an intervention to increase the use statins in people at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease) in primary care?

Thank you for participating in today's interview. Using the information you provided, we will work on developing an intervention to improve the treatment of dyslipidemia in patients who are at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease)?

Appendix B: Focus Group Guide for patients

Thank you for agreeing to participate in our focus group today. There are many risk factors for heart attacks and stroke. Today we want to focus on one risk factor being high cholesterol. High cholesterol is a major risk factor for heart attacks, strokes and circulatory problems. There are no symptoms of high cholesterol and it is diagnosed by a lab test that your doctor would order. Importantly, we work for the University of Calgary and have no relationship with any medication companies.

We wish to discuss your experience in managing *cholesterol* with medications in order to better understand how we might help family physicians (*doctors*) treat high cholesterol.

1. Experience with high cholesterol

Think about the last time your doctor has sent you for a cholesterol test. Did your doctor talk to you about the results? Treatment? What kind of treatment was discussed (diet, exercise, a medication)?

Put yourself in the position of being told that you need to take a medication for your cholesterol. What factors would make you more likely to take it? What factors would make you not want to take it? Reasons, side effects, costs

- Would you use any resources to help you decide?
 - o Doctor
 - \circ Dietician
 - o Internet
 - Family, friends

What would you think if your doctor told you that your cholesterol wasn't all that high, but because of your other health conditions she wanted to start you on a cholesterol lowering medication to reduce your risk of heart attack and stroke?

Do you think it would be helpful to get the actual result of your cholesterol level sent directly from the lab to you?

Currently, cancer screening programs send letters to patients about their results and next steps. What are your thoughts for something similar for high cholesterol?

BMJ Open

What about information about recommended treatments and potential side effects? Would you find this to be invasive of your privacy (i.e. info from the lab about treatment and not your doctor)?

How would you feel about taking a letter with these recommendations to your doctor to discuss about a medication for high cholesterol?

How do you feel your doctor would respond to you bringing this information?

What things on the letter would make it helpful?

-length, colour, graphics,

Who should this letter be coming from in order to have it received in the most positive way possible?

- A non-clinical academic researcher (Dr. XXXX)
- Head of the Calgary Laboratory Services (Dr. Christopher Naugler)
- A lipid specialist (Dr. Sonia Butalia, Alex Leung)
- An academic family doctor (Dr. Kerry McBrien)
- A respected community family doctor
- The lead of Dyslipidemia Guidelines (Dr. Todd Anderson)
- Dr. Richard Lewanczuk, Senior Medical Director for Primary Care, Chronic Disease Management, Community and Rural for Alberta Health Services
- Someone else

Would it be helpful to receive a reminder or follow-up letter?

• How much later should this be sent, so as to be useful and not annoying?

Do you have any additional comments or suggestions for developing an way to increase the use the treatment of people with high cholesterol? **Appendix C: Facilitated Relay Letter**



Date: XXXX-XX-XX

Dear Dr. [Physician Last Name],

RE: [Patient Name]

As you may recall, your Primary Care Network is involved in a study with the University of Calgary. This is an investigator-initiated study with public funding from the [*Canadian Institutes of Health Research*].

Dyslipidemia is a major risk factor for myocardial infarction and stroke¹⁻². As you know, in patients like [name], statins are indicated for their dyslipidemia because they are proven to reduce cardiovascular outcomes and mortality³⁻⁴. Because of numerous randomized controlled trials, guidelines recommend statin use in individuals with history of previous cardiovascular disease, diabetes, or chronic renal failure⁵.

We are writing to you to consider initiating a statin in your patient. We know the importance of the therapeutic relationship that you have with your patients and know that we do not know your patient like you do. The purpose of this letter is to assist in you in your discussion with [name], about using a statin medication.

[Name] may not be taking a statin because of underestimation of their personal risk of cardiovascular disease, fear of side-effects, previous side-effects, or cost. If cost is a concern, compassionate programs are available for several statin medications. Please kindly call our study telephone number to assist in facilitating this.

The most common side effect from statins is muscle aches, and the frequency of statin-induced rhabdomyolysis is very rare (i.e. < 1 in 10,000 patients per year on statins)⁶. Studies suggest that there are several proven methods for managing people who have experienced muscle aches. For those unable to tolerate daily high intensity statins, some statin is still better than none, and the following strategies can be considered:

- 1. *Reducing the dose of statin*. i.e. Atorvastatin 10-20mg or Rosuvastatin 2.5-5mg⁷.
- Trying a low potency statin medication. Lower potency statins seem to be less strongly associated with muscle aches. Fluvastatin and Pravastatin were much less likely than Simvastatin and Atorvastatin to cause myalgia⁸. For your reference, maximum doses of these low potency statins, and their equivalencies are:

3

3	
4	
5	
6	
4 5 7 8 9 10 11	
8	
9	
10	
11	
12	
13	
14	
12 13 14 15 16 17	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	
27	
20	
20	
20	
21	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
56 57	
5/	

58

59

60

Pravastatin 80mg = Atorvastatin 20mg = Rosuvastatin 10mg Fluvastatin XL 80mg = Atorvastatin 10mg = Rosuvastatin 5mg

3. *Reducing dose or lengthening administration interval.* Studies have demonstrated that greater than 70% of patients affected by myalgias were able to tolerate every other day administration with no recurrence of muscle symptoms⁹.

There is a small chance that your patient may have been misclassified with a statin indicated condition. We sincerely apologize for this and would be most appreciative if you can call or fax us to let us know.

We welcome any questions or comments so please kindly contact us at 403-955-8327 (or fax 403-955-8249), for more information.

Sincerely, Sonia Butalia MD, FRCPC, MSc and the study team

References

- 1. Yusuf S, Hawken S, Ôunpuu S, et al. The Lancet. 2004;364(9438):937-952.
- 2. O'Donnell MJ, Xavier D, Liu L, et al. The Lancet. 2010;376(9735):112-123.
- 3. Cholesterol Treatment Trialists Collaboration. The Lancet. 2010;376(9753):1670-1681.
- 4. Cholesterol Treatment Trialists Collaborators. The Lancet. 2012;380(9841):581-590.
- 5. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2016;32(11):1263-1282.

- 6. Graham DJ, Staffa JA, Shatin D, et al. JAMA. 2004;292(21):2585-2590.
- 7. Arca M, Pigna G. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2011;4:155-166.
- 8. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Cardiovascular Drugs and Therapy. December 01 2005;19(6):403-414.
- 9. Bellosta S, Paoletti R, Corsini A. Circulation. June 15, 2004 2004;109(23 suppl 1):III-50-III-57.

<u>Strategies for Enhancing Cholesterol Lowering Medication Use</u> <u>Among Patients at High Cardiovascular Disease Risk: Patient and</u> <u>General Practitioners' Perspectives on a Facilitated Relay</u> <u>Intervention</u>

Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

No	Item	Guide questions/ description	Response
Domain 1: Research team and reflexivity			
Personal Characteristics	(°C		
1.	Interviewer/facilitator	Which author/s conducted the interview or focus group?	Line 137
2.	Credentials	What were the researcher's credentials? <i>E.g. PhD, MD</i>	Author information
3.	Occupation	What was their occupation at the time of the study?	Line 137
4.	Gender	Was the researcher male or female?	Line 137
5.	Experience and training	What experience or training did the researcher have?	Line 137

Page 29 of 32

No	Item	Guide questions/ description	Response
Relationship with participants			
participants			
6.	Relationship established	Was a relationship established prior to study commencement?	Line 138-139
7.	Participant knowledge of the interviewer	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	Not discussed
	Interviewer	What characteristics were reported about the interviewer/facilitator? e.g. <i>Bias, assumptions,</i> <i>reasons and interests in</i>	Not discussed
8.	characteristics	the research topic	
Domain 2: study design		0	5
Theoretical framework			
		What methodological orientation was stated to underpin the study? <i>e.g.</i> <i>grounded theory</i> , <i>discourse anglusis</i>	Qualitative Description – Line 98
9.	Methodological orientation and Theory	discourse analysis, ethnography, phenomenology, content analysis	

No	Item	Guide questions/ description	Response
Participant selection			
10.	Sampling	How were participants selected? <i>e.g. purposive,</i> <i>convenience, consecutive,</i> <i>snowball</i>	GP – Snowball (line 106-107) Patients – Convenience (line 116)
11.	Method of approach	How were participants approached? e.g. <i>face-to-</i> <i>face, telephone, mail,</i> <i>email</i>	Line 106-120
	<u> </u>		
		How many participants	Line 173
12.	Sample size	were in the study?	Line 186
13.	Non-participation	How many people refused to participate or dropped out? Reasons?	Line 176-177
Setting		2	
		Where was the data	Line 137
	Setting of data	collected? e.g. <i>home</i> ,	Line 137
14.	collection	clinic, workplace	
15.	Presence of non- participants	Was anyone else present besides the participants and researchers?	Line 143
16.	Description of sample	What are the important characteristics of the sample? <i>e.g. demographic data, date</i>	Line 174-195

Page 31 of 32

No	Item	Guide questions/ description	Response
Data collection			
17.	Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	Appendix A& B
18.	Repeat interviews	Were repeat interviews carried out? If yes, how many?	No
19.	Audio/visual recording	Did the research use audio or visual recording to collect the data?	Line 146
20.	Field notes	Were field notes made during and/or after the interview or focus group?	Line 143-144
21.	Duration	What was the duration of the interviews or focus group?	Line 142-143
22.	Data saturation	Was data saturation discussed?	Line 140 + limitations section
23.	Transcripts returned	Were transcripts returned to participants for comment and/or correction?	No
Domain 3: analysis and findings			

No	Item	Guide questions/ description	Response
Data analysis			
24.	Number of data coders	How many data coders coded the data?	Line 156-160
25.	Description of the coding tree	Did authors provide a description of the coding tree?	Line 157
26.	Derivation of themes	Were themes identified in advance or derived from the data?	Line 157-158 (inductive)
27.	Software	What software, if applicable, was used to manage the data?	Line 164-165
28.	Participant checking	Did participants provide feedback on the findings?	Line 414-415
Reporting		1	
29.	Quotations presented	Were participant quotations presented to illustrate the themes / findings? Was each quotation identified? e.g. participant number	In-text and Table 3
30.	Data and findings consistent	Was there consistency between the data presented and the findings?	Yes

2				
3 4 5 6 7	No	Item	Guide questions/ description	Response
7 8 9 10 11	31.	Clarity of major themes	Were major themes clearly presented in the findings?	Results section
12 13 14 15 16	32.	Clarity of minor themes	Is there a description of diverse cases or discussion of minor themes?	Table 2 & 3
17 18 19 20 21		themes		
22 23 24 25 26				
27 28 29 30 31				
32 33 34 35 36				
37 38 39 40				
41 42 43 44 45				
46 47 48 49				
50 51 52 53 54				
55 56 57 58 59				
60		For peer review only - http://bm	ijopen.bmj.com/site/about/gi	uidelines.xhtml

BMJ Open

Strategies for Enhancing the Initiation of Cholesterol Lowering Medication Among Patients at High Cardiovascular Disease Risk: A Qualitative Descriptive Exploration of Patient and General Practitioners' Perspectives on a Facilitated Relay Intervention in Alberta, Canada

Journal:	BMJ Open		
Manuscript ID	bmjopen-2020-038469.R1		
Article Type:	Original research		
Date Submitted by the Author:	19-Sep-2020		
Complete List of Authors:	Campbell, David; University of Calgary Cumming School of Medicine, Department of Medicine Lee, Rachelle; University of Ottawa McBrien, Kerry; University of Calgary, Family Medicine Anderson, Todd; University of Calgary Cumming School of Medicine, Department of Cardiac Sciences Quan, Hude; University of Calgary, Community Health Sciences Leung, Alexander; University of Calgary Cumming School of Medicine, Department of Medicine Chen, Guanmin; University of Calgary Cumming School of Medicine, Community Health Sciences Lu, Mingshan ; University of Calgary, Economics Naugler, Christopher; University of Calgary, Pathology and Laboratory Medicine; Calgary Laboratory Services, Butalia, Sonia; University of Calgary Cumming School of Medicine, Department of Medicine		
Primary Subject Heading :	Cardiovascular medicine		
Secondary Subject Heading:	Diabetes and endocrinology, General practice / Family practice, Health services research, Qualitative research, Renal medicine		
Keywords:	QUALITATIVE RESEARCH, GENERAL MEDICINE (see Internal Medicine), Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Cardiology < INTERNAL MEDICINE, PREVENTIVE MEDICINE		
	·		

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3		Strategies for Enhancing the Initiation of Cholesterol Lowering Medication Among Patients at High
4		Cardiovascular Disease Risk: A Qualitative Descriptive Exploration of Patient and General
5		Practitioners' Perspectives on a Facilitated Relay Intervention in Alberta, Canada
6		,,,,,,
7		David J.T. Campbell, MD PhD FRCPC ^{1,2,3}
8		Rachelle C.W. Lee, MSc ⁴
9		
10		Kerry A. McBrien, MD MPH CCFP ^{2,5}
11 12		Todd J. Anderson, MD PhD FRCPC ³
12		Hude Quan, MD PhD ²
14		Alexander A.C. Leung, MD MPH FRCPC ^{1,2,3}
15		Guanmin Chen, MD PhD ²
16		Mingshan Lu, PhD ^{2,6}
17		Christopher Naugler, MD FRCPC ^{2,7}
18		Sonia Butalia, MD MSc FRCPC ^{1,2}
19		
20		1 – Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
21		2 – Department of Community Health Sciences, Cumming School of Medicine, University of Calgary,
22		Calgary, AB, Canada
23		
24		3 – Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB,
25		Canada
26		4 – Department of Innovation in Medical Education, Faculty of Medicine, University of Ottawa, Ottawa,
27		ON, Canada
28		5 – Department of Family Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB,
29		Canada
30		6 – Department of Economics, Faculty of Arts, University of Calgary, Calgary, AB, Canada
31		7 – Department of Pathology & Laboratory Medicine, Cumming School of Medicine, University of
32		Calgary, Calgary, AB, Canada
33		
34		Correspondence:
35		Dr. David J.T. Campbell
36		·
37		TRW 3E33, 3280 Hospital Dr NW
38		Calgary, AB, Canada T2N 4Z6
39		dcampbel@ucalgary.ca
40		403-210-9511
41		
42		Word count: Main text (4861 words), abstract (283 words), 3 tables, 1 figure, 3 appendices
43	1	
44 45		
45		
40		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2		
3		ABSTRACT
4	2	ADSTRACT
5	2	
6	3	Objective: The objective of our study was to explore the perspectives of patients and general
7	4	practitioners (GPs) regarding interventions to increase initiation of cholesterol lowering medication (or
8	5	statins), including a proposed laboratory-based facilitated relay intervention.
9	6	
10	7	Design: Qualitative descriptive study using interviews and focus groups for data collection, and thematic
11	8	analysis for data analysis.
12	9	
13	10	Setting: Primary care providers and patients in Calgary, Alberta, Canada.
14	11	
15	12	Participants: 17 General Practitioners with primarily community-based, non-academic practices with at
16	13	least 1 year of practice experience participated in semi-structured interviews. 14 patients at high risk of
17	14	cardiovascular disease participated in focus groups.
18		cardiovascular disease participated in locus groups.
19 20	15 16	Main outcome measurer Evaluation of strategies that might he used to exhause the press intim of
20	16	Main outcome measures: Exploration of strategies that might be used to enhance the prescription of,
22	17	and adherence to statin therapy for patients with statin-indicated conditions.
22	18	
24	19	Results: GPs proposed a variety of interventions to improve statin prescription, including electronic
25	20	record audit solutions, GP directed education and patient-oriented campaigns. Patients expressed that
26	21	they may benefit from being provided access to their laboratory test results, as well as targeted
27	22	education. Both parties provided positive feedback on the proposed laboratory-based facilitated relay
28	23	intervention, while pointing out areas for improvement. Notably, GPs were concerned that the patient-
29	24	directed component of the intervention might jeopardize their therapeutic relationship, and patients
30	25	were concerned about accidental disclosure of their personal information. Important considerations for
31	26	the design of facilitated relay messaging should include brevity, simplicity and the provision of contact
32	27	information for questions.
33	28	
34	29	Conclusions: GPs and patients described several suggestions for increasing statin initiation and
35	30	welcomed the proposal of a laboratory-based facilitated relay strategy. These findings support further
36	31	testing of this intervention which may enhance GPs' ability to successfully engage patients in
37		
38	32	cardiovascular risk reduction through statin therapy.
39 40	33	
40	34	Keywords: focus groups, qualitative research, interviews, statins, facilitated relay
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54 57		
55		
56 57		
57 58		n
58 59		2
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2		
3 4	35	Strengths & Limitations of this Study
5	36	
6	37	• This is a qualitative study, with relatively few participants – therefore we cannot say definitively
7	38	if the views represented here represent those of all patients and prescribers.
8	39	 We sampled physician participants to the point of saturation, which means that we are
9	40	confident the views represented here span the breadth of those held by physicians.
10	41	• The patient sample we recruited may not be representative of the broader population, as many
11	42	of them had previously stated an interest in quality improvement and research – and therefore
12	43	may be attuned to the importance of preventive therapies more than other members of the
13	44	general public. Additionally, this group was not sampled to saturation, as opposed to the
14	45	physician participants.
15 16	46	 Given the context-dependent nature of qualitative data, the applicability of these findings to
17	47	other settings is not certain.
18	48	 One of the major strengths of this study is the depth and richness of the qualitative data that
19	49	were collected. By asking questions in an open-ended manner, we were able to record detailed
20	50	accounts and opinions.
21	51	
22	52	
23	53	
24	55 54	
25		Vaccular disease, including coronany artery disease, parinharal artery disease, and corobrayascular
26 27	55	Vascular disease, including coronary artery disease, peripheral artery disease, and cerebrovascular
27 28	56	disease, remains among the leading causes of mortality worldwide (1). A class of medications, HMG-CoA
20	57	reductase inhibitors, commonly known as statins, have been proven to be effective for lowering the risk
30	58	of vascular events (2). Individuals who have previously had vascular disease (i.e. secondary prevention)
31	59	derive a greater absolute risk reduction from statins than those who have never had vascular disease
32	60	(i.e. primary prevention) (3). There are some individuals who have never had vascular disease, such as
33	61	those with diabetes or chronic kidney disease, who also have been shown in randomized controlled
34	62	trials to benefit from therapy (4-6). Despite over 30 years of clinical use, efficacy, safety and cost-
35	63	effectiveness data (7, 8), only 23% to 55% of individuals who would benefit take this medication and
36	64	fewer than half of individuals are treated to target cholesterol levels(7, 9-11). There is substantial
37	65	unwanted variability in dyslipidemia management and health system intervention is required to
38 39	66	promote equitable treatment (12, 13). The lack of statin treatment for patients with indicated conditions
40	67	results in significant excess morbidity and mortality. In Canada, specifically, if all patients with
41	68	indications for statins were treated, this would result in nearly 40,000 cardiovascular events avoided
42	69	(14). In the United States, 13% of cardiovascular deaths could be averted with perfect statin adherence
43	70	among patients at high cardiovascular risk (15).
44	71	
45	72	Physicians and patients face numerous barriers when it comes to prescribing and adhering to statin
46	73	therapy, from the providers perspective this includes lack of knowledge, conflicting clinical guidelines,
47	74	lack of systems to identify patients who should be taking statins (16). On the other hand, patients often
48	75	experience or fear side effects or are simply averse to taking additional medications (16). Furthermore,
49 50	76	patients that face social disadvantages such as low income, lack of health insurance, and minority race
50 51	77	are more likely to not use statins (17). A large US-based survey found that side effects were common
52	78	and that many former statin users were unsatisfied with the explanation provided by their prescriber
53	79	about the importance of the medication (18). Providers need resources to help them provide this
54	80	counselling to patients and to arm them with strategies to mitigate common statin side effects, like
55	81	muscle aches (19).
56	82	
57		
58		3

59

BMJ Open

5
4
5
6
7
8
9
10
11
12
13
14
15
16 17 18
17
19
20 21
21
22
23
24
25
25 26
27 28
28
29
30
30 31
32
52

There are clearly many challenges that lead to the observed clinical treatment gap for patients who have indications for statin treatment. However, some studies have shown that such treatment gaps, in related conditions like hypertension, can be closed using quality improvement strategies (20-22). Integrated quality improvement strategies that target both patients and healthcare providers are more likely to achieve quality indicators than strategies which only target one aspect in isolation (21). One such strategy is facilitated relay. Facilitated relay is a quality improvement strategy whereby information about individual patients is sent directly to healthcare providers through a means other than the usual clinical encounter (23). Despite the establishment and promotion of facilitated relay and other quality improvement strategies, there remain significant treatment gaps in hypertension (24) and other chronic conditions (25). Furthermore, while facilitated relay has been shown to be effective in improving a number of cardiovascular risk factors (21, 26), it remains among the least commonly used quality improvement strategies (27) and has not been explored in the management of dyslipidemia. For an intervention to have the potential to maximum impact, it is important to have the input of key stakeholders prior to the application of any intervention with a qualitative study being suited to do so (28). This allows for the development of a higher quality intervention, rather than one that relies on physician feedback alone (29). As such, the objective of our study was to explore the perspectives of patients and GPs regarding interventions to increase cholesterol lowering medication (or statin) prescription, including specific feedback on a proposed laboratory-based facilitated relay intervention.

METHODS:

Study Design

We conducted a qualitative descriptive study (28) to explore patients' and general practitioners' (GPs) perspectives on interventions to increase initiation of statins for cardiovascular risk reduction and treatment of high cholesterol. In addition to generic thoughts on potential hypothetical interventions, we specifically sought directed feedback and perceptions on the acceptability of the proposed facilitated relay intervention from both patients and GPs (30). We used the consolidated criteria for reporting qualitative research (COREQ) as the reporting framework for this study (31).

Proposed Intervention

We drew from behaviour change theory to develop a facilitated relay intervention to increase statin prescriptions (32-34) (Figure 1). Our proposed intervention partners with our province's single laboratory system to identify individuals who have elevated cholesterol levels, statin-indicated conditions, and who are not currently filling prescriptions for statins. Our lab system has access to province-wide administrative databases, including labs, pharmacy dispensations, and hospitalization data. For every elevated LDL-cholesterol level, the lab would have an algorithm that would check the patients' records for evidence of statin-indicated conditions (administrative markers of myocardial infarction, stroke, diabetes, or chronic kidney disease), and would then identify if they have recently filled a statin prescription. This is possible because of province-wide, linkable databases. For patients who are not filling statins, but who should be, their GP who had ordered the cholesterol levels and the patient, will then each receive a letter outlining the indication for treatment and the potential to benefit from statin therapy. The patient letter will encourage them to speak to their GP, and the GP letter will encourage them to make an appointment to discuss directly with the patient - both with the objective to initiate or renew statin prescriptions. We felt that it was important to include patients in the facilitated

relay to empower them in discussions with their GP and to enable shared decision-making (35), which has been demonstrated to improve adherence with statins (36).

Participant Recruitment

General Practitioners: We recruited general practitioners to participate in individual interviews, using a snowball sampling approach. First, we asked key stakeholders in areas of primary care, endocrinology, nephrology and cardiology affiliated with the university medical centre, to recommend community-based (non-academic) GPs to participate in the study. Individuals were then contacted by telephone and email with a formal invitation to participate. GPs who met the following criteria were enrolled: (1) currently practicing in community general practice settings; and, (2) have at least one year of experience as a GP. We sampled participants purposively based on several key demographic characteristics in order to achieve representation across a range of ages, genders and practice types.

Patients: We recruited patients who would qualify as recipients of the proposed intervention. Specifically, we were interested in recruiting those at high risk of cardiovascular disease, who self-reported a prior history of high cholesterol, preferably with co-existing vascular disease (myocardial infarction, stroke or peripheral vascular disease), diabetes, or chronic kidney disease. Using a convenience sampling approach, we invited patients who were part of an established advisory panel and previously agreed to be contacted about research opportunities for study participation (37, 38). In addition, patients were recruited using poster advertisements placed throughout the academic health sciences centre and in various clinical care areas where care is provided to patients with diabetes, heart disease and kidney disease.

Data Collection

Data was collected from September 2018 to November 2018 using both qualitative semi-structured interviews (with GPs) and focus groups (with patients). We chose focus groups for patients as rich personal disclosures are more likely to occur in this setting than in individual interviews (39). However, we purposely used individually scheduled interviews to offset potential aversion to focus groups by community-based GPs due to their competing clinical demands. Furthermore, we wanted to recruit from both urban and rural locales which is more challenging to do in a focus group.

Question Guides: Both focus groups and interviews were guided by question guides (Appendix A & B) which were developed based on a review of the literature (40, 41) and discussion with the research team. These were designed so that they initially asked study participants what they thought would be effective strategies or interventions to improve statin uptake (i.e. prescribing, patient use and adherence). After they had given their unprompted views, participants were then given a brief explanation of facilitated relay, the specifics of the proposed intervention (Figure 1), and they were shown a copy of the proposed intervention letter for GPs (Appendix C). After briefing participants on the principles and practices of facilitated relay and showing them our preliminary documents for the intervention, we asked for feedback. They were then asked for their specific feedback on this intervention.

Provider Interviews: All interviews were conducted in-person (in clinician offices) or via telephone, by a female trained research assistant (RCWL) with oversight by experienced study team members. Physician interviews were continued until the point of theoretical saturation when no new information emerged

1	
2	
3	177
4	
	178
5	179
6	
7	180
	181
8	
9	182
10	183
11	184
12	185
13	
	186
14	187
15	
	188
16	189
17	
18	190
	191
19	
20	192
21	193
22	194
23	195
24	
	196
25	197
26	
27	198
	199
28	
29	200
30	201
31	202
32	203
33	
	204
34	205
35	
36	206
	207
37	
38	208
39	209
40	210
41	211
42	
43	212
	213
44	
45	214
46	215
47	216
48	217
49	218
50	219
51	
	220
52	221
53	
54	222

59

60

from the interviews (42). Because the research objective was relatively focused, interviews were briefand lasted approximately 30 to 45 minutes.

Patient Focus Groups: None of the study team were acquainted with or involved in the clinical care of the patients who participated. We convened two focus groups in our academic medical centre which each lasted approximately 90 minutes. No one but researchers (including 1 facilitator and 2 field-note takers) and participants were present. Focus group facilitators tried to ensure that there were no dominant members and provide all participants with equal opportunity to voice their opinions.

186 Interviews and focus group proceedings were digitally audio-recorded and transcribed verbatim by a
187 professional transcriptionist. Field notes were taken to inform data analysis. All data were anonymized
188 and stored securely. Signed informed consent was received from each study participant. Gift cards were
189 provided to all participants. Ethics approval was granted from the University's Health Research Ethics
190 Board.

2 Data Analysis

Analysis was completed using conventional qualitative content analysis (43), a method of interpreting interview data with the goal of describing the phenomenon of interest. Transcripts for the initial three interviews were reviewed by three team members (DC, RL and SB), with the objective of inductively establishing a preliminary coding template that was used for subsequent data analysis. All transcripts were then analyzed by two reviewers (DC and RL). Codes were generated from the interview data and systematically applied to identify themes and patterns. The process was iterative, reflexive, and interactive as continual data collection and analysis shaped each other. For example, code titles or definitions identified based on earlier interviews were modified according to the data collected during subsequent interviews. The team met together to review the coding to elicit discussion about the coding strategy and attempted to achieve consensus to resolve coding discrepancies. NVivo 12 (Doncaster, Australia) qualitative data analysis software was used to facilitate the coding process.

206 **Patient and public involvement**

Patient partners and family members from the Libin Cardiovascular Institute's established patient and family member advisory group (44) voiced that *prevention* was one of their top research priorities for cardiovascular health. This work is related to prevention of cardiovascular disease. Patients were included in focus groups.

13 **RESULTS**

In total, we eventually reached out to 27 GPs to invite them to participate, 4 declined to participate, 3
didn't respond to the invitation, 19 were scheduled for interviews, with 2 cancelling. We reached
saturation after having completed 17 individual GP interviews (Table 1a). The majority were women
(88%) with 65% having graduated from medical school within the last ten years. All GPs spent more
than 50% of their time in clinical practice, most were in urban centers within Primary Care Networks
(PCNs). PCNs are networks of GPs that share interdisciplinary resources to enhance the delivery of
primary care within geographical regions(45); they are associated with improved chronic disease care
and outcomes(46).

56 224 **Table 1a.** Descriptive statistics for General Practitioners (n = 17).

Physician characteristics	Total (%)
Age (years)	
< 40	13 (76)
40 - 60	4 (24)
Gender	
Man	2 (12)
Woman	15 (88)
Years of primary care practice	
< 10	14 (83)
10 – 20	3 (18)
Years since medical school graduation	
< 10	11 (65)
≥10	6 (35)
Primary Care Network membership	
Yes	15 (88)
No	2 (12)
Location of primary care practice	
Urban	13 (76)
Rural	4 (24)
Focused practice interest	
Yes*	9 (53)
No	8 (47)
Clinical practice last 12 months	
Estimated number of patients at high CVD risk	
< 20	1 (6)
20 to 99	7 (41)
≥100	9 (53)
Use of endocrinology consultation services	
Yes	5 (29)
No	12 (71)
Use of cardiology consultation services	
Yes	10 (59)
No	7 (41)
Use of nephrology consultation services	
Yes	3 (18)
No	14 (82)
	. <i>.</i>
Proportion of patients who would be considered high risk	Mean: 32%
on the basis of cardiovascular risk factors (n=14)	Range 10-75%
	-
Proportion of high-risk patients who have a current LDL-	Mean: 82%
level on file (n=9)	Range 70-90%
* Focused practice, or special interest types: care of the elder	y (n = 2), emergency medicin
urgent care (n = 1), refugee medicine (n = 1), obstetrics (n = 2)	, indigenous health (n = 2), la
1).	
7	
7	

60

BMJ Open

1 2 3 4 5 6	229 230 231	Our patient focus groups had 8 and 6 participants, respective represented among patients, with a similar number of men a	and women. Nearly all had a general
7	232	practitioner and were also followed by medical specialist(s).	
8 9	233 234	group were diabetes, history of myocardial infarction and ele history of stroke, chronic kidney disease, or peripheral arteri	-
10	235	history of scroke, enrolle kuncy discuse, of peripheral arter	
11	236	Table 1b. Descriptive statistics for patient participants based	on self-report (n = 14).
12		Patient characteristics	Total (%)
13 14		Age (years)	
14		< 40	2 (15)
16		40 - 60	5 (39)
17		> 60	6 (46)
18		Gender	
19		Men	6 (46)
20		Women	7 (54)
21		Chronic condition qualifying as "high CVD risk"	
22 23		High cholesterol only	3 (23)
23		Diabetes only	6 (46)
25		Myocardial infarct (MI) only 💦 🚫	1 (8)
26		Diabetes & MI	3 (23)
27		Has a primary care provider	
28		Yes	12 (92)
29		No	1 (8)
30		Followed by a medical specialist	
31 32		Yes	10 (77)
33		No	3 (23)
34		Self-reported awareness of high cholesterol levels	
35		Yes	11 (85)
36		No	² 2 (15)
37		Current use of statin medication	
38		Yes	6 (46)
39		If not, had spoken with physicians about statins	3 (23)
40 41		If not, had not spoken with physicians about statins	4 (31)
42		*Note one participant did not complete a demographic	
43		questionnaire	
44	237		
45	238		
46	239	General suggestions for potential interventions	
47	240		
48 49	241	Several themes arose regarding interventions to improve sta	
49 50	242	portion of the interviews (Table 2). General practitioner part	
51	243	may be improved by: (1) enhancing aspects of physician edu	
52	244	prescribing; and, (2) implementation of support tools to help	
53	245	identification of patients for whom statins are indicated. In a	
54	246	access to their own laboratory results may enable them to be	e more effective self-advocates.
55	247		
56 57			
58		8	
50		8	

Providers	Treatment of	Patients with chronic kidney disease:		
	specific Sub- populations	<i>"I struggle with the GFRs [glomerular filtration rate] – knowing when it would be safe, when it wouldn't be safe. I do get confused as to the dosing based on GFR."</i> (GP-05)		
		Patients who previously experienced side effects with statin(s): <i>"I have one strategy but if somebody is still like 'no, it's completely not tolerable for me' then I don't know what the next step is after that."</i> (GP-13)		
		Elderly patients:		
	Ç	"getting some better understanding about the elderly. Are there any contraindications to starting on statin therapy? Is there one statin that may be more beneficial than another?" (GP-10)		
		Patients with hypertriglyceridemia:		
		"I always find it hard to know what to do with triglycerides more		
	Treatment to	education around how to manage those [patients]." (GP-15) "Most people in my office are confused about what we are doing in		
	Targets *	terms of treating to the target of 2 mmol/L, because the cardiologist is still sending consults about that, but then we have these family medicine evidence-based groups saying that targets don't matter".		
		(GP-02)		
		"I know the TOP [Towards Optimized Practice] guidelines don't necessarily correlate with CCS [Canadian Cardiovascular Society] guidelines, so there are several schools of thought". (GP-09)		
		"There's no real way to unify the guidelines, but to have an education session on why they're different and how to approach it so maybe you'll break down patient populations that fit better with one guidelin versus another". (GP-08)		
	Preferred modality of Education	"we have a lot of drug reps [representatives] coming to town, so it would be great to have more [education] that was not pharma, absolutely". (GP-04)		
	EMR-based tools	"One thing that would be helpful for me is if there was some automati flag that came when I saw a patient that would alert to the fact that their treatment is not optimized for their conditions". (GP-06)		
Patients	Laboratory Results	"I would like to get a copy, in addition to the doctor. I can do with it what I want" (Pt-09)		
		"It gets you questioning things so that you can come back to your doctor and say 'I saw these numbers, what does that mean? What do need to do?'" (Pt-02)		

1 2		
3		Enhanced "What if somebody was going regularly to a lab, and a clinician sort of
4		education goes: 'How are you doing on this?". (Pt-08)
5	248	EMR: electronic medical record
6 7	249	* Specialist guidelines, the 2016 Canadian Cardiovascular Society guideline (47) advocates that patients
8	250	at high risk (based on risk calculators) or those with 'statin-indicated conditions' (defined as diabetes,
9	251	chronic kidney disease, or preexisting vascular disease be treated with statin therapy to achieve a target
10	252	LDL-c level of < 2.0 mmol/L. GP Guidelines, the 2015 TOP Alberta Guideline (48) encourages GPs to treat
11	253	high risk patients with moderate-to-high intensity statins and should not repeat lipid levels, or attempt
12	254	to treat to a fixed target.
13	255	
14	256	
15	250	1) General practitioner <i>education:</i>
16	258	1) General practitioner education.
17		Nearly all CDs highlighted that there are general areas of knowledge that sould be helstered in order to
18 10	259	Nearly all GPs highlighted that there are general areas of knowledge that could be bolstered in order to
19 20	260	enhance statin prescription. One of the main content areas in which they sought enhanced education
20	261	related to the treatment of specific patient sub-populations, in particular those with chronic kidney
22	262	disease, prior statin side effects, elderly patients, and those with other concurrent lipid disorders (i.e.
23	263	hypertriglyceridemia).
24	264	
25	265	Whether providers should be treating patients to a specific cholesterol level was a major source of
26	266	confusion. They frequently referenced receiving conflicting advice, including a contradiction in clinical
27	267	practice guidelines(49), some of which advocate for a 'fire and forget' approach(8, 50), while
28	268	Canadian(7) and European(51) specialist guidelines recommend a 'treat-to-target' approach(7).
29	269	
30 21	270	Regarding the modality of education sessions, most preferred in-person education sessions delivered at
31 32	271	their clinics and delivered by someone who did not have clear conflicts of interest with pharmaceutical
33	272	companies. Many GPs also suggested the use of handouts, tools or algorithms to simplify their decision-
34	273	making process.
35	274	
36	275	2) General practitioner tools
37	276	
38	277	In addition to education, several GPs suggested that the use of automated tools would facilitate their
39	278	prescribing of statins. Most felt that they would benefit from optimizing the use of their electronic
40	279	medical records (EMR) to 'flag' individuals who were at high cardiovascular risk or had elevated
41	280	cholesterol levels. Other GPs spoke of wishing for a 'running list' of eligible patients, while some
42	281	mentioned using an employee or contractor designated as a panel manager to perform these tasks.
43 44	282	
44	283	3) Patient results and information
46	284	
47	285	Many patients independently indicated that they would like to have access to their lipid test results,
48	286	without needing to rely on this being conveyed to them by their general practitioner. Some patients also
49	287	suggested that providing them with their own results might reduce the frequency of unnecessary follow-
50	288	up visits; and as a result, alleviate related financial burden on the healthcare system. Doing so was also
51	289	thought to help foster patient engagement with their GP. Patients also felt that having greater access to
52	290	information about cholesterol and treatment might facilitate more patients being on statin therapy.
53	291	Suggestions were made to deliver this through enhanced patient-facing materials (i.e. brochures), as
54 55	292	well as pharmacists or lab technicians who were able to discuss results and treatment options. Further
55 56	232	wen as pharmacists of lab technicians who were able to discuss results and treatment options. Fullier
50 57		
58		10
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

information about patient education, shared decision-making, and clinical decision support tools are described in our other report from this work (16). Feedback on the proposed facilitated relay intervention Emerging themes regarding our proposed intervention were organized into four major categories: (1) general feedback and impression; (2) suggested changes; (3) intervention details; and, (4) workflow processing considerations. 1) General feedback and impression General practitioners responded with strongly positive feedback (Table 3), which included that they found the information to be helpful and direct. They generally felt that the letter was written in a clear fashion and with a respectful tone. Several mentioned that the information provided them with reassurance and credibility in making recommendations to their patients. GPs also voiced some questions and potential concerns after hearing about our proposed intervention. These concerns included whether the introduction of a facilitated relay intervention might increase their workload, lead to possible disclosure to patients of new diagnoses of conditions that qualified them as high risk (i.e. diabetes), and pose a threat to their therapeutic relationships with patients. In addition, logistical issues around how the letter will be best delivered to ordering providers and patients were raised as concerns. Patients generally felt that bringing their facilitated relay letter to a scheduled appointment would be positive in their relationship by providing structure to the follow-up encounter, holding GPs to account, and enhancing patient-provider communication. Even though most were generally positive, some patients expressed concern about the facilitated relay intervention, including the possibility for privacy breaches and increasing patient anxieties. 2) Suggested information to remove or add We asked GPs specifically what they would like to see changed in the preliminary materials shown. Almost unanimously, they suggested that the letter would be more appreciated if it were shortened to fit on one page. Several participants suggested removing the references, mention of clinical studies, and guideline citations to make it more reader-friendly. There was also a preference voiced for revising the introductory paragraphs to have direct relevance to individual patient(s): "I'm going to read it for sure, but then when you start to read it, people might put it down and say 'oh this is a study intervention', [but] if you have the first thing at the very top: 'you know this person has been identified as being at risk' – then it's about the patient rather than being about the studies". (GP-16) A few GPs voiced opinions that specific additions could be made to improve the letter's utility. These suggestions included adding: information about health behavior change ("the whole picture, as opposed to just medication" (GP-04)); adding contact information for a specialist; and details about how/why a particular individual was flagged as eligible for the facilitated relay intervention: "It would be helpful if I got a name, condition and then the statin-indicated condition, and where the condition was pulled from". (GP-01) For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2		
3	341	
4	342	Patient feedback was notable for also suggesting that the intervention provide contact information, in
5	343	case they have further questions about interpreting their results:
6	344	
7	345	"back that up with a helpline for somebody that doesn't know what the [results] mean" (Pt-10).
8	346	
9		Similar to physicians, patients expressed a strong preference for brevity: "If I have to go through 14
10 11	347	pages of information to figure out what that means, I'm sorry, I don't have time for that" (Pt-07).
12	348	
13	349	However, numerous patients also stressed the importance of not only providing results or diagnoses,
14	350	but also giving some basic education and an action plan to follow.
15	351	
16	352	3) Intervention details
17	353	
18	354	In addition to general feedback, we also explicitly asked GPs whether they would prefer to receive
19	355	information about their patient in the form of facilitated relay (individual letter for each patient
20	356	identified) or 'audit and feedback' (summary report including a group of their patient panel). A summary
21	357	list or report (audit and feedback) was preferred by roughly 2/3 of the general practitioners interviewed.
22	358	Regarding receiving letters for each patient, participants stated:
23	359	
24	360	"this is going to get tiresome very quickly" (GP-05)
25	361	
26 27	362	"Am I going to get this letter 20 times? I'm probably just going to read it once" (GP-03)
27 28	363	An r going to get this letter 20 times? I'm probably just going to read it once (Or OS)
28 29	364	[a list would] decrease paper burden, decrease the chance of it getting misplaced". (GP-13)
30	365	[u list would] decrease puper builden, decrease the chance of it getting misplaced . (GP-13)
31		While the (audit and foodback' approach was more popular some CDs ware clearly in favor of facilitated
32	366	While the 'audit and feedback' approach was more popular, some GPs were clearly in favor of facilitated
33	367	relay: "I can't even think of the amount of work it would take to do it patient-specific. I'd love it. Sure go
34	368	for it, if you have the means to do it, then why not?" (GP-10)
35	369	
36	370	We also asked pointedly about how providers would feel about receiving a follow-up reminder from the
37	371	study team, if patients' had not filled the prescription as recommended in the initial letter. The response
38	372	was split with roughly half of the general practitioners stating that a reminder would not be necessary.
39	373	
40	374	Those who felt a reminder would be acceptable generally agreed that a 6 month window should be
41 42	375	sufficient to ascertain whether or not the patient would have started on therapy: "There are people that
42 43	376	have a three-month wait list time, you may have to pick an interval more like six-months to appeal to the
43 44	377	masses". (GP-13)
45	378	
46	379	Most patients felt that they would benefit from receiving a follow-up reminder. After considerable
47	380	discussion amongst the groups, consensus was achieved that follow-up should not happen prior to four
48	381	months, and possibly even as long as six months after the initial contact. One participant stated: "close
49	382	enough that I vaguely remember that I meant to do something with that, but not a few weeks later, [so]
50	383	it's not irritating". (GP-17)
51	384	
52	385	We also asked patients if they had a preference for who had signed the letter. Most felt that having
53	386	letters come from a local specialist in cardiology or endocrinology would be preferable to having them
54		
55	387	signed by another GP.
56	388	
57 50		10
58 59		12
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

> 4) Workflow processing considerations (General practitioners only)

To each GP we asked specific details about how our intervention letter would be received in their offices and what would happen upon receipt. The majority stated that such a letter would be opened and processed by their front-desk staff. One participant clarified that the information on the envelope would determine who opened it: "if it's addressed to me then it will come to me, if it has a patient name for *me, then it goes through our document people [who file it]"*. (GP-09)

Once the letter has been opened, different offices employed a variety of different processes. In many practices, it would be given directly to the GP; while in others it would be scanned directly into a patient's file in an electronic medical record, yet in others, the hardcopy would be filed in a patient's

 chart.

In terms of the preferred delivery modality, most GPs felt that electronic delivery directly via the EMR platform would be the preferred method of receiving the intervention. However, a number still felt that conventional delivery via paper mail or fax would be preferable. Even those who expressed a preference for conventional delivery, many elaborated that such letters would often be scanned into a patient's electronic file: "if it was to come by mail or fax, then they have to scan it onto the computer" (GP-11). A few GPs described systems which can do this process automatically: "our office works with a new web system, so everything that comes in via the fax actually goes directly into the computer and they then allocate to the patient". (GP-11)

Table 3. Positive and negative feedback on facilitated relay intervention from general practitioners and patients

(General Practitioners		Patients	
Positive				
Composition	"Overall I thought it was worded quite well and was very clear" (GP- 08)	Provides structure to interaction	"My doctor would be okay with that It gives them a little checklist of things to talk about". (Pt-05)	
	"I think it's appropriate, it didn't take me very long to get through" (GP-16)	0	5,	
Tone	"it's written in a way that doesn't make you feel stupid, I guess" (GP- 11) "it's good because [it's] not telling you to do this [start statin therapy], but telling you to have a	Enhances communication	"I think that's good 'cause these doctors, some guys don't communicate." (Pt-13)	
Credibility	conversation]." (GP-17) "it gives family physicians more confidence to do those things and know the specialists are behind them in that recommendation" (GP-02)	Increases doctor accountability	"I think it keeps them [doctors] honest as well. They should actually be proactive in terms of having that information already, but that's not always the case. So I don't have a problem with a patient having all	

	"there's so much information for people to sift through if you can get valid information that's corroborated and consistent, that's helpful" (GP-15)		their information at their disposal". (Pt-14)
Direct	"it's a good idea it tells you what to do, which is great. You don't have to look up the guideline every time" (GP-04) "it's just one of those extra little reminders that takes the brain power out of the work you have to	Increases patient accountability	"If [patients] are encouraged to work with their doctor to monitor your numbers, you have a bit of control as well as the doctor like working together". (Pt-03)
	do day-to-day" (GP-06)		
Information	"[side effects] are what people hear about in the news a lot, so it's very helpful to have some numbers around it, and strategies to address that" (GP-09) "All the suggestions that you made are excellent. I'm reading through this and I'm like ' oh yeah, I didn't realize this' and ' this is something I can do for some of my patients'" (GP-12)	Provides peace of mind	"It gives me a little peace of mind in that we've talked about all of the things that are important and that should be covered that we haven't left anything out". (Pt-05)
	No	gative	
Increased	"I would caution against anything	Privacy	"You know what, my doctor isn't
workload	that causes more documents or more paperwork there's already so much" (GP-16)	concerns	going to send it out to me, anyway. It's going to go on to a receptionist, who might pass it on to somebody else in the office, so there's no guarantee of privacy there" (Pt-05) "Privacy is always an issue. I mean it' like, the less information that's out there about you, the better off you are, period. I don't care what it is" (Pt-07)
Disclosing new diagnoses	"my concern is that they get this information from a letter my preference would be that it came straight to me" (GP-01)	Difficulty interpreting results	"Some people might know all the numbers and everything else, I don't You give me a bunch of numbers, it means nothing to me. So unless the doctor explained it to me I'd rather talk to my doctor" (Pt-07)

2	
3	
4	
5	
6	
7	
8	
9 10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22 23	
23 24	411
25	412
26	413
27	414
28	415
29	416
30	417
31	418
32	419
33	420
34 35	421
35 36	422
37	423
38	424
39	425
40	425
41	420
42	428
43	420
44	429
45 46	430
46 47	
47 48	432
40 49	433
50	434
51	435
52	436
53	437
54	438
55	439

59

60

1

	Therapeutic	"If the patient gets a letter that's	Provoking	"There are people who are coming
	relationship	like 'you need to be on a statin' and	Anxieties	down with every disease known to
		we already had a conversation that		man, so for someone like that, that
		they didn't need a statin. That		kind of information would just send
		could cause some issues in the		them off the deep-end, right?" (Pt-
		therapeutic relationship." (GP-04)		05)
	Logistical	"What if a person gets a check from	Lack of	"You mentioned mail outs and things
	concerns	a walk-in clinic? My concern is then	engagement	like that have they proven to be
		is that walk-in clinic docs are just		effective, though, 'cause how many
		going to ignore this letter" (MD-05)		people read them? How many people
				understand them? I don't think there
		"If it goes to the patient,		would be a lot of point in it, 'cause I
		sometimes you get lots of mail and		don't think people pay that much
		they may just discard it" (MD-10)		attention" (Pt-09)
			Sense of	"Some will [say] 'I can't talk to my
			intimidation	doctor like that'. There will be some
				people who might be intimidated to
				initiate that conversation" (Pt-03)
411				
412				
413	DISCUSSION			
414		<u> </u>		
415		nave a more limited role in certain popu		
416		2, 53), they are important for the prev		•
417	•	atherosclerotic disease and in those w		
418	study, both GF	s and patients acknowledged that ther	e is the potential to	o improve the prescription and

419 use of statin therapy among those at high risk for cardiovascular disease. In unprompted questions, GPs
 420 acknowledged that there was a need for improved physician education on this topic, and that tools to
 421 help identify and track patients would be helpful. Patients also suggested that providing themselves with
 422 laboratory test results and information on treatment options may result in better medical care,
 423 generally supporting our hypothesis that facilitating shared decision making was a key element of a
 424 novel intervention. When shown the proposed intervention, both groups were strongly supportive of
 425 the facilitated relay intervention. While there were clear benefits to the intervention, some potential

426 downsides were raised from both GPs and patient perspectives. In general, all recipients would prefer 427 letters to be succinct, yet contain high yield information and provide contact information where 428 clarification could be sought.

430 A number of interventions have been attempted to address the problem of statin underuse. A number 431 of patient-centered approaches have been tried with varying success (22). While active forms of 432 education, like cognitive education and behavioural counselling seem to work (54), more passive forms 433 of education are often unsuccessful at changing behaviour, as in the recent ISLAND trial which found 434 their intervention, comprised of a mail and phone education strategy to encourage patients to take 435 prescribed medication, had no impact on adherence (55). Others have found that multifaceted 436 interventions focusing on enhancing care provision through team-based care may be effective at 437 increasing statin adherence (56).

However, when trying to target the problem of low statin prescribing, interventions directed only at
patients are not likely to work. An alternate approach is to facilitate GPs ability to identify and prescribe

BMJ Open

statins, to those in whom they are appropriate (57), through audit and feedback or facilitated relay. An

educational audit and feedback intervention regarding dyslipidemia treatment in Italian primary care practices was shown to increase adherence to statins by approximately 10% (58). Improved communication and shared decision making, which are explicit goals of facilitated relay interventions, can improve patient adherence (59). While these and other studies have reviewed the clinical efficacy of quality improvement strategies (21), few have used detailed qualitative methods as we have done. One large qualitative study interviewed audit and feedback experts to generate hypotheses about the various factors that may contribute to the efficacy of such interventions (60). Others have used qualitative methods to highlight the barriers physicians face in encouraging adherence (61), but ours is unique in using such methods to design and develop an intervention to address these challenges. Finally, we also appreciate that as much as there is underuse of statins, there is also overuse, for example, in people with short life expectancy. Perhaps interventions to increase initiation may also include a component that conveys statin benefits are measured in years rather than months. The fact that participants suggested elements of our facilitated relay intervention in the unprompted portion of the interviews lends credibility and face validity to the proposed intervention. However, it is notable that while GPs felt they would benefit from having internal systems to monitor patients' records, none independently suggested a strategy mediated by an independent third party (such as facilitated relay or audit and feedback), as we have proposed. Investigators who wish to implement facilitated relay interventions to enhance adherence to medical therapies can use the findings of this study to help develop interventions that are more likely to be acceptable to both GPs and patients. One of the main findings is to ensure that any such information is brief and high yield, containing patient identifiers early to capture general practitioner's attention. Such interventions can be strengthened by incorporating education on controversial or little-known topics. Patients strongly preferred any

correspondence to also contain direct suggestions or an action plan. Workflow and processing of these letters needs to be considered and interventions designed to be as minimally disruptive to clinical practice as possible - with most physicians preferring that it be embedded directly within the EMR; yet in healthcare settings (like ours) where there is marked heterogeneity in the use and type of EMRs, this may not be possible.

There are limitations to this study. Firstly, as in most qualitative studies, the number of participants was relatively small. This limitation is mitigated by the fact that physician interviews proceeded until the point of saturation. Patient data were not collected in this manner, and these themes may not be fully saturated and we appreciate this as a limitation. Furthermore, the patient sample we recruited may not be representative of the broader population, as many of them had previously stated an interest in quality improvement and research and therefore may be attuned to the importance of preventive therapies more than other members of the general public. Secondly, given the context-dependent nature of qualitative data, the applicability of these findings to other settings is not certain. Yet physicians face similar problems (i.e. time constraints, patient complexity and comorbidities and patient resistance to medical therapies) in numerous facets of medical care; therefore, it is conceivable that the findings of this study would apply to interactions between patients and GPs in other clinical settings. Due to time constraints of participants and researchers, member checking was not undertaken in this study. Finally, it is important to note that feedback was sought specifically about the proposed intervention. However, given the details reported, we feel that these findings are likely to be helpful to others proposing similar quality improvement interventions. One of the major strengths of this study is the depth and richness of the qualitative data that were collected. By asking questions in an open-ended manner, we were able to record detailed accounts and opinions. Another strength of this work is the

fact that we also sought patient input into the development of this intervention, rather than relying on physician feedback alone. Statin therapy has been demonstrated to effectively lower cholesterol and reduce the risk of cardiovascular events and death in individuals at high risk of cardiovascular disease. Despite this, they remain underused. There are patient, provider and system factors that contribute to the underuse of statins. Facilitated relay interventions hold promise as a potential method to address this important care gap. Our study sought perspectives of both healthcare providers and patients, which will be incorporated into intervention design to maximize acceptability. Insights gained from qualitative data will be used to improve the likelihood of success and achieve the desired clinical impact. The insights about these interventions are also likely to be of interest to many researchers and clinicians who are considering and designing provider- and/or patient-facing interventions to improve the uptake of preventive medications. Contributions DJTC, RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and methods. The study design was conceived by DJTC and SB. DJTC wrote the first draft of the study protocol. Data collection and analysis was completed by DJTC, RCWL and SB. KAM, TJA, HQ, AACL, GC, ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed substantively to further revisions of the manuscript and have consented to the publication of this version.

511 Data Availability Statement

512 No additional data available. Given that qualitative data are not deidentified and tell individuals'
513 personal stories, data cannot be shared beyond the scope of this project, as per our research ethics
514 board.

34 515 35 516 Competing Interest Statement

517 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently 518 offer testing in the jurisdiction under study.

38 51939 520


BMJ Open

1		
1 2		
3	521	References
4	522	References
5	523	1. World Health Organization. The top 10 causes of death 2018 [Available from:
6 7	525 524	 World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
8	525	2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association
9	526	Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions:
10	527	A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97.
11	528	3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ.
12	529	2019;367:15674.
13 14	530	4. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary
14	531	prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative
16	532	Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet.
17	533	2004;364(9435):685-96.
18	534	5. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of
19	535	lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study
20 21	536	of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92.
22	537	6. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative G. MRC/BHF
23	538	Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a
24	539	randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-16.
25	540	7. Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian
26	541	Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of
27 28	542	Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2016;32(11):1263-82.
20	543	8. Grundy SM, Stone NJ. 2018 American Heart Association/American College of
30	544	Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention.
31	545 546	JAMA Cardiol. 2019;4(6):589-91. 9. Butalia S, Lewin A, Simpson S, Dasgupta K, Khan N, Pilote L, et al. Sex-based disparities in
32	540 547	9. Butalia S, Lewin A, Simpson S, Dasgupta K, Khan N, Pilote L, et al. Sex-based disparities in cardioprotective medication use in adults with diabetes. Diabetol Metab Syndr. 2014;5(6):117.
33 34	548	10. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R, et al. 2012 Update of
35	549	the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the
36	550	Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2013;29(2):151-67.
37	551	11. Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular Risk and Statin Use in
38	552	the United States. The Annals of Family Medicine. 2014;12(3):215-23.
39	553	12. Gamble JM, Butalia S. Medical Practice Variations in Diabetes Mellitus. In: Johnson A, Stukel T,
40 41	554	editors. Medical Practice Variations. Health Services Research: Springer US; 2015. p. 1-40.
42	555	13. Tu JV, Chu A, Maclagan L, Austin PC, Johnston S, Ko DT, et al. Regional variations in ambulatory
43	556	care and incidence of cardiovascular events. Canadian Medical Association Journal. 2017;189(13):E494-
44	557	E501.
45	558	14. Hennessy DA, Tanuseputro P, Tuna M, Bennett C, Perez R, Shields M, et al. Population health
46 47	559	impact of statin treatment in Canada. Health Rep. 2016;27(1):20-8.
47 48	560	15. Yang Q, Zhong Y, Gillespie C, Merritt R, Bowman B, George MG, et al. Assessing potential
49	561	population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases
50	562	in the USA: population-based modelling study. BMJ Open. 2017;7(1):e011684.
51	563	16. Butalia S, Lee-Krueger R, McBrien K, Leung A, Anderson T, Quan H, et al. Barriers and Facilitators
52	564 565	to Using Statins: A Qualitative Study with Patients and Family Physicians Canadian Journal of Cardiology Open. 2020;Online ahead of print.
53 54	202	Open. 2020,011111e alleau of print.
54		
56		
57		
58		18
59 60		For peer review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml

17. Schroff P, Gamboa CM, Durant RW, Oikeh A, Richman JS, Safford MM. Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. J Am Heart Assoc. 2017;6(9). 18. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208-15. 19. Jacobson TA, Khan A, Maki KC, Brinton EA, Cohen JD. Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. J Clin Lipidol. 2018;12(1):78-88. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in 20. primary care: a systematic review. CMAJ. 1997;156(12):1705-12. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality 21. improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012;379(9833):2252-61. Rash JA, Campbell DJ, Tonelli M, Campbell TS. A systematic review of interventions to improve 22. adherence to statin medication: What do we know about what works? Prev Med. 2016;90:155-69. 23. Walsh J, McDonald KM, Shojania KG, Sundaram V, Nayak S, Davies S, et al. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies (Vol 3: Hypertension Care). AHRQ Technical Reviews. Rockville (MD)2005. 24. Zhang Y, Moran AE. Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension Among Young Adults in the United States, 1999 to 2014. Hypertension. 2017;70(4):736-42. 25. Jardine MJ, Kasiske B, Adu D, Alrukhaimi M, Ashuntantang GE, Basnet S, et al. Closing the gap between evidence and practice in chronic kidney disease. Kidney Int Suppl (2011). 2017;7(2):114-21. 26. Walsh JM, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, et al. Quality improvement strategies for hypertension management: a systematic review. Med Care. 2006;44(7):646-57. 27. Campbell DJ, Sargious P, Lewanczuk R, McBrien K, Tonelli M, Hemmelgarn B, et al. Use of chronic disease management programs for diabetes: in Alberta's primary care networks. Can Fam Physician. 2013;59(2):e86-92. 28. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):7. Pope C, van Royen P, Baker R. Qualitative methods in research on healthcare quality. Qual Saf 29. Health Care. 2002;11(2):148-52. 30. Ayala GX, Elder JP. Qualitative methods to ensure acceptability of behavioral and social interventions to the target population. J Public Health Dent. 2011;71 Suppl 1:S69-79. 31. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-57. 32. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. 33. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7:37. 34. Michie S, Johnston M, Francis J, Hardeman W, Eccles M. From Theory to Intervention: Mapping Theoretically Derived Behavioural Determinants to Behaviour Change Techniques. Applied Psychology. 2008;57(4):660-80. 35. Barrett B, Ricco J, Wallace M, Kiefer D, Rakel D. Communicating statin evidence to support shared decision-making. BMC Fam Pract. 2016;17:41. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, et al. Helping patients with 36. type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167(10):1076-82.

1		
2		
3	614	37. Santana M, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Working Together with
4	615	Patients and Clinician Researchers to Improve Cardiovascular Health. 2018 SPOR Summit; Ottawa, ON.
5	616	38. Santana M, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Working Together: Co-
6 7	617	designing Priorities for Patient-Oriented Cardiovascular Research by Patients, Clinicians, and
8	618	Researchers. Canadian Association for Health Services and Policy Research (CAHSPR); Halifax, NS2019.
9	619	39. Guest G, Namey E, Taylor J, Eley N, McKenna K. Comparing focus groups and individual
10	620	interviews: findings from a randomized study. Int J Soc Res Methodol. 2017;20(6):693-708.
11	621	40. Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the implementation
12	622	of coronary heart disease prevention in primary care. Br J Gen Pract. 2003;53(494):684-9.
13	623	41. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to
14	624	long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291.
15 16	625	42. Walker JL. The use of saturation in qualitative research. Can J Cardiovasc Nurs. 2012;22(2):37-
17	626	46.
18	627	43. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res.
19	628	2005;15(9):1277-88.
20	629	44. Santana MJ, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Patients, clinicians and
21	630	researchers working together to improve cardiovascular health: a qualitative study of barriers and
22	631	priorities for patient-oriented research. BMJ Open. 2020;10(2):e031187.
23 24	632	45. Drew P, Jones B, Norton D. Team effectiveness in primary care networks in Alberta. Healthc Q.
25	633	2010;13(3):33-8.
26	634	46. Manns BJ, Tonelli M, Zhang J, Campbell DJT, Sargious P, Ayyalasomayajula B, et al. Enrolment in
27	635	primary care networks: impact on outcomes and processes of care for patients with diabetes. Canadian
28	636	Medical Association Journal. 2012;184(2):E144-E52.
29	637	47. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian
30 31	638	Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of
32	639	Cardiovascular Disease in the Adult. Can J Cardiol. 2016;32(11):1263-82.
33	640	48. Toward Optimized Practice Cardiovascular Disease Risk Working Group. Prevention and
34	641	management of cardiovascular disease risk in primary care clinical practice guideline Edmonton, AB:
35	642	Toward Optimized Practice; 2015 [Available from:
36	643	https://top.albertadoctors.org/CPGs/Lists/CPGDocumentList/CVD-Risk-CPG.pdf.
37	644	49. Tibrewala A, Jivan A, Oetgen WJ, Stone NJ. A Comparative Analysis of Current Lipid Treatment
38	645	Guidelines: Nothing Stands Still. J Am Coll Cardiol. 2018;71(7):794-9.
39 40	646	50. Toward Optimized Practice (TOP) Cardiovascular Disease Risk Working Group. Prevention and
41	647	management of cardiovascular disease risk in primary care clinical practice
42	648	guideline 2015 [Available from:
43	649	http://www.topalbertadoctors.org/download/1655/Lipid%20Pathway%20CPG.pdf? 20150916105016.
44	650	51. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS
45	651	Guidelines for the Management of Dyslipidaemias. Rev Esp Cardiol (Engl Ed). 2017;70(2):115.
46 47	652	52. Kristensen M, Christensen PM, Hallas J. The effect of statins on average survival in randomised
47 48	653	trials, an analysis of end point postponement. BMJ Open. 2014;5(007118).
49	654	53. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular
50	655	disease take a statin? BMJ. 2013;347:f6123.
51	656	54. Jornten-Karlsson M, Pintat S, Molloy-Bland M, Berg S, Ahlqvist M. Patient-Centered
52	657	Interventions to Improve Adherence to Statins: A Narrative Synthesis of Systematically Identified
53	658	Studies. Drugs. 2016;76(15):1447-65.
54 55		
55		
57		
58		20
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

55. Ivers NM, Schwalm JD, Bouck Z, McCready T, Taljaard M, Grace SL, et al. Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial. BMJ. 2020;369:m1731. 56. van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R. Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev. 2016;12:CD004371. Kaya H, Beton O, Yilmaz M. How to increase level of patients' awareness regarding the 57. importance of statins despite the influence of the media? International Journal of Cardiology. 2016;207:164. 58. Casula M, Tragni E, Piccinelli R, Zambon A, De Fendi L, Scotti L, et al. A simple informative intervention in primary care increases statin adherence. Eur J Clin Pharmacol. 2016;72(2):227-34. 59. Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566-77. Colquhoun HL, Carroll K, Eva KW, Grimshaw JM, Ivers N, Michie S, et al. Advancing the literature 60. on designing audit and feedback interventions: identifying theory-informed hypotheses. Implement Sci. 2017;12(1):117. Kvarnström K, Airaksinen M, Liira H. Barriers and facilitators to medication adherence: a 61. qualitative study with general practitioners. BMJ Open. 2018;8(1):e015332.






Figure 1: Laboratory-Based Facilitated-Relay Intervention Dashed lines: traditional interface between lab and ordering provider

Appendix A: Interview Guide for health care professional

Thank you for agreeing to participate in our interview today. We wish to discuss your experience in managing dyslipidemia (or high cholesterol) in order to better understand how we might help family physicians treat dyslipidemia (or high cholesterol). We have a proposed intervention and would like your assistance in how to enrich it.

1. Experience managing dyslipidemia

Please describe any challenges or difficulties that you experience in identifying and managing patients with dyslipidemia?

- Do you use any resources to guide you in the management of these patients?
 - Canadian Cardiovascular Society Guidelines
 - Diabetes Canada Guidelines
 - TOP guidelines

In addition to measuring a patient's lipids, what are some other parameters that you consider when assessing a patient for dyslipidemia, and how to optimally manage this condition?

2. Dyslipidemia-related practices

In your practice, do you find it helpful to quantify a patient's LDL-cholesterol or get a lipid panel?

If yes,

- Are there certain populations in whom you find this test most helpful?
- What is your chosen method/diagnostic test to do so?
 - Fasting or random lipid profile
 - Total cholesterol
 - HDL-cholesterol
 - LDL-cholesterol
 - ApoB
- How does this information change your clinical practice?
- How often do you repeat cholesterol testing for patients with with conditions that puts them at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease)?

If no,

- Why is it not particularly helpful?
 - Don't know which test to do
 - Don't know how to order it
 - Don't know in whom it is indicated

Don't know what to do with the results

In thinking about your practice, what proportion of your patients with conditions that put them at high risk for cardiovascular disease (i.e. previous myocardial infarction, stroke, diabetes, and/or chronic kidney disease) have had their lipid profile assessed in the past 12 months?

What are some of the reasons this does not happen (in your practice and in others')?

- Didn't think it was indicated/for whom it is indicated
- Too many things to attend to
- Not perceived to be an important issue amongst all other disease/conditions that FPs manage
- Patient factors (doesn't go for test)

3. Intervention

If we wanted to increase the use of statins among people at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease), what might be done? What tools, resources, prompts may help facilitate increased treatment of dyslipidemia?

In your opinion, what type of educational intervention is most effective in disseminating clinical practice guidelines to family physicians? (i.e. conferences, local lectures, treatment recommendations on lab results).

We are considering the use of a facilitated relay strategy, where patient's information from Calgary Laboratory Services is used to identify those who have indications for statin therapy. Those who are not currently filling statin prescriptions at the pharmacy would receive a letter from the lab indicating that they may benefit from statins. They will be encouraged to bring this letter in to discuss this with you.

How would family physicians respond to receiving a letter from the lab prompting them to consider starting their patient on statin treatment?

- What would be the characteristics of such a letter that would make it more likely to succeed?
 - Short/Pictorial/Colorful

Would it be more helpful to have this information specific about one named patient, or rather have an audit of your entire practice that would indicate what proportion of eligible patients with statin-indicated conditions are currently being treated with statins? (i.e. Audit and Feedback)

How should such an intervention either on a specific patient or about your entire practice be received?

• Mail/Fax/EMR/combo

How would such an intervention be processed in your office?

- Who would open the envelope?
- What would they do with it? (give it to you, put it in the patient's chart)
- How likely would you be to see this information?

Who should this letter be coming from in order to have it received in the most positive way possible?

- A non-clinical academic researcher (Dr. XXXX)
- Head of the Calgary Laboratory Services (Dr. Christopher Naugler)
- A lipid specialist (Dr. Sonia Butalia, Alex Leung)
- An academic family doctor (Dr. Kerry McBrien)
- A respected community family doctor
- The lead of Dyslipidemia Guidelines (Dr. Todd Anderson)
- Dr. Cello Tonelli, Associate Vice-President (Research) at the University of Calgary
- Dr. Richard Lewanczuk, Senior Medical Director for Primary Care, Chronic Disease Management, Community and Rural for Alberta Health Services
- Someone else

Would it be helpful to receive a reminder or follow-up letter?

• How much later should this be sent, so as to be useful and not annoying?

If the intervention provided you with patient-oriented material about this subject, and asked you to share it with your patients, how would you feel about doing so?

- What content should be included in this patient-oriented material to enhance statin use?
- What format should this material be in? Electronic, hard-copy? How should it be delivered? Mail, email?
- Would you share it in a clinical setting?
- Would you be willing to mail it to patients directly?

Do you have any additional comments or suggestions for developing an intervention to increase the use statins in people at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease) in primary care?

Thank you for participating in today's interview. Using the information you provided, we will work on developing an intervention to improve the treatment of dyslipidemia in patients who are at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease)?

Appendix B: Focus Group Guide for patients

Thank you for agreeing to participate in our focus group today. There are many risk factors for heart attacks and stroke. Today we want to focus on one risk factor being high cholesterol. High cholesterol is a major risk factor for heart attacks, strokes and circulatory problems. There are no symptoms of high cholesterol and it is diagnosed by a lab test that your doctor would order. Importantly, we work for the University of Calgary and have no relationship with any medication companies.

We wish to discuss your experience in managing *cholesterol* with medications in order to better understand how we might help family physicians (*doctors*) treat high cholesterol.

1. Experience with high cholesterol

Think about the last time your doctor has sent you for a cholesterol test. Did your doctor talk to you about the results? Treatment? What kind of treatment was discussed (diet, exercise, a medication)?

Put yourself in the position of being told that you need to take a medication for your cholesterol. What factors would make you more likely to take it? What factors would make you not want to take it? Reasons, side effects, costs

- Would you use any resources to help you decide?
 - o Doctor
 - \circ Dietician
 - o Internet
 - Family, friends

What would you think if your doctor told you that your cholesterol wasn't all that high, but because of your other health conditions she wanted to start you on a cholesterol lowering medication to reduce your risk of heart attack and stroke?

Do you think it would be helpful to get the actual result of your cholesterol level sent directly from the lab to you?

Currently, cancer screening programs send letters to patients about their results and next steps. What are your thoughts for something similar for high cholesterol?

What about information about recommended treatments and potential side effects? Would you find this to be invasive of your privacy (i.e. info from the lab about treatment and not your doctor)?

How would you feel about taking a letter with these recommendations to your doctor to discuss about a medication for high cholesterol?

How do you feel your doctor would respond to you bringing this information?

What things on the letter would make it helpful?

-length, colour, graphics,

Who should this letter be coming from in order to have it received in the most positive way possible?

- A non-clinical academic researcher (Dr. XXXX)
- Head of the Calgary Laboratory Services (Dr. Christopher Naugler)
- A lipid specialist (Dr. Sonia Butalia, Alex Leung)
- An academic family doctor (Dr. Kerry McBrien)
- A respected community family doctor
- The lead of Dyslipidemia Guidelines (Dr. Todd Anderson)
- Dr. Richard Lewanczuk, Senior Medical Director for Primary Care, Chronic Disease Management, Community and Rural for Alberta Health Services
- Someone else

Would it be helpful to receive a reminder or follow-up letter?

• How much later should this be sent, so as to be useful and not annoying?

Do you have any additional comments or suggestions for developing an way to increase the use the treatment of people with high cholesterol?

Appendix C: Facilitated Relay Letter



Date: XXXX-XX-XX

Dear Dr. [Physician Last Name],

RE: [Patient Name]

As you may recall, your Primary Care Network is involved in a study with the University of Calgary. This is an investigator-initiated study with public funding from the [*Canadian Institutes of Health Research*].

Dyslipidemia is a major risk factor for myocardial infarction and stroke¹⁻². As you know, in patients like [name], statins are indicated for their dyslipidemia because they are proven to reduce cardiovascular outcomes and mortality³⁻⁴. Because of numerous randomized controlled trials, guidelines recommend statin use in individuals with history of previous cardiovascular disease, diabetes, or chronic renal failure⁵.

We are writing to you to consider initiating a statin in your patient. We know the importance of the therapeutic relationship that you have with your patients and know that we do not know your patient like you do. The purpose of this letter is to assist in you in your discussion with [name], about using a statin medication.

[Name] may not be taking a statin because of underestimation of their personal risk of cardiovascular disease, fear of side-effects, previous side-effects, or cost. If cost is a concern, compassionate programs are available for several statin medications. Please kindly call our study telephone number to assist in facilitating this.

The most common side effect from statins is muscle aches, and the frequency of statin-induced rhabdomyolysis is very rare (i.e. < 1 in 10,000 patients per year on statins)⁶. Studies suggest that there are several proven methods for managing people who have experienced muscle aches. For those unable to tolerate daily high intensity statins, some statin is still better than none, and the following strategies can be considered:

- 1. *Reducing the dose of statin*. i.e. Atorvastatin 10-20mg or Rosuvastatin 2.5-5mg⁷.
- Trying a low potency statin medication. Lower potency statins seem to be less strongly associated with muscle aches. Fluvastatin and Pravastatin were much less likely than Simvastatin and Atorvastatin to cause myalgia⁸. For your reference, maximum doses of these low potency statins, and their equivalencies are:

 Pravastatin 80mg = Atorvastatin 20mg = Rosuvastatin 10mg Fluvastatin XL 80mg = Atorvastatin 10mg = Rosuvastatin 5mg

3. Reducing dose or lengthening administration interval. Studies have demonstrated that greater than 70% of patients affected by myalgias were able to tolerate every other day administration with no recurrence of muscle symptoms⁹.

There is a small chance that your patient may have been misclassified with a statin indicated condition. We sincerely apologize for this and would be most appreciative if you can call or fax us to let us know.

We welcome any questions or comments so please kindly contact us at 403-955-8327 (or fax 403-955-8249), for more information.

Sincerely, Sonia Butalia MD, FRCPC, MSc and the study team See telle

References

- 1. Yusuf S, Hawken S, Ôunpuu S, et al. The Lancet. 2004;364(9438):937-952.
- O'Donnell MJ, Xavier D, Liu L, et al. The Lancet. 2010;376(9735):112-123. 2.
- Cholesterol Treatment Trialists Collaboration. The Lancet. 2010;376(9753):1670-1681. 3.
- Cholesterol Treatment Trialists Collaborators. The Lancet. 2012;380(9841):581-590. 4.
- Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines 5. for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2016;32(11):1263-1282.
- Graham DJ, Staffa JA, Shatin D, et al. JAMA. 2004;292(21):2585-2590. 6.
- Arca M, Pigna G. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2011;4:155-7. 166.
- 8. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Cardiovascular Drugs and Therapy. December 01 2005;19(6):403-414.
- 9. Bellosta S, Paoletti R, Corsini A. Circulation. June 15, 2004 2004;109(23 suppl 1):III-50-III-57.

<u>Strategies for Enhancing Cholesterol Lowering Medication Use</u> <u>Among Patients at High Cardiovascular Disease Risk: Patient and</u> <u>General Practitioners' Perspectives on a Facilitated Relay</u> <u>Intervention</u>

Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

No	Item	Guide questions/ description	Response
Domain 1: Research			
team and reflexivity			
Personal Characteristics	Ċ,		
		Which author/s conducted the interview or focus	Line 137
1.	Interviewer/facilitator	group?	
2.	Credentials	What were the researcher's credentials? <i>E.g. PhD</i> , <i>MD</i>	Author information
			K
		What was their occupation	Line 137
3.	Occupation	at the time of the study?	
		Was the researcher male	Line 137
4.	Gender	or female?	
	Experience and	What experience or training did the researcher	Line 137
5.	training	have?	

Item	Guide questions/ description	Response
Relationship established	Was a relationship established prior to study commencement?	Line 138-139
Participant knowledge of the interviewer	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	Not discussed
Interviewer	What characteristics were reported about the interviewer/facilitator? e.g. <i>Bias, assumptions,</i> <i>reasons and interests in</i>	Not discussed
characteristics	the research topic	
		5
Methodological orientation and	What methodological orientation was stated to underpin the study? <i>e.g.</i> grounded theory, discourse analysis, ethnography, phenomenology, content	Qualitative Description – Line 98
	Relationship established Participant knowledge of the interviewer characteristics	ItemdescriptionItemdescriptionRelationship establishedWas a relationship established prior to study commencement?Participant knowledge of the interviewerWhat did the participants know about the researcher? e.g. personal goals, reasons for doing the researchParticipant knowledge of the interviewerWhat characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topicInterviewerWhat characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topicInterviewerWhat methodological orientation was stated to underpin the study? e.g. grounded theory, discourse analysis, ethnography, phenomenology, content

Page 33 of 35

No	Item	Guide questions/ description	Response
Participant selection			
10.	Sampling	How were participants selected? e.g. purposive, convenience, consecutive, snowball	GP – Snowball (line 106-107) Patients – Convenience (line 116)
11.	Method of approach	How were participants approached? e.g. <i>face-to-</i> <i>face, telephone, mail,</i> <i>email</i>	Line 106-120
	<u> </u>		
		How many participants	Line 173
12.	Sample size	were in the study?	Line 186
13.	Non-participation	How many people refused to participate or dropped out? Reasons?	Line 176-177
Setting		2	
		Where was the data	Line 137
14.	Setting of data collection	collected? e.g. <i>home, clinic, workplace</i>	Line 142
15.	Presence of non- participants	Was anyone else present besides the participants and researchers?	Line 143
16.	Description of sample	What are the important characteristics of the sample? <i>e.g. demographic data, date</i>	Line 174-195

No	Item	Guide questions/ description	Response
Data collection			
17.	Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	Appendix A& B
18.	Repeat interviews	Were repeat interviews carried out? If yes, how many?	No
19.	Audio/visual recording	Did the research use audio or visual recording to collect the data?	Line 146
20.	Field notes	Were field notes made during and/or after the interview or focus group?	Line 143-144
21.	Duration	What was the duration of the interviews or focus group?	Line 142-143
22.	Data saturation	Was data saturation discussed?	Line 140 + limitations section
23.	Transcripts returned	Were transcripts returned to participants for comment and/or correction?	No
Domain 3: analysis and findings			

No	Item	Guide questions/ description	Response
Data analysis			
24.	Number of data coders	How many data coders coded the data?	Line 156-160
25.	Description of the coding tree	Did authors provide a description of the coding tree?	Line 157
26.	Derivation of themes	Were themes identified in advance or derived from the data?	Line 157-158 (inductive)
27.	Software	What software, if applicable, was used to manage the data?	Line 164-165
28.	Participant checking	Did participants provide feedback on the findings?	Line 414-415
Reporting		7	
29.	Quotations presented	Were participant quotations presented to illustrate the themes / findings? Was each quotation identified? e.g. participant number	In-text and Table 3
30.	Data and findings consistent	Was there consistency between the data presented and the findings?	Yes

No	Item	Guide questions/ description	Response
	Clarity of major	Were major themes clearly	Results section
31.	themes	presented in the findings?	
		Is there a description of	Table 2 & 3
	Clarity of minor	diverse cases or discussion	
32.	themes	of minor themes?	

BMJ Open

Strategies for Enhancing the Initiation of Cholesterol Lowering Medication Among Patients at High Cardiovascular Disease Risk: A Qualitative Descriptive Exploration of Patient and General Practitioners' Perspectives on a Facilitated Relay Intervention in Alberta, Canada

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-038469.R2
Article Type:	Original research
Date Submitted by the Author:	05-Oct-2020
Complete List of Authors:	Campbell, David; University of Calgary Cumming School of Medicine, Department of Medicine Lee, Rachelle; University of Ottawa McBrien, Kerry; University of Calgary, Family Medicine Anderson, Todd; University of Calgary Cumming School of Medicine, Department of Cardiac Sciences Quan, Hude; University of Calgary, Community Health Sciences Leung, Alexander; University of Calgary Cumming School of Medicine, Department of Medicine Chen, Guanmin; University of Calgary Cumming School of Medicine, Community Health Sciences Lu, Mingshan ; University of Calgary, Economics Naugler, Christopher; University of Calgary, Pathology and Laboratory Medicine; Calgary Laboratory Services, Butalia, Sonia; University of Calgary Cumming School of Medicine, Department of Medicine
Primary Subject Heading :	Cardiovascular medicine
Secondary Subject Heading:	Diabetes and endocrinology, General practice / Family practice, Health services research, Qualitative research, Renal medicine
Keywords:	QUALITATIVE RESEARCH, GENERAL MEDICINE (see Internal Medicine), Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Cardiology < INTERNAL MEDICINE, PREVENTIVE MEDICINE
	·

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3		Strategies for Enhancing the Initiation of Cholesterol Lowering Medication Among Patients at High
4		Cardiovascular Disease Risk: A Qualitative Descriptive Exploration of Patient and General
5		Practitioners' Perspectives on a Facilitated Relay Intervention in Alberta, Canada
6		,,,,,,
7		David J.T. Campbell, MD PhD FRCPC ^{1,2,3}
8		Rachelle C.W. Lee, MSc ⁴
9		
10		Kerry A. McBrien, MD MPH CCFP ^{2,5}
11 12		Todd J. Anderson, MD PhD FRCPC ³
12		Hude Quan, MD PhD ²
14		Alexander A.C. Leung, MD MPH FRCPC ^{1,2,3}
15		Guanmin Chen, MD PhD ²
16		Mingshan Lu, PhD ^{2,6}
17		Christopher Naugler, MD FRCPC ^{2,7}
18		Sonia Butalia, MD MSc FRCPC ^{1,2}
19		
20		1 – Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
21		2 – Department of Community Health Sciences, Cumming School of Medicine, University of Calgary,
22		Calgary, AB, Canada
23		
24		3 – Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB,
25		Canada
26		4 – Department of Innovation in Medical Education, Faculty of Medicine, University of Ottawa, Ottawa,
27		ON, Canada
28		5 – Department of Family Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB,
29		Canada
30		6 – Department of Economics, Faculty of Arts, University of Calgary, Calgary, AB, Canada
31		7 – Department of Pathology & Laboratory Medicine, Cumming School of Medicine, University of
32		Calgary, Calgary, AB, Canada
33		
34		Correspondence:
35		Dr. David J.T. Campbell
36		·
37		TRW 3E33, 3280 Hospital Dr NW
38		Calgary, AB, Canada T2N 4Z6
39		dcampbel@ucalgary.ca
40		403-210-9511
41		
42		Word count: Main text (4861 words), abstract (283 words), 3 tables, 1 figure, 3 appendices
43	1	
44 45		
45		
40		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2		
3		ABSTRACT
4	2	
5	3	Objective: The objective of our study was to explore the perspectives of patients and general
6	4	practitioners (GPs) regarding interventions to increase initiation of cholesterol lowering medication (or
7	5	statins), including a proposed laboratory-based facilitated relay intervention.
8	6	statilis), including a proposed laboratory-based facilitated relay intervention.
9 10	7	Design: Qualitative descriptive study using interviews and focus groups for data collection, and thematic
11		
12	8	analysis for data analysis.
13	9	Catting: Driven and and instigate and action to in Calgary, Alberta, Canada
14	10	Setting: Primary care providers and patients in Calgary, Alberta, Canada.
15	11	Perticipants 47 Canada Destition and with animality companyity have descent and and an experimential sections with at
16	12	Participants: 17 General Practitioners with primarily community-based, non-academic practices with at
17	13	least 1 year of practice experience participated in semi-structured interviews. 14 patients at high risk of
18	14	cardiovascular disease participated in focus groups.
19	15	
20	16	Main outcome measures: Exploration of strategies that might be used to enhance the prescription of,
21 22	17	and adherence to statin therapy for patients with statin-indicated conditions.
22	18	
24	19	Results: GPs proposed a variety of interventions to improve statin prescription, including electronic
25	20	record audit solutions, GP directed education and patient-oriented campaigns. Patients expressed that
26	21	they may benefit from being provided access to their laboratory test results, as well as targeted
27	22	education. Both parties provided positive feedback on the proposed laboratory-based facilitated relay
28	23	intervention, while pointing out areas for improvement. Notably, GPs were concerned that the patient-
29	24	directed component of the intervention might jeopardize therapeutic relationships, and patients were
30	25	concerned about accidental disclosure of personal health information. Important considerations for the
31	26	design of facilitated relay messaging should include brevity, simplicity and the provision of contact
32 33	27	information for inquiries.
34	28	
35	29	Conclusions: GPs and patients described several suggestions for increasing statin initiation and
36	30	welcomed the proposal of a laboratory-based facilitated relay strategy. These findings support further
37	31	testing of this intervention which may enhance GPs' ability to successfully engage patients in
38	32	cardiovascular risk reduction through statin therapy.
39	33	
40	34	Keywords: focus groups, qualitative research, interviews, statins, facilitated relay
41		
42 43		
43 44		
45		
46		
47		
48		
49		
50		
51		
52		
53 54		
54 55		
56		
57		
58		2
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1

59

2		
3	35	Strengths & Limitations of this Study
4	36	-
5 6	37	• This is a qualitative study, with relatively few participants – therefore we cannot say definitively
0 7	38	if the views represented here represent those of all patients and prescribers.
8	39	• We sampled physician participants to the point of saturation, which means that we are
9	40	confident the views represented here span the breadth of those held by physicians.
10	41	• The patient sample we recruited may not be representative of the broader population, as many
11	42	of them had previously stated an interest in quality improvement and research – and therefore
12	43	may be attuned to the importance of preventive therapies more than other members of the
13	44	general public. Additionally, this group was not sampled to saturation, as opposed to the
14	45	physician participants.
15	46	 Given the context-dependent nature of qualitative data, the applicability of these findings to
16 17	40	other settings is not certain.
17 18		
19	48	• One of the major strengths of this study is the depth and richness of the qualitative data that
20	49 50	were collected. By asking questions in an open-ended manner, we were able to record detailed
21	50	accounts and opinions.
22	51	
23	52	
24	53	INTRODUCTION
25	54	
26	55	Vascular disease, including coronary artery disease, peripheral artery disease, and cerebrovascular
27 28	56	disease, remains among the leading causes of mortality worldwide (1). A class of medications, HMG-CoA
28 29	57	reductase inhibitors, commonly known as statins, have proven to be effective for lowering the risk of
30	58	vascular events (2). Individuals who have previously had vascular disease (i.e. secondary prevention)
31	59	derive a greater absolute risk reduction from statins than those who have never had vascular disease
32	60	(i.e. primary prevention) (3). There are some individuals who have never had vascular disease, such as
33	61	those with diabetes or chronic kidney disease, who have also been shown in randomized controlled
34	62	trials to benefit from therapy (4-6). Despite over 30 years of clinical use, efficacy, safety and cost-
35	63	effectiveness data (7, 8), only 23% to 55% of individuals who would benefit take this medication and
36	64	fewer than half of individuals are treated to target cholesterol levels (7, 9-11). There is substantial
37	65	unwanted variability in dyslipidemia management, and health system intervention is required to
38 39	66	promote equitable treatment (12, 13). The lack of statin treatment for patients with indicated conditions
40	67	results in significant excess morbidity and mortality. In Canada, specifically, if all patients with
41	68	indications for statins were treated, this would result in nearly 40,000 averted cardiovascular events
42	69	annually (14). In the United States, 13% of cardiovascular deaths could be prevented with perfect statin
43	70	adherence among patients at high cardiovascular risk (15).
44	71	
45	72	Physicians and patients face numerous barriers when it comes to prescribing and adhering to statin
46	73	therapy, from the providers perspective this includes lack of knowledge, conflicting clinical guidelines,
47	74	lack of systems to identify patients who should be taking statins (16). On the other hand, patients often
48 49	75	experience or fear side effects or are simply averse to taking additional medications (16). Furthermore,
50	76	patients that face social disadvantages such as low income, lack of health insurance, and minority race
51	77	are more likely to not use statins (17). A large US-based survey found that side effects were common
52	78	and that many former statin users were unsatisfied with the explanation provided by their prescriber
53	79	about the importance of the medication (18). Providers need resources to help them provide this
54	80	counselling to patients and to arm them with strategies to mitigate common statin side effects, like
55	81	muscle aches (19).
56	82	
57 58		c
JŐ		3

BMJ Open

2		
3	83	There are clearly many challenges that lead to the observed clinical treatment gap for patients who have
4	84	indications for statin treatment. However, some studies have shown that such treatment gaps, in
5	85	related conditions like hypertension, can be closed using quality improvement strategies (20-22).
6	86	Integrated quality improvement strategies that target both patients and healthcare providers are more
7	87	likely to achieve quality indicators than strategies which only target one aspect in isolation (21). One
8 9	88	such strategy is facilitated relay. Facilitated relay is a quality improvement strategy whereby information
9 10	89	about individual patients is sent directly to healthcare providers through a means other than the usual
11	90	clinical encounter (23). Despite the establishment and promotion of facilitated relay and other quality
12	90 91	improvement strategies, there remain significant treatment gaps in hypertension (24) and other chronic
13	92	conditions (25). Furthermore, while facilitated relay has been shown to be effective in improving a
14	93	number of cardiovascular risk factors (21, 26), it remains among the least commonly used quality
15	93 94	improvement strategies (27) and has not been explored in the management of dyslipidemia.
16	94 95	improvement strategies (27) and has not been explored in the management of dysipidemia.
17	95 96	For an intervention to have the potential to yield maximum impact, it is important to qualitatively seek
18 19	90 97	the input of key stakeholders prior to the application of any intervention (28). This allows for the
20	98	
20	98 99	development of a higher quality intervention, rather than one that relies on physician feedback alone (29). As such, the objective of our study was to explore the perspectives of both patients and general
22	99 100	
23	100	practitioners' (GPs) regarding interventions to increase cholesterol lowering medication (or statin)
24		prescription, including specific feedback on a proposed laboratory-based facilitated relay intervention.
25	102	
26	103	METHODS:
27	104 105	Study Design
28 29	105	Study Design
30	106 107	We conducted a qualitative descriptive study (28) to explore patients' and GPs' perspectives on
31	107	interventions to increase initiation of statins for cardiovascular risk reduction and treatment of high
32	108	cholesterol in those at high cardiovascular risk. In addition to generic thoughts on potential hypothetical
33	109	interventions, we specifically sought directed feedback and perceptions on the acceptability of the
34	110	proposed facilitated relay intervention from both patients and GPs (30). We used the consolidated
35	112	criteria for reporting qualitative research (COREQ) as the reporting framework for this study (31).
36	112	
37 38	113	Proposed Intervention
39	114	rioposed intervention
40	115	We drew from behaviour change theory to develop a facilitated relay intervention to increase statin
41	117	prescriptions (32-34) (Figure 1). Our proposed intervention partners with our province's single unified
42	118	laboratory system to identify individuals who have elevated cholesterol levels, statin-indicated
43	119	conditions, and who are not currently filling prescriptions for statins. Our lab system has access to
44	120	province-wide administrative databases, including labs, pharmacy dispensations, and hospitalization
45 46	121	data. For every elevated LDL-cholesterol level, the lab would have an algorithm that would check the
40	122	patients' records for evidence of statin-indicated conditions (administrative markers of myocardial
48	123	infarction, stroke, diabetes, or chronic kidney disease), and would then identify if the patient has
49	124	recently filled a statin prescription. This is possible because of province-wide, linkable databases. For
50	125	patients who are not filling statins, but who should be, their GP (who had ordered the cholesterol level)
51	126	and the patient, will then each receive a letter outlining the indication for treatment and the potential to
52	127	benefit from statin therapy. The patient letter will encourage them to speak to their GP, and the GP
53	128	letter will encourage them to make an appointment to discuss directly with the patient - both with the
54 55	129	objective to initiate or renew statin prescriptions. We felt that it was important to include patients in the
55 56		
57		
50		

58

59

60

facilitated relay to empower them in discussions with their GP and to enable shared decision-making(35), which has been demonstrated to improve adherence with statins (36).

133 Participant Recruitment

General Practitioners: We recruited general practitioners to participate in individual interviews, using a snowball sampling approach. First, we asked key stakeholders in areas of primary care, endocrinology, nephrology and cardiology affiliated with the university medical centre, to recommend community-based (non-academic) GPs to participate in the study. Individuals were then contacted by telephone and email with a formal invitation to participate. GPs who met the following criteria were enrolled: (1) currently practicing in community general practice settings; and, (2) at least one year of experience working as a GP in independent practice. We sampled participants purposively based on several key demographic characteristics in order to achieve representation across a range of ages, genders and practice types.

Patients: We recruited patients who would qualify as recipients of the proposed intervention. Specifically, we were interested in recruiting those at high risk of cardiovascular disease, who self-reported a prior history of high cholesterol, preferably with co-existing vascular disease (myocardial infarction, stroke or peripheral vascular disease), diabetes, or chronic kidney disease. Using a convenience sampling approach, we invited patients who were part of an established advisory panel and previously agreed to be contacted about research opportunities for study participation (37, 38). In addition, patients were recruited using poster advertisements placed throughout the academic health sciences centre and in various clinical care areas where care is provided to patients with diabetes, heart disease and kidney disease.

155 Data Collection

Data was collected from September 2018 to November 2018 using both qualitative semi-structured interviews (with GPs) and focus groups (with patients). We chose focus groups for patients as rich personal disclosures are more likely to occur in this setting than in individual interviews (39). However, we purposely used individually scheduled interviews to offset potential aversion to focus groups by community-based GPs due to their competing clinical demands. Furthermore, we wanted to recruit from both urban and rural locales which is more challenging to do in a focus group.

Question Guides: Both focus groups and interviews were guided by question guides (Appendix A & B) which were developed based on a review of the literature (40, 41) and discussion with the research team. These were designed so that they initially asked study participants what they thought would be effective strategies or interventions to improve statin uptake (i.e. prescribing, patient use and adherence). After they had given their unprompted views, participants were then given a brief explanation of facilitated relay, the specifics of the proposed intervention (Figure 1), and they were shown a copy of the proposed intervention letter for GPs (Appendix C). After briefing participants on the principles and practices of facilitated relay and showing them our preliminary documents for the intervention, we asked them to provide feedback on this proposed intervention.

Provider Interviews: All interviews were conducted in-person (in clinician offices) or via telephone, by a
 female trained research assistant (RCWL) with oversight by experienced study team members. Physician
 interviews were continued until the point of theoretical saturation when no new information emerged

1	
1	
2	
3	177
4	
т —	178
5	
6	179
6	180
7	190
	181
8	
9	182
10	183
11	184
12	185
	102
13	186
14	
	187
15	
16	188
17	189
	190
18	
19	191
20	192
21	193
22	104
	194
23	195
24	
27	196
25	
26	197
27	198
	199
28	199
29	200
30	201
31	
	202
32	
	203
33	204
34	
	205
35	
36	206
37	207
38	208
	200
39	209
40	210
41	
	211
42	
43	212
	213
44	
	214
45	
46	215
47	216
48	217
49	218
50	219
51	
	220
52	

59

60

from the interviews (42). Because the research objective was relatively focused, interviews were briefand lasted approximately 30 to 45 minutes.

Patient Focus Groups: None of the study team were acquainted with or involved in the clinical care of
 the patients who participated. We convened two focus groups in our academic medical centre which
 each lasted approximately 90 minutes. No one but researchers (including 1 facilitator and 2 field-note
 takers) and participants were present. Focus group facilitators tried to ensure that there were no
 dominant members and provide all participants with equal opportunity to voice their opinions.

186 Interviews and focus group proceedings were digitally audio-recorded and transcribed verbatim by a
 187 professional transcriptionist. Field notes were recorded to inform data analysis. All data were
 188 anonymized and stored securely. Signed informed consent was received from each study participant.
 189 Gift cards were provided to all participants. Ethics approval was granted from the University's Health
 190 Research Ethics Board.

92 Data Analysis

94 Analysis was completed using conventional qualitative content analysis (43), a method of interpreting 95 interview data with the goal of describing the phenomenon of interest. Transcripts for the initial three 96 interviews were reviewed by three team members (DJTC, RCWL and SB), with the objective of 97 inductively establishing a preliminary coding template that was used for subsequent data analysis. All 98 transcripts were then analyzed by two reviewers (DJTC and RCWL). Codes were generated from the 99 interview data and systematically applied to identify themes and patterns. The process was iterative, 00 reflexive, and interactive as continual data collection and analysis shaped each other. For example, code 01 titles or definitions identified based on earlier interviews were modified according to the data collected 02 during subsequent interviews. The team met together to review the coding to elicit discussion about the 03 coding strategy and attempted to achieve consensus to resolve coding discrepancies. NVivo 12 04 (Doncaster, Australia) qualitative data analysis software was used to facilitate the coding process.

206 **Patient and public involvement**

Patient partners and family members from the Libin Cardiovascular Institute's established patient and family member advisory group (44) voiced that *prevention* was one of their top research priorities for cardiovascular health. This work is related to prevention of cardiovascular disease. Patients were included in focus groups.

13 **RESULTS**

15 In total, we eventually reached out to 27 GPs to invite them to participate, 4 declined to participate, 4 16 didn't respond to the invitation, 19 were scheduled for interviews, with 2 cancelling. We reached 17 saturation after having completed 17 individual GP interviews (Table 1a). The majority were women 18 (88%) with 65% having graduated from medical school within the last ten years. All GPs spent more 19 than 50% of their time in clinical practice, most were in urban centers within Primary Care Networks 20 (PCNs). PCNs are networks of GPs that share interdisciplinary resources to enhance the delivery of 221 primary care within geographical regions (45); they are associated with improved chronic disease care 53 222 and outcomes(46). 54 223 55

56 224 **Table 1a.** Descriptive statistics for General Practitioners (n = 17).

	Physician characteristics	Total (%)
	Age (years)	
	< 40	13 (76)
	40 - 60	4 (24)
	Gender	
	Man	2 (12)
	Woman	15 (88)
	Years of primary care practice	
	< 10	14 (83)
	10 – 20	3 (18)
	Years since medical school graduation	- ()
	< 10	11 (65)
	≥10	6 (35)
		0 (33)
	Primary Care Network membership	1E (00)
	Yes	15 (88)
	No	2 (12)
	Location of primary care practice	
	Urban	13 (76)
	Rural	4 (24)
	Focused practice interest	
	Yes*	9 (53)
	No	8 (47)
	Clinical practice last 12 months	
	Estimated number of patients at high CVD risk	
	< 20	1 (6)
	20 to 99	7 (41)
	≥100	9 (53)
		5 (55)
	Use of endocrinology consultation services	F (20)
	Yes	5 (29)
	No	12 (71)
	Use of cardiology consultation services	
	Yes	10 (59)
	No	7 (41)
	Use of nephrology consultation services	
	Yes	3 (18)
	No	14 (82)
		· · /
	Proportion of patients in their practice who would be	Mean: 32%
	considered high risk on the basis of cardiovascular risk	Range 10-75%
	factors (n=14)	
	Descention of high viel postions in the incomption of the terms	
	Proportion of high-risk patients in their practice who have a	
	current LDL-level on file (n=9)	Range 70-90%
5	* Focused practice, or special interest types: care of the elderly	
26	urgent care (n = 1), refugee medicine (n = 1), obstetrics (n = 2),	indigenous health (n = 2), la
27	1).	
	7	
		to /ob out /out dollar
	For peer review only - http://bmiopen.bmi.com/si	revapour/ourgennes xntml

58

59

60

BMJ Open

1		
2		
3	228	
4	229	
5	230	Our patient focus groups had 8 and 6 participants, respectively (Table 1b). There was a range of ages
7	231	represented among patients, with a similar number of men and women. Nearly all had a general
8	232	practitioner and were also followed by medical specialist(s). The conditions represented in our patient
9	233	group were diabetes, history of myocardial infarction and elevated cholesterol level; none reported a
10	234	history of stroke, chronic kidney disease, or peripheral arterial disease.
11	235	

Table 1b. Descriptive statistics for patient participants based on self-report (n = 14).

12	230	Table 15. Descriptive statistics for patient participants based	on self-report (n = 14).
13 14		Patient characteristics	Total (%)
14		Age (years)	
16		< 40	2 (15)
17		40 - 60	5 (39)
18		> 60	6 (46)
19		Gender	
20		Men	6 (46)
21		Women	7 (54)
22		Chronic condition qualifying as "high CVD risk"	7 (34)
23		High cholesterol only	3 (23)
24			
25		Diabetes only	6 (46)
26		Myocardial infarct (MI) only	1 (8)
27		Diabetes & MI	3 (23)
28		Has a primary care provider	
29		Yes	12 (92)
30		No	1 (8)
31		Followed by a medical specialist	
32		Yes	10 (77)
33 34		No	3 (23)
35		Self-reported awareness of high cholesterol levels	
36		Yes	11 (85)
37		No	2 (15)
38		Current use of statin medication	- ()
39		Yes	6 (46)
40		If not, had spoken with physicians about statins	3 (23)
41		If not, had not spoken with physicians about statins	4 (31)
42			+(31)
43		*Note one participant did not complete a demographic	
44		questionnaire	
45	237		
46	238		
47	239	General suggestions for potential interventions	
48 40	240		
49 50	241	Several themes arose regarding interventions to improve sta	tin initiation during the unprompted
50 51	242	portion of the interviews (Table 2). GPs described that statin	prescribing may be improved by: (1)
51	243	enhancing aspects of physician education to promote appropriate ap	priate statin prescribing; and, (2)
52	244	implementation of support tools to help physicians in decision	
54	245	whom statins are indicated. In addition, patients suggested t	-
55	246	results may enable them to be more effective self-advocates	-
56	247		-
57	~ r/		

Providers	Treatment of	Patients with chronic kidney disease:
	specific Sub- populations	"I struggle with the GFRs [glomerular filtration rate] – knowing when it would be safe, when it wouldn't be safe. I do get confused as to the dosing based on GFR." (GP-05)
		Patients who previously experienced side effects with statin(s): <i>"I have one strategy but if somebody is still like 'no, it's completely not tolerable for me' then I don't know what the next step is after that."</i> (GP-13)
		Elderly patients:
	Ç	"getting some better understanding about the elderly. Are there any contraindications to starting on statin therapy? Is there one statin that may be more beneficial than another?" (GP-10)
		Patients with hypertriglyceridemia:
		"I always find it hard to know what to do with triglycerides more
	Treatment to	education around how to manage those [patients]." (GP-15) "Most people in my office are confused about what we are doing in
	Targets *	terms of treating to the target of 2 mmol/L, because the cardiologist is still sending consults about that, but then we have these family medicine evidence-based groups saying that targets don't matter".
		(GP-02)
		"I know the TOP [Towards Optimized Practice] guidelines don't necessarily correlate with CCS [Canadian Cardiovascular Society] guidelines, so there are several schools of thought". (GP-09)
		"There's no real way to unify the guidelines, but to have an education session on why they're different and how to approach it so maybe you'll break down patient populations that fit better with one guidelin versus another". (GP-08)
	Preferred modality of Education	"we have a lot of drug reps [representatives] coming to town, so it would be great to have more [education] that was not pharma, absolutely". (GP-04)
	EMR-based tools	"One thing that would be helpful for me is if there was some automati flag that came when I saw a patient that would alert to the fact that their treatment is not optimized for their conditions". (GP-06)
Patients	Laboratory Results	"I would like to get a copy, in addition to the doctor. I can do with it what I want" (Pt-09)
		"It gets you questioning things so that you can come back to your doctor and say 'I saw these numbers, what does that mean? What do need to do?'" (Pt-02)

1 2		
3		Enhanced "What if somebody was going regularly to a lab, and a clinician sort of
4		education goes: 'How are you doing on this?". (Pt-08)
5 6	248	EMR: electronic medical record
0 7	249	* Specialist guidelines, the 2016 Canadian Cardiovascular Society guideline (47) advocates that patients
8	250	at high risk (based on risk calculators) or those with 'statin-indicated conditions' (defined as diabetes,
9	251	chronic kidney disease, or preexisting vascular disease be treated with statin therapy to achieve a target
10	252	LDL-c level of < 2.0 mmol/L. GP Guidelines, the 2015 TOP Alberta Guideline (48) encourages GPs to treat
11	253	high risk patients with moderate-to-high intensity statins and should not repeat lipid levels, or attempt
12	253	to treat to a fixed target.
13		
14	255	
15	256	
16	257	1) General practitioner <i>education:</i>
17	258	
18	259	Nearly all GPs highlighted that there are general areas of knowledge that could be bolstered in order to
19	260	enhance statin prescription. One of the main content areas in which they sought enhanced education
20	261	related to the treatment of specific patient sub-populations, in particular those with chronic kidney
21	262	disease, patients who have had prior statin intolerance/side-effects, elderly patients, and those with
22	263	other concurrent lipid disorders (i.e. hypertriglyceridemia).
23 24	264	
24 25	265	Whether providers should be treating patients to a specific cholesterol level was a major source of
26	266	confusion. They frequently referenced receiving conflicting advice, including a contradiction in clinical
27	267	practice guidelines(49), some of which advocate for a 'fire and forget' approach(8, 50), while
28	268	Canadian(7) and European(51) specialist guidelines recommend a 'treat-to-target' approach(7).
29	269	
30	270	Regarding the modality of education sessions, most preferred in-person education sessions delivered at
31	271	their clinics and delivered by someone who did not have clear conflicts of interest with pharmaceutical
32	271	companies. Many GPs also suggested the use of handouts, tools or algorithms to simplify their decision-
33	272	
34	273	making process.
35		2) Concerni prostitionen teolo
36	275	2) General practitioner tools
37	276	
38 39	277	In addition to education, several GPs suggested that the use of automated tools would facilitate their
39 40	278	prescribing of statins. Most felt that they would benefit from optimizing the use of their electronic
40	279	medical records (EMR) to 'flag' individuals who were at high cardiovascular risk or had elevated
42	280	cholesterol levels. Other GPs spoke of wishing for a 'running list' of eligible patients, while some
43	281	mentioned using an employee or contractor designated as a panel manager to perform these tasks.
44	282	
45	283	3) Patient results and information
46	284	
47	285	Many patients independently indicated that they would like to have access to their lipid test results,
48	286	without needing to rely on this being conveyed to them by their general practitioner. Some patients also
49	287	suggested that providing them with their own results might reduce the frequency of unnecessary follow-
50	288	up visits; and as a result, alleviate related financial burden on the healthcare system. Doing so was also
51	289	thought to help foster patient engagement with their GP.
52	290	
53	291	Patients also felt that having greater access to information about cholesterol and treatment might
54 55	292	facilitate more patients being on statin therapy. Suggestions were made to deliver this through
55 56	292	enhanced patient-facing materials (i.e. brochures), as well as pharmacists or lab technicians who were
56 57	293	ennanced patient-facing materials (i.e. brochures), as well as pharmacists of idd technicidiis Who were
57 58		10
59		10
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

able to discuss results and treatment options. Further information about patient education, shared decision-making, and clinical decision support tools are described in our other report from this work (16). Feedback on the proposed facilitated relay intervention Emerging themes regarding our proposed intervention were organized into four major categories: (1) general feedback and impression; (2) suggested changes; (3) intervention details; and, (4) workflow processing considerations. 1) General feedback and impression General practitioners responded to the proposed intervention with strongly positive feedback (Table 3), which included stating that they found the information to be helpful and direct. They generally felt that the letter was written in a clear fashion and with a respectful tone. Several mentioned that the information provided them with reassurance and credibility in making recommendations to their patients. GPs also voiced some questions and potential concerns after hearing about our proposed intervention. These concerns included whether the introduction of a facilitated relay intervention might increase their workload, lead to possible disclosure to patients of new diagnoses of conditions that qualified them as high risk (i.e. diabetes), and pose a threat to their therapeutic relationships with patients. In addition, logistical issues around how the letter will be best delivered to ordering providers and patients were raised as concerns. Patients generally felt that bringing their facilitated relay letter to a scheduled appointment would be positive in their relationship by providing structure to the follow-up encounter, holding GPs to account, and enhancing patient-provider communication. Even though most were generally positive, some patients expressed concern about the facilitated relay intervention, including the possibility for privacy breaches and increasing patient anxieties. 2) Suggested information to remove or add We asked GPs specifically what they would like to see changed in the preliminary materials shown. Almost unanimously, they suggested that the letter would be more appreciated if it the two-page document were shortened to fit on one page. Several participants suggested removing the references, mention of clinical studies, and guideline citations to make it more reader-friendly. There was also a preference voiced for revising the introductory paragraphs to have direct relevance to individual patient(s): "I'm going to read it for sure, but then when you start to read it, people might put it down and say 'oh this is a study intervention', [but] if you have the first thing at the very top: 'you know this person has been identified as being at risk' – then it's about the patient rather than being about the studies". (GP-16) A few GPs voiced opinions that specific additions could be made to improve the letter's utility. These suggestions included adding: information about health behavior change ("the whole picture, as opposed to just medication" (GP-04)); adding contact information for a specialist; and details about how/why a For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2		
3	342	particular individual was flagged as eligible for the facilitated relay intervention: "It would be helpful if I
4 5	343	got a name, condition and then the statin-indicated condition, and where the condition was pulled
5 6	344	from". (GP-01)
7	345	
8	346	Patient feedback was notable for also suggesting that the intervention provide contact information, in
9	347	case they have further questions about interpreting their results: <i>"back that up with a helpline for</i>
10	348	somebody that doesn't know what the [results] mean" (Pt-10). Similar to physicians, patients expressed
11	349	a strong preference for brevity: "If I have to go through 14 pages of information to figure out what that
12	350	means, I'm sorry, I don't have time for that" (Pt-07).
13	351	
14	352	However, numerous patients also stressed the importance of not only providing results or diagnoses,
15		
16	353	but also giving some basic education and an action plan to follow.
17	354	
18	355	3) Intervention details
19	356	
20	357	In addition to general feedback, we also explicitly asked GPs whether they would prefer to receive
21	358	information about their patient in the form of facilitated relay (individual letter for each patient
22 23	359	identified) or 'audit and feedback' (summary report including a group of their patient panel). A summary
23 24	360	list or report (audit and feedback) was preferred by roughly 2/3 of the general practitioners interviewed.
25	361	Regarding receiving letters for each patient, participants stated:
26	362	
27	363	"this is going to get tiresome very quickly" (GP-05)
28	364	
29	365	"Am I going to get this letter 20 times? I'm probably just going to read it once" (GP-03)
30	366	
31	367	"[a list would] decrease paper burden, decrease the chance of it getting misplaced". (GP-13)
32	368	
33	369	While the 'audit and feedback' approach was more popular, some GPs were clearly in favor of facilitated
34	370	relay: "I can't even think of the amount of work it would take to do it patient-specific. I'd love it. Sure go
35	371	for it, if you have the means to do it, then why not?" (GP-10)
36 37	372	
37 38	373	We also asked pointedly about how providers would feel about receiving a follow-up reminder from the
39	374	study team, if patients had not filled the prescription as recommended in the initial letter. The response
40		
41	375	was split with roughly half of the general practitioners stating that a reminder would not be necessary.
42	376	These whe falls a remainder would be accordable and well, accord that a Correct window should be
43	377	Those who felt a reminder would be acceptable generally agreed that a 6 month window should be
44	378	sufficient to ascertain whether or not the patient would have started on therapy: "There are people that
45	379	have a three-month wait list time, you may have to pick an interval more like six-months to appeal to the
46	380	<i>masses"</i> . (GP-13)
47	381	
48	382	Most patients felt that they would benefit from receiving a follow-up reminder. After considerable
49 50	383	discussion amongst the groups, consensus was achieved that follow-up should not happen prior to four
50 51	384	months, and possibly even as long as six months after the initial contact. One participant stated: "close
52	385	enough that I vaguely remember that I meant to do something with that, but not a few weeks later, [so]
52	386	it's not irritating". (GP-17)
54	387	
55		
56		
57		
58		12
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

We also asked patients if they had a preference for who had signed the letter. Most felt that having letters come from a local specialist in cardiology or endocrinology would be preferable to having them signed by another GP.

4) Workflow processing considerations (General practitioners only)

To each GP we asked specific details about how our intervention letter would be received in their offices and what would happen upon receipt. The majority stated that such a letter would be opened and processed by their front-desk staff. One participant clarified that the information on the envelope would determine who opened it: "if it's addressed to me then it will come to me, if it has a patient name for me, then it goes through our document people [who file it]". (GP-09)

Once the letter has been opened, different offices employed a variety of different processes. In many practices, it would be given directly to the GP; while in others it would be scanned directly into a patient's file in an electronic medical record, yet in others, the hardcopy would be filed in a patient's chart.

In terms of the preferred delivery modality, most GPs felt that electronic delivery directly via the EMR platform would be the preferred method of receiving the intervention. However, a number still felt that conventional delivery via paper mail or fax would be preferable. Even those who expressed a preference for conventional delivery, many elaborated that such letters would often be scanned into a patient's electronic file: "if it was to come by mail or fax, then they have to scan it onto the computer" (GP-11). A few GPs described systems which can do this process automatically: "our office works with a new web system, so everything that comes in via the fax actually goes directly into the computer and they then allocate to the patient". (GP-11)

Table 3. Positive and negative feedback on facilitated relay intervention from general practitioners and patients

(General Practitioners	4	Patients
	Ро	sitive	
Composition	"Overall I thought it was worded quite well and was very clear" (GP- 08) "I think it's appropriate, it didn't take me very long to get through" (GP-16)	Provides structure to interaction	"My doctor would be okay with that It gives them a little checklist of things to talk about". (Pt-05)
Tone	"it's written in a way that doesn't make you feel stupid, I guess" (GP- 11) "it's good because [it's] not telling you to do this [start statin therapy], but telling you to have a conversation]." (GP-17)	Enhances communication	"I think that's good 'cause these doctors, some guys don't communicate." (Pt-13)

Credibility	"it gives family physicians more	Increases	"I think it keeps them [doctors]
	confidence to do those things and	doctor	honest as well. They should actually
	know the specialists are behind	accountability	be proactive in terms of having that
	them in that recommendation"		information already, but that's not
	(GP-02)		always the case. So I don't have a
			problem with a patient having all
	"there's so much information for		their information at their disposal".
	people to sift through if you can		(Pt-14)
	get valid information that's		
	corroborated and consistent, that's		
	helpful" (GP-15)		
Direct	"it's a good idea it tells you what	Increases	"If [patients] are encouraged to wor
	to do, which is great. You don't	patient	with their doctor to monitor your
	have to look up the guideline every	accountability	numbers, you have a bit of control a
	time" (GP-04)		well as the doctor like working
			together". (Pt-03)
	"it's just one of those extra little		
	reminders that takes the brain		
	power out of the work you have to		
	do day-to-day" (GP-06)		
Information	"[side effects] are what people hear	Provides peace	"It gives me a little peace of mind in
	about in the news a lot, so it's very	of mind	that we've talked about all of the
	helpful to have some numbers		things that are important and that
	around it, and strategies to address		should be covered that we haven'
	that" (GP-09)		left anything out". (Pt-05)
	"All the suggestions that you made		
	"All the suggestions that you made are excellent. I'm reading through		
	this and I'm like ' oh yeah, I didn't		
	realize this' and ' this is something I		
	can do for some of my patients'"		
	(GP-12)		
	(0, 22)		
		gative	
Increased	"I would caution against anything	Privacy	"You know what, my doctor isn't
workload	that causes more documents or	concerns	going to send it out to me, anyway.
	more paperwork there's already		It's going to go on to a receptionist,
	so much" (GP-16)		who might pass it on to somebody
			else in the office, so there's no
			guarantee of privacy there" (Pt-05)
			"Privacy is always an issue. I mean i
			like, the less information that's out
			there about you, the better off you
			are, period. I don't care what it is"
			(Pt-07)

[Disclosing new	"my concern is that they get this	Difficulty	"Some people might know all the
	diagnoses	information from a letter my	interpreting	numbers and everything else, I don't.
		preference would be that it came	results	You give me a bunch of numbers, it
		straight to me" (GP-01)		means nothing to me. So unless the
				doctor explained it to me I'd rather
				talk to my doctor" (Pt-07)
	Therapeutic	"If the patient gets a letter that's	Provoking	"There are people who are coming
	relationship	like 'you need to be on a statin' and	Anxieties	down with every disease known to
	•	we already had a conversation that		man, so for someone like that, that
		they didn't need a statin. That		kind of information would just send
		could cause some issues in the		them off the deep-end, right?" (Pt-
		therapeutic relationship." (GP-04)		05)
	Logistical	"What if a person gets a check from	Lack of	"You mentioned mail outs and things
	concerns	a walk-in clinic? My concern is then	engagement	like that have they proven to be
		is that walk-in clinic docs are just		effective, though, 'cause how many
		going to ignore this letter" (MD-05)		people read them? How many people
				understand them? I don't think there
		"If it goes to the patient,		would be a lot of point in it, 'cause I
		sometimes you get lots of mail and		don't think people pay that much
		they may just discard it" (MD-10)		attention" (Pt-09)
			Sense of	"Some will [say] 'I can't talk to my
			intimidation	doctor like that'. There will be some
				people who might be intimidated to
				initiate that conversation" (Pt-03)
414				
415				
416	DISCUSSION			
417				
418		have a more limited role in certain pop		
419		52, 53), they are important for the prev		
420		vascular disease and in those with dial		
421		patients acknowledged that there is the	•	
422	••	among those at high risk for cardiovas		
423	-	I that there was a need for improved pl	•	· · ·
424	• •	nd track patients would be helpful. Pat		
425		t results and information on treatment	• •	-
426		porting our hypothesis that facilitating s		
427		ition. When shown the proposed interv		
428		relay intervention. While there were c		
429		re raised by both GPs and patients. In g	-	•
430		ontain high yield information and prov	ide contact morma	ation where clarification could be
431	sought.			
432 433	Manyintoryor	tions have been attempted to address	the problem of sta	tin underuse. A number of
433 434	•	ntions have been attempted to address	•	
	•	red approaches have been tried with va		
435 436		e cognitive education and behavioural on re often unsuccessful at changing beha	-	• • •
u≺n	or education a	ne onten unsuccessiul at changing bena	aviour, as in the rec	ETTE ISLAND UTAL WHICH TOUND

437 their intervention, comprised of a mail and phone education strategy to encourage patients to take

prescribed medication, had no impact on adherence (55). Others have found that multifaceted
interventions focusing on enhancing care provision through team-based care may be effective at
increasing statin adherence (56).

- However, when trying to target the problem of low statin prescribing, interventions directed only at patients are not likely to work. An alternate approach is to facilitate GPs ability to identify and prescribe statins, to those in whom they are appropriate (57), through audit and feedback or facilitated relay. An educational audit and feedback intervention regarding dyslipidemia treatment in Italian primary care practices was shown to increase adherence to statins by approximately 10% (58). Improved communication and shared decision making, which are explicit goals of facilitated relay interventions, can improve patient adherence (59). While these and other studies have reviewed the clinical efficacy of quality improvement strategies (21), few have used detailed qualitative methods as we have done. One large qualitative study interviewed audit and feedback experts to generate hypotheses about the various factors that may contribute to the efficacy of such interventions (60). Others have used qualitative methods to highlight the barriers physicians face in encouraging adherence (61), but ours is unique in using such methods to design and develop an intervention to address these challenges. Finally, we also appreciate that as much as there is underuse of statins, there is also overuse, for example, in people with short life expectancy. Perhaps interventions to increase initiation may also include a component that conveys statin benefits are measured in years rather than months.
- The fact that participants suggested elements of our facilitated relay intervention in the unprompted portion of the interviews lends credibility and face validity to the proposed intervention. However, it is notable that while GPs felt they would benefit from having internal systems to monitor patients' records, none independently suggested a strategy mediated by an independent third party (such as facilitated relay or audit and feedback), as we have proposed. Investigators who wish to implement facilitated relay interventions to enhance adherence to medical therapies can use the findings of this study to help develop interventions that are more likely to be acceptable to both GPs and patients. One of the main findings is to ensure that any information provided is brief and high yield, containing patient identifiers early to capture general practitioner's attention. Such interventions can be strengthened by incorporating education on controversial or little-known topics. Patients strongly preferred any correspondence to also contain direct suggestions or an action plan. Workflow and processing of these letters needs to be considered and interventions designed to be as minimally disruptive to clinical practice as possible – with most physicians preferring that it be embedded directly within the EMR; yet in healthcare settings (like ours) where there is marked heterogeneity in the use and type of EMRs, this may not be possible.
- There are limitations to this study. Firstly, as in most qualitative studies, the number of participants was relatively small. This concern over sample size is mitigated by the fact that physician interviews proceeded until the point of saturation. Patient data were not collected in this manner, and these themes may not be fully saturated and we appreciate this as a limitation. Furthermore, the patient sample we recruited may not be representative of the broader population, as many of them had previously stated an interest in quality improvement and research and therefore may be attuned to the importance of preventive therapies more than other members of the general public. Secondly, given the context-dependent nature of qualitative data, the applicability of these findings to other settings is not certain. Yet physicians in most settings face similar problems (i.e. time constraints, patient complexity and comorbidities and patient resistance to medical therapies) in numerous facets of medical care; therefore, it is conceivable that the findings of this study would apply to interactions between patients and GPs in other clinical settings. Due to time constraints of participants and researchers, member

1		
2		
3 4	486	checking was not undertaken in this study. Finally, it is important to note that feedback was sought
5	487	specifically about the proposed intervention. However, given the details reported, we feel that these
6	488	findings are likely to be helpful to others proposing similar quality improvement interventions. One of
7	489	the major strengths of this study is the depth and richness of the qualitative data that were collected. By
8	490	asking questions in an open-ended manner, we were able to record detailed accounts and opinions.
9	491	Another strength of this work is the fact that we also sought patient input into the development of this
10	492	intervention, rather than relying on physician feedback alone.
11	493	
12	494	Statin therapy has been demonstrated to effectively lower cholesterol and reduce the risk of
13	495	cardiovascular events and death in individuals at high risk of cardiovascular disease. Despite this, they
14 15	496	remain underused. There are patient, provider and system factors that contribute to statin underuse.
15 16	497	Facilitated relay interventions hold promise as a potential method to address this important care gap.
17	498	Our study sought perspectives of both healthcare providers and patients, which will be incorporated
18	499	into intervention design to maximize acceptability. Insights gained from qualitative data will be used to
19	500	improve the likelihood of success and achieve the desired clinical impact. The insights about these
20	501	interventions are also likely to be of interest to many researchers and clinicians who are considering and
21	502	designing provider- and/or patient-facing interventions to improve the uptake of preventive
22	503	medications.
23	504	
24	505	Contributions
25	506	DJTC, RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and
26 27	507	methods. The study design was conceived by DJTC and SB. DJTC wrote the first draft of the study
27 28	508	protocol. Data collection and analysis was completed by DJTC, RCWL and SB. KAM, TJA, HQ, AACL, GC,
20 29	509	ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of
30	510	the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed
31	511	substantively to further revisions of the manuscript and have consented to the publication of this
32	512	version.
33	512	
34	513 514	Funding
35	514 515	Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada.
36	515	Funding for this project was provided by a research grant to soma butana nom Diabetes Canada.
37		Data Availability Statement
38 39	517	
40	518	No additional data available. Given that qualitative data are not deidentified and tell individuals'
41	519	personal stories, data cannot be shared beyond the scope of this project, as per our research ethics
42	520	board.
43	521	
44	522	Competing Interest Statement
45	523	DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently
46	524	offer testing in the jurisdiction under study.
47	525	
48	526	
49 50		
50 51		
52		
53		
54		
55		
56		
57		
58		17
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
00		


BMJ Open

1		
2		
3	527	References
4	528	
5	529	1 Morld Health Organization. The ten 10 causes of death 2018 [Available from:
6 7	529 530	 World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
8	530	2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association
9	532	Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions:
10	533	A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97.
11	534	3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ.
12	535	2019;367:15674.
13 14	536	4. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary
14	537	prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative
16	538	Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet.
17	539	2004;364(9435):685-96.
18	540	5. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of
19	541	lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study
20 21	542	of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92.
21	543	6. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative G. MRC/BHF
23	544	Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a
24	545	randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-16.
25	546	7. Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian
26	547	Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of
27	548	Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2016;32(11):1263-82.
28 29	549	8. Grundy SM, Stone NJ. 2018 American Heart Association/American College of
30	550	Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention.
31	551	JAMA Cardiol. 2019;4(6):589-91.
32	552	9. Butalia S, Lewin A, Simpson S, Dasgupta K, Khan N, Pilote L, et al. Sex-based disparities in
33	553	cardioprotective medication use in adults with diabetes. Diabetol Metab Syndr. 2014;5(6):117.
34 35	554 555	10. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R, et al. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the
36	556	Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2013;29(2):151-67.
37	557	11. Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular Risk and Statin Use in
38	558	the United States. The Annals of Family Medicine. 2014;12(3):215-23.
39	559	12. Gamble JM, Butalia S. Medical Practice Variations in Diabetes Mellitus. In: Johnson A, Stukel T,
40	560	editors. Medical Practice Variations. Health Services Research: Springer US; 2015. p. 1-40.
41 42	561	13. Tu JV, Chu A, Maclagan L, Austin PC, Johnston S, Ko DT, et al. Regional variations in ambulatory
43	562	care and incidence of cardiovascular events. Canadian Medical Association Journal. 2017;189(13):E494-
44	563	E501.
45	564	14. Hennessy DA, Tanuseputro P, Tuna M, Bennett C, Perez R, Shields M, et al. Population health
46	565	impact of statin treatment in Canada. Health Rep. 2016;27(1):20-8.
47	566	15. Yang Q, Zhong Y, Gillespie C, Merritt R, Bowman B, George MG, et al. Assessing potential
48 49	567	population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases
50	568	in the USA: population-based modelling study. BMJ Open. 2017;7(1):e011684.
51	569	16. Butalia S, Lee-Krueger R, McBrien K, Leung A, Anderson T, Quan H, et al. Barriers and Facilitators
52	570	to Using Statins: A Qualitative Study with Patients and Family Physicians Canadian Journal of Cardiology
53	571	Open. 2020;Online ahead of print.
54 55		
55 56		
57		
58		18
59		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60		for peer review only - http://binjopen.binj.com/site/about/guidelines.xhtml

17. Schroff P, Gamboa CM, Durant RW, Oikeh A, Richman JS, Safford MM. Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. J Am Heart Assoc. 2017;6(9). 18. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208-15. 19. Jacobson TA, Khan A, Maki KC, Brinton EA, Cohen JD. Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. J Clin Lipidol. 2018;12(1):78-88. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in 20. primary care: a systematic review. CMAJ. 1997;156(12):1705-12. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality 21. improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012;379(9833):2252-61. Rash JA, Campbell DJ, Tonelli M, Campbell TS. A systematic review of interventions to improve 22. adherence to statin medication: What do we know about what works? Prev Med. 2016;90:155-69. 23. Walsh J, McDonald KM, Shojania KG, Sundaram V, Nayak S, Davies S, et al. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies (Vol 3: Hypertension Care). AHRQ Technical Reviews. Rockville (MD)2005. 24. Zhang Y, Moran AE. Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension Among Young Adults in the United States, 1999 to 2014. Hypertension. 2017;70(4):736-42. 25. Jardine MJ, Kasiske B, Adu D, Alrukhaimi M, Ashuntantang GE, Basnet S, et al. Closing the gap between evidence and practice in chronic kidney disease. Kidney Int Suppl (2011). 2017;7(2):114-21. 26. Walsh JM, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, et al. Quality improvement strategies for hypertension management: a systematic review. Med Care. 2006;44(7):646-57. 27. Campbell DJ, Sargious P, Lewanczuk R, McBrien K, Tonelli M, Hemmelgarn B, et al. Use of chronic disease management programs for diabetes: in Alberta's primary care networks. Can Fam Physician. 2013;59(2):e86-92. 28. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):7. Pope C, van Royen P, Baker R. Qualitative methods in research on healthcare quality. Qual Saf 29. Health Care. 2002;11(2):148-52. 30. Ayala GX, Elder JP. Qualitative methods to ensure acceptability of behavioral and social interventions to the target population. J Public Health Dent. 2011;71 Suppl 1:S69-79. 31. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-57. 32. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. 33. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7:37. Michie S, Johnston M, Francis J, Hardeman W, Eccles M. From Theory to Intervention: Mapping 34. Theoretically Derived Behavioural Determinants to Behaviour Change Techniques. Applied Psychology. 2008;57(4):660-80. 35. Barrett B, Ricco J, Wallace M, Kiefer D, Rakel D. Communicating statin evidence to support shared decision-making. BMC Fam Pract. 2016;17:41. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, et al. Helping patients with 36. type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167(10):1076-82. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2		
3	620	37. Santana M, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Working Together with
4	621	Patients and Clinician Researchers to Improve Cardiovascular Health. 2018 SPOR Summit; Ottawa, ON.
5	622	38. Santana M, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Working Together: Co-
6	623	designing Priorities for Patient-Oriented Cardiovascular Research by Patients, Clinicians, and
7 8	624	Researchers. Canadian Association for Health Services and Policy Research (CAHSPR); Halifax, NS2019.
9	625	39. Guest G, Namey E, Taylor J, Eley N, McKenna K. Comparing focus groups and individual
10	626	interviews: findings from a randomized study. <i>Int J Soc Res Methodol</i> . 2017;20(6):693-708.
11	627	40. Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the implementation
12	628	of coronary heart disease prevention in primary care. Br J Gen Pract. 2003;53(494):684-9.
13	629	41. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to
14	630	long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291.
15 16	631	42. Walker JL. The use of saturation in qualitative research. Can J Cardiovasc Nurs. 2012;22(2):37-
17	632	46.
18	633	43. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res.
19	634	2005;15(9):1277-88.
20	635	44. Santana MJ, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Patients, clinicians and
21	636	researchers working together to improve cardiovascular health: a qualitative study of barriers and
22	637	priorities for patient-oriented research. BMJ Open. 2020;10(2):e031187.
23 24	638	45. Drew P, Jones B, Norton D. Team effectiveness in primary care networks in Alberta. Healthc Q.
24	639	2010;13(3):33-8.
26	640	46. Manns BJ, Tonelli M, Zhang J, Campbell DJT, Sargious P, Ayyalasomayajula B, et al. Enrolment in
27	641	primary care networks: impact on outcomes and processes of care for patients with diabetes. Canadian
28	642	Medical Association Journal. 2012;184(2):E144-E52.
29	643	47. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian
30	644	Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of
31 32	645	Cardiovascular Disease in the Adult. Can J Cardiol. 2016;32(11):1263-82.
33	646	48. Toward Optimized Practice Cardiovascular Disease Risk Working Group. Prevention and
34	647	management of cardiovascular disease risk in primary care clinical practice guideline Edmonton, AB:
35	648	Toward Optimized Practice; 2015 [Available from:
36	649	https://top.albertadoctors.org/CPGs/Lists/CPGDocumentList/CVD-Risk-CPG.pdf.
37	650	49. Tibrewala A, Jivan A, Oetgen WJ, Stone NJ. A Comparative Analysis of Current Lipid Treatment
38	651	Guidelines: Nothing Stands Still. J Am Coll Cardiol. 2018;71(7):794-9.
39 40	652	50. Toward Optimized Practice (TOP) Cardiovascular Disease Risk Working Group. Prevention and
40	653	management of cardiovascular disease risk in primary care clinical practice
42	654	guideline 2015 [Available from:
43	655	http://www.topalbertadoctors.org/download/1655/Lipid%20Pathway%20CPG.pdf? 20150916105016.
44	656	51. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS
45	657	Guidelines for the Management of Dyslipidaemias. Rev Esp Cardiol (Engl Ed). 2017;70(2):115.
46 47	658	52. Kristensen M, Christensen PM, Hallas J. The effect of statins on average survival in randomised
47 48	659	trials, an analysis of end point postponement. BMJ Open. 2014;5(007118).
49	660	53. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular
50	661	disease take a statin? BMJ. 2013;347:f6123.
51	662	54. Jornten-Karlsson M, Pintat S, Molloy-Bland M, Berg S, Ahlqvist M. Patient-Centered
52	663	Interventions to Improve Adherence to Statins: A Narrative Synthesis of Systematically Identified
53	664	Studies. Drugs. 2016;76(15):1447-65.
54 55		
55 56		
57		
58		20
59		Ear poor raviou and http://bmianan.hmi.com/site/abaut/suidalinaa.ubted
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

55. Ivers NM, Schwalm JD, Bouck Z, McCready T, Taljaard M, Grace SL, et al. Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial. BMJ. 2020;369:m1731. 56. van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R. Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev. 2016;12:CD004371. Kaya H, Beton O, Yilmaz M. How to increase level of patients' awareness regarding the 57. importance of statins despite the influence of the media? International Journal of Cardiology. 2016;207:164. 58. Casula M, Tragni E, Piccinelli R, Zambon A, De Fendi L, Scotti L, et al. A simple informative intervention in primary care increases statin adherence. Eur J Clin Pharmacol. 2016;72(2):227-34. 59. Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566-77. Colquhoun HL, Carroll K, Eva KW, Grimshaw JM, Ivers N, Michie S, et al. Advancing the literature 60. on designing audit and feedback interventions: identifying theory-informed hypotheses. Implement Sci. 2017;12(1):117. Kvarnström K, Airaksinen M, Liira H. Barriers and facilitators to medication adherence: a 61. qualitative study with general practitioners. BMJ Open. 2018;8(1):e015332.






Figure 1: Laboratory-Based Facilitated-Relay Intervention Dashed lines: traditional interface between lab and ordering provider

Appendix A: Interview Guide for health care professional

Thank you for agreeing to participate in our interview today. We wish to discuss your experience in managing dyslipidemia (or high cholesterol) in order to better understand how we might help family physicians treat dyslipidemia (or high cholesterol). We have a proposed intervention and would like your assistance in how to enrich it.

1. Experience managing dyslipidemia

Please describe any challenges or difficulties that you experience in identifying and managing patients with dyslipidemia?

- Do you use any resources to guide you in the management of these patients?
 - Canadian Cardiovascular Society Guidelines
 - Diabetes Canada Guidelines
 - TOP guidelines

In addition to measuring a patient's lipids, what are some other parameters that you consider when assessing a patient for dyslipidemia, and how to optimally manage this condition?

2. Dyslipidemia-related practices

In your practice, do you find it helpful to quantify a patient's LDL-cholesterol or get a lipid panel?

If yes,

- Are there certain populations in whom you find this test most helpful?
- What is your chosen method/diagnostic test to do so?
 - Fasting or random lipid profile
 - Total cholesterol
 - HDL-cholesterol
 - LDL-cholesterol
 - ApoB
- How does this information change your clinical practice?
- How often do you repeat cholesterol testing for patients with with conditions that puts them at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease)?

If no,

- Why is it not particularly helpful?
 - Don't know which test to do
 - Don't know how to order it
 - Don't know in whom it is indicated

Don't know what to do with the results

In thinking about your practice, what proportion of your patients with conditions that put them at high risk for cardiovascular disease (i.e. previous myocardial infarction, stroke, diabetes, and/or chronic kidney disease) have had their lipid profile assessed in the past 12 months?

What are some of the reasons this does not happen (in your practice and in others')?

- Didn't think it was indicated/for whom it is indicated
- Too many things to attend to
- Not perceived to be an important issue amongst all other disease/conditions that FPs manage
- Patient factors (doesn't go for test)

3. Intervention

If we wanted to increase the use of statins among people at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease), what might be done? What tools, resources, prompts may help facilitate increased treatment of dyslipidemia?

In your opinion, what type of educational intervention is most effective in disseminating clinical practice guidelines to family physicians? (i.e. conferences, local lectures, treatment recommendations on lab results).

We are considering the use of a facilitated relay strategy, where patient's information from Calgary Laboratory Services is used to identify those who have indications for statin therapy. Those who are not currently filling statin prescriptions at the pharmacy would receive a letter from the lab indicating that they may benefit from statins. They will be encouraged to bring this letter in to discuss this with you.

How would family physicians respond to receiving a letter from the lab prompting them to consider starting their patient on statin treatment?

- What would be the characteristics of such a letter that would make it more likely to succeed?
 - Short/Pictorial/Colorful

Would it be more helpful to have this information specific about one named patient, or rather have an audit of your entire practice that would indicate what proportion of eligible patients with statin-indicated conditions are currently being treated with statins? (i.e. Audit and Feedback)

How should such an intervention either on a specific patient or about your entire practice be received?

• Mail/Fax/EMR/combo

How would such an intervention be processed in your office?

- Who would open the envelope?
- What would they do with it? (give it to you, put it in the patient's chart)
- How likely would you be to see this information?

Who should this letter be coming from in order to have it received in the most positive way possible?

- A non-clinical academic researcher (Dr. XXXX)
- Head of the Calgary Laboratory Services (Dr. Christopher Naugler)
- A lipid specialist (Dr. Sonia Butalia, Alex Leung)
- An academic family doctor (Dr. Kerry McBrien)
- A respected community family doctor
- The lead of Dyslipidemia Guidelines (Dr. Todd Anderson)
- Dr. Cello Tonelli, Associate Vice-President (Research) at the University of Calgary
- Dr. Richard Lewanczuk, Senior Medical Director for Primary Care, Chronic Disease Management, Community and Rural for Alberta Health Services
- Someone else

Would it be helpful to receive a reminder or follow-up letter?

• How much later should this be sent, so as to be useful and not annoying?

If the intervention provided you with patient-oriented material about this subject, and asked you to share it with your patients, how would you feel about doing so?

- What content should be included in this patient-oriented material to enhance statin use?
- What format should this material be in? Electronic, hard-copy? How should it be delivered? Mail, email?
- Would you share it in a clinical setting?
- Would you be willing to mail it to patients directly?

Do you have any additional comments or suggestions for developing an intervention to increase the use statins in people at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease) in primary care?

Thank you for participating in today's interview. Using the information you provided, we will work on developing an intervention to improve the treatment of dyslipidemia in patients who are at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease)?

Appendix B: Focus Group Guide for patients

Thank you for agreeing to participate in our focus group today. There are many risk factors for heart attacks and stroke. Today we want to focus on one risk factor being high cholesterol. High cholesterol is a major risk factor for heart attacks, strokes and circulatory problems. There are no symptoms of high cholesterol and it is diagnosed by a lab test that your doctor would order. Importantly, we work for the University of Calgary and have no relationship with any medication companies.

We wish to discuss your experience in managing *cholesterol* with medications in order to better understand how we might help family physicians (*doctors*) treat high cholesterol.

1. Experience with high cholesterol

Think about the last time your doctor has sent you for a cholesterol test. Did your doctor talk to you about the results? Treatment? What kind of treatment was discussed (diet, exercise, a medication)?

Put yourself in the position of being told that you need to take a medication for your cholesterol. What factors would make you more likely to take it? What factors would make you not want to take it? Reasons, side effects, costs

- Would you use any resources to help you decide?
 - o Doctor
 - \circ Dietician
 - o Internet
 - Family, friends

What would you think if your doctor told you that your cholesterol wasn't all that high, but because of your other health conditions she wanted to start you on a cholesterol lowering medication to reduce your risk of heart attack and stroke?

Do you think it would be helpful to get the actual result of your cholesterol level sent directly from the lab to you?

Currently, cancer screening programs send letters to patients about their results and next steps. What are your thoughts for something similar for high cholesterol?

What about information about recommended treatments and potential side effects? Would you find this to be invasive of your privacy (i.e. info from the lab about treatment and not your doctor)?

How would you feel about taking a letter with these recommendations to your doctor to discuss about a medication for high cholesterol?

How do you feel your doctor would respond to you bringing this information?

What things on the letter would make it helpful?

-length, colour, graphics,

Who should this letter be coming from in order to have it received in the most positive way possible?

- A non-clinical academic researcher (Dr. XXXX)
- Head of the Calgary Laboratory Services (Dr. Christopher Naugler)
- A lipid specialist (Dr. Sonia Butalia, Alex Leung)
- An academic family doctor (Dr. Kerry McBrien)
- A respected community family doctor
- The lead of Dyslipidemia Guidelines (Dr. Todd Anderson)
- Dr. Richard Lewanczuk, Senior Medical Director for Primary Care, Chronic Disease Management, Community and Rural for Alberta Health Services
- Someone else

Would it be helpful to receive a reminder or follow-up letter?

• How much later should this be sent, so as to be useful and not annoying?

Do you have any additional comments or suggestions for developing an way to increase the use the treatment of people with high cholesterol?

Appendix C: Facilitated Relay Letter



Date: XXXX-XX-XX

Dear Dr. [Physician Last Name],

RE: [Patient Name]

As you may recall, your Primary Care Network is involved in a study with the University of Calgary. This is an investigator-initiated study with public funding from the [*Canadian Institutes of Health Research*].

Dyslipidemia is a major risk factor for myocardial infarction and stroke¹⁻². As you know, in patients like [name], statins are indicated for their dyslipidemia because they are proven to reduce cardiovascular outcomes and mortality³⁻⁴. Because of numerous randomized controlled trials, guidelines recommend statin use in individuals with history of previous cardiovascular disease, diabetes, or chronic renal failure⁵.

We are writing to you to consider initiating a statin in your patient. We know the importance of the therapeutic relationship that you have with your patients and know that we do not know your patient like you do. The purpose of this letter is to assist in you in your discussion with [name], about using a statin medication.

[Name] may not be taking a statin because of underestimation of their personal risk of cardiovascular disease, fear of side-effects, previous side-effects, or cost. If cost is a concern, compassionate programs are available for several statin medications. Please kindly call our study telephone number to assist in facilitating this.

The most common side effect from statins is muscle aches, and the frequency of statin-induced rhabdomyolysis is very rare (i.e. < 1 in 10,000 patients per year on statins)⁶. Studies suggest that there are several proven methods for managing people who have experienced muscle aches. For those unable to tolerate daily high intensity statins, some statin is still better than none, and the following strategies can be considered:

- 1. *Reducing the dose of statin*. i.e. Atorvastatin 10-20mg or Rosuvastatin 2.5-5mg⁷.
- Trying a low potency statin medication. Lower potency statins seem to be less strongly associated with muscle aches. Fluvastatin and Pravastatin were much less likely than Simvastatin and Atorvastatin to cause myalgia⁸. For your reference, maximum doses of these low potency statins, and their equivalencies are:

 Pravastatin 80mg = Atorvastatin 20mg = Rosuvastatin 10mg Fluvastatin XL 80mg = Atorvastatin 10mg = Rosuvastatin 5mg

3. Reducing dose or lengthening administration interval. Studies have demonstrated that greater than 70% of patients affected by myalgias were able to tolerate every other day administration with no recurrence of muscle symptoms⁹.

There is a small chance that your patient may have been misclassified with a statin indicated condition. We sincerely apologize for this and would be most appreciative if you can call or fax us to let us know.

We welcome any questions or comments so please kindly contact us at 403-955-8327 (or fax 403-955-8249), for more information.

Sincerely, Sonia Butalia MD, FRCPC, MSc and the study team See telle

References

- 1. Yusuf S, Hawken S, Ôunpuu S, et al. The Lancet. 2004;364(9438):937-952.
- O'Donnell MJ, Xavier D, Liu L, et al. The Lancet. 2010;376(9735):112-123. 2.
- Cholesterol Treatment Trialists Collaboration. The Lancet. 2010;376(9753):1670-1681. 3.
- Cholesterol Treatment Trialists Collaborators. The Lancet. 2012;380(9841):581-590. 4.
- Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines 5. for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2016;32(11):1263-1282.
- Graham DJ, Staffa JA, Shatin D, et al. JAMA. 2004;292(21):2585-2590. 6.
- Arca M, Pigna G. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2011;4:155-7. 166.
- 8. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Cardiovascular Drugs and Therapy. December 01 2005;19(6):403-414.
- 9. Bellosta S, Paoletti R, Corsini A. Circulation. June 15, 2004 2004;109(23 suppl 1):III-50-III-57.

<u>Strategies for Enhancing Cholesterol Lowering Medication Use</u> <u>Among Patients at High Cardiovascular Disease Risk: Patient and</u> <u>General Practitioners' Perspectives on a Facilitated Relay</u> <u>Intervention</u>

Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

No	Item	Guide questions/ description	Response
Domain 1: Research			
team and reflexivity			
Personal Characteristics	Ċ,		
		Which author/s conducted the interview or focus	Line 137
1.	Interviewer/facilitator	group?	
2.	Credentials	What were the researcher's credentials? <i>E.g. PhD</i> , <i>MD</i>	Author information
			K
		What was their occupation	Line 137
3.	Occupation	at the time of the study?	
		Was the researcher male	Line 137
4.	Gender	or female?	
	Experience and	What experience or training did the researcher	Line 137
5.	training	have?	

Item	Guide questions/ description	Response
Relationship established	Was a relationship established prior to study commencement?	Line 138-139
Participant knowledge of the interviewer	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	Not discussed
Interviewer	What characteristics were reported about the interviewer/facilitator? e.g. <i>Bias, assumptions,</i> <i>reasons and interests in</i>	Not discussed
characteristics	the research topic	
		5
Methodological orientation and	What methodological orientation was stated to underpin the study? <i>e.g.</i> grounded theory, discourse analysis, ethnography, phenomenology, content	Qualitative Description – Line 98
	Relationship established Participant knowledge of the interviewer characteristics	ItemdescriptionItemdescriptionRelationship establishedWas a relationship established prior to study commencement?Participant knowledge of the interviewerWhat did the participants know about the researcher? e.g. personal goals, reasons for doing the researchParticipant knowledge of the interviewerWhat characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topicInterviewerWhat characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topicInterviewerWhat methodological orientation was stated to underpin the study? e.g. grounded theory, discourse analysis, ethnography, phenomenology, content

Page 33 of 35

No	Item	Guide questions/ description	Response
Participant selection			
10.	Sampling	How were participants selected? e.g. purposive, convenience, consecutive, snowball	GP – Snowball (line 106-107) Patients – Convenience (line 116)
11.	Method of approach	How were participants approached? e.g. <i>face-to-</i> <i>face, telephone, mail,</i> <i>email</i>	Line 106-120
	<u> </u>		
		How many participants	Line 173
12.	Sample size	were in the study?	Line 186
13.	Non-participation	How many people refused to participate or dropped out? Reasons?	Line 176-177
Setting		2	
		Where was the data	Line 137
14.	Setting of data collection	collected? e.g. <i>home, clinic, workplace</i>	Line 142
15.	Presence of non- participants	Was anyone else present besides the participants and researchers?	Line 143
16.	Description of sample	What are the important characteristics of the sample? <i>e.g. demographic data, date</i>	Line 174-195

No	Item	Guide questions/ description	Response
Data collection			
17.	Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	Appendix A& B
18.	Repeat interviews	Were repeat interviews carried out? If yes, how many?	No
19.	Audio/visual recording	Did the research use audio or visual recording to collect the data?	Line 146
20.	Field notes	Were field notes made during and/or after the interview or focus group?	Line 143-144
21.	Duration	What was the duration of the interviews or focus group?	Line 142-143
22.	Data saturation	Was data saturation discussed?	Line 140 + limitations section
23.	Transcripts returned	Were transcripts returned to participants for comment and/or correction?	No
Domain 3: analysis and findings			

No	Item	Guide questions/ description	Response
Data analysis			
24.	Number of data coders	How many data coders coded the data?	Line 156-160
25.	Description of the coding tree	Did authors provide a description of the coding tree?	Line 157
26.	Derivation of themes	Were themes identified in advance or derived from the data?	Line 157-158 (inductive)
27.	Software	What software, if applicable, was used to manage the data?	Line 164-165
28.	Participant checking	Did participants provide feedback on the findings?	Line 414-415
Reporting		7	
29.	Quotations presented	Were participant quotations presented to illustrate the themes / findings? Was each quotation identified? e.g. participant number	In-text and Table 3
30.	Data and findings consistent	Was there consistency between the data presented and the findings?	Yes

No	Item	Guide questions/ description	Response
	Clarity of major	Were major themes clearly	Results section
31.	themes	presented in the findings?	
		Is there a description of	Table 2 & 3
	Clarity of minor	diverse cases or discussion	
32.	themes	of minor themes?	

BMJ Open

Strategies for Enhancing the Initiation of Cholesterol Lowering Medication Among Patients at High Cardiovascular Disease Risk: A Qualitative Descriptive Exploration of Patient and General Practitioners' Perspectives on a Facilitated Relay Intervention in Alberta, Canada

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-038469.R3
Article Type:	Original research
Date Submitted by the Author:	17-Oct-2020
Complete List of Authors:	Campbell, David; University of Calgary Cumming School of Medicine, Department of Medicine Lee, Rachelle; University of Ottawa McBrien, Kerry; University of Calgary, Family Medicine Anderson, Todd; University of Calgary Cumming School of Medicine, Department of Cardiac Sciences Quan, Hude; University of Calgary, Community Health Sciences Leung, Alexander; University of Calgary Cumming School of Medicine, Department of Medicine Chen, Guanmin; University of Calgary Cumming School of Medicine, Community Health Sciences Lu, Mingshan ; University of Calgary, Economics Naugler, Christopher; University of Calgary, Pathology and Laboratory Medicine; Calgary Laboratory Services, Butalia, Sonia; University of Calgary Cumming School of Medicine, Department of Medicine
Primary Subject Heading :	Cardiovascular medicine
Secondary Subject Heading:	Diabetes and endocrinology, General practice / Family practice, Health services research, Qualitative research, Renal medicine
Keywords:	QUALITATIVE RESEARCH, GENERAL MEDICINE (see Internal Medicine), Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Cardiology < INTERNAL MEDICINE, PREVENTIVE MEDICINE

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3		Strategies for Enhancing the Initiation of Cholesterol Lowering Medication Among Patients at High
4		Cardiovascular Disease Risk: A Qualitative Descriptive Exploration of Patient and General
5		Practitioners' Perspectives on a Facilitated Relay Intervention in Alberta, Canada
6		,,,,,,
7		David J.T. Campbell, MD PhD FRCPC ^{1,2,3}
8		Rachelle C.W. Lee, MSc ⁴
9		
10		Kerry A. McBrien, MD MPH CCFP ^{2,5}
11 12		Todd J. Anderson, MD PhD FRCPC ³
12		Hude Quan, MD PhD ²
14		Alexander A.C. Leung, MD MPH FRCPC ^{1,2,3}
15		Guanmin Chen, MD PhD ²
16		Mingshan Lu, PhD ^{2,6}
17		Christopher Naugler, MD FRCPC ^{2,7}
18		Sonia Butalia, MD MSc FRCPC ^{1,2}
19		
20		1 – Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
21		2 – Department of Community Health Sciences, Cumming School of Medicine, University of Calgary,
22		Calgary, AB, Canada
23		
24		3 – Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB,
25		Canada
26		4 – Department of Innovation in Medical Education, Faculty of Medicine, University of Ottawa, Ottawa,
27		ON, Canada
28		5 – Department of Family Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB,
29		Canada
30		6 – Department of Economics, Faculty of Arts, University of Calgary, Calgary, AB, Canada
31		7 – Department of Pathology & Laboratory Medicine, Cumming School of Medicine, University of
32		Calgary, Calgary, AB, Canada
33		
34		Correspondence:
35		Dr. David J.T. Campbell
36		·
37		TRW 3E33, 3280 Hospital Dr NW
38		Calgary, AB, Canada T2N 4Z6
39		dcampbel@ucalgary.ca
40		403-210-9511
41		
42		Word count: Main text (4861 words), abstract (283 words), 3 tables, 1 figure, 3 appendices
43	1	
44 45		
45		
40		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2		
3		ABSTRACT
4	2	
5	3	Objective: The objective of our study was to explore the perspectives of patients and general
6	4	practitioners (GPs) regarding interventions to increase initiation of cholesterol lowering medication (or
7	5	statins), including a proposed laboratory-based facilitated relay intervention.
8	6	statilis), including a proposed laboratory-based facilitated relay intervention.
9 10	7	Design: Qualitative descriptive study using interviews and focus groups for data collection, and thematic
11		
12	8	analysis for data analysis.
13	9	Catting: Driven and and instigate and action to in Calgary, Alberta, Canada
14	10	Setting: Primary care providers and patients in Calgary, Alberta, Canada.
15	11	Perticipants 47 Canada Destition and with animality companyity have descent and and an experimential sections with at
16	12	Participants: 17 General Practitioners with primarily community-based, non-academic practices with at
17	13	least 1 year of practice experience participated in semi-structured interviews. 14 patients at high risk of
18	14	cardiovascular disease participated in focus groups.
19	15	
20	16	Main outcome measures: Exploration of strategies that might be used to enhance the prescription of,
21 22	17	and adherence to statin therapy for patients with statin-indicated conditions.
22	18	
24	19	Results: GPs proposed a variety of interventions to improve statin prescription, including electronic
25	20	record audit solutions, GP directed education and patient-oriented campaigns. Patients expressed that
26	21	they may benefit from being provided access to their laboratory test results, as well as targeted
27	22	education. Both parties provided positive feedback on the proposed laboratory-based facilitated relay
28	23	intervention, while pointing out areas for improvement. Notably, GPs were concerned that the patient-
29	24	directed component of the intervention might jeopardize therapeutic relationships, and patients were
30	25	concerned about accidental disclosure of personal health information. Important considerations for the
31	26	design of facilitated relay messaging should include brevity, simplicity and the provision of contact
32 33	27	information for inquiries.
34	28	
35	29	Conclusions: GPs and patients described several suggestions for increasing statin initiation and
36	30	welcomed the proposal of a laboratory-based facilitated relay strategy. These findings support further
37	31	testing of this intervention which may enhance GPs' ability to successfully engage patients in
38	32	cardiovascular risk reduction through statin therapy.
39	33	
40	34	Keywords: focus groups, qualitative research, interviews, statins, facilitated relay
41		
42 43		
43 44		
45		
46		
47		
48		
49		
50		
51		
52		
53 54		
54 55		
56		
57		
58		2
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Strengths & Limitations of this Study

- This is a qualitative study, with relatively few participants therefore we cannot say definitively if the views represented here represent those of all patients and prescribers.
- We sampled physician participants to the point of saturation, which means that we are confident the views represented here span the breadth of those held by physicians.
- The patient sample we recruited may not be representative of the broader population, as many of them had previously stated an interest in quality improvement and research and this group was not sampled to saturation.
 - Given the context-dependent nature of qualitative data, the applicability of these findings to other settings is not certain.
 - By collecting qualitative data through open-ended questions, we were able to record detailed accounts and opinions.

INTRODUCTION

Vascular disease, including coronary artery disease, peripheral artery disease, and cerebrovascular disease, remains among the leading causes of mortality worldwide (1). A class of medications, HMG-CoA reductase inhibitors, commonly known as statins, have proven to be effective for lowering the risk of vascular events (2). Individuals who have previously had vascular disease (i.e. secondary prevention) derive a greater absolute risk reduction from statins than those who have never had vascular disease (i.e. primary prevention) (3). There are some individuals who have never had vascular disease, such as those with diabetes or chronic kidney disease, who have also been shown in randomized controlled trials to benefit from therapy (4-6). Despite over 30 years of clinical use, efficacy, safety and cost-effectiveness data (7, 8), only 23% to 55% of individuals who would benefit take this medication and fewer than half of individuals are treated to target cholesterol levels (7, 9-11). There is substantial unwanted variability in dyslipidemia management, and health system intervention is required to promote equitable treatment (12, 13). The lack of statin treatment for patients with indicated conditions results in significant excess morbidity and mortality. In Canada, specifically, if all patients with indications for statins were treated, this would result in nearly 40,000 averted cardiovascular events annually (14). In the United States, 13% of cardiovascular deaths could be prevented with perfect statin adherence among patients at high cardiovascular risk (15).

Physicians and patients face numerous barriers when it comes to prescribing and adhering to statin therapy, from the providers perspective this includes lack of knowledge, conflicting clinical guidelines, lack of systems to identify patients who should be taking statins (16). On the other hand, patients often experience or fear side effects or are simply averse to taking additional medications (16). Furthermore, patients that face social disadvantages such as low income, lack of health insurance, and minority race are more likely to not use statins (17). A large US-based survey found that side effects were common and that many former statin users were unsatisfied with the explanation provided by their prescriber about the importance of the medication (18). Providers need resources to help them provide this counselling to patients and to arm them with strategies to mitigate common statin side effects, like muscle aches (19).

80 There are clearly many challenges that lead to the observed clinical treatment gap for patients who have
 81 indications for statin treatment. However, some studies have shown that such treatment gaps, in
 82 related conditions like hypertension, can be closed using quality improvement strategies (20-22).

84

85

86

87

88

89

90

91

92 93

94

95

96

97

98

99 100

101 102

103 104

105

106

107

108

109

110 111

112 113

114

115

116 117

118

119

120

121

122

123

124

125

126 127

128

129

METHODS:

Study Design

Proposed Intervention

BMJ Open

Integrated quality improvement strategies that target both patients and healthcare providers are more

such strategy is facilitated relay. Facilitated relay is a quality improvement strategy whereby information

about individual patients is sent directly to healthcare providers through a means other than the usual

clinical encounter (23). Despite the establishment and promotion of facilitated relay and other quality

conditions (25). Furthermore, while facilitated relay has been shown to be effective in improving a

number of cardiovascular risk factors (21, 26), it remains among the least commonly used quality

the input of key stakeholders prior to the application of any intervention (28). This allows for the

improvement strategies (27) and has not been explored in the management of dyslipidemia.

improvement strategies, there remain significant treatment gaps in hypertension (24) and other chronic

For an intervention to have the potential to yield maximum impact, it is important to qualitatively seek

development of a higher quality intervention, rather than one that relies on physician feedback alone

(29). As such, the objective of our study was to explore the perspectives of both patients and general

prescription, including specific feedback on a proposed laboratory-based facilitated relay intervention.

practitioners' (GPs) regarding interventions to increase cholesterol lowering medication (or statin)

We conducted a qualitative descriptive study (28) to explore patients' and GPs' perspectives on

interventions to increase initiation of statins for cardiovascular risk reduction and treatment of high

interventions, we specifically sought directed feedback and perceptions on the acceptability of the

proposed facilitated relay intervention from both patients and GPs (30). We used the consolidated

We drew from behaviour change theory to develop a facilitated relay intervention to increase statin

province-wide administrative databases, including labs, pharmacy dispensations, and hospitalization

data. For every elevated LDL-cholesterol level, the lab would have an algorithm that would check the

recently filled a statin prescription. This is possible because of province-wide, linkable databases. For

benefit from statin therapy. The patient letter will encourage them to speak to their GP, and the GP

letter will encourage them to make an appointment to discuss directly with the patient - both with the objective to initiate or renew statin prescriptions. We felt that it was important to include patients in the

facilitated relay to empower them in discussions with their GP and to enable shared decision-making

(35), which has been demonstrated to improve adherence with statins (36).

patients who are not filling statins, but who should be, their GP (who had ordered the cholesterol level)

and the patient, will then each receive a letter outlining the indication for treatment and the potential to

patients' records for evidence of statin-indicated conditions (administrative markers of myocardial

infarction, stroke, diabetes, or chronic kidney disease), and would then identify if the patient has

laboratory system to identify individuals who have elevated cholesterol levels, statin-indicated conditions, and who are not currently filling prescriptions for statins. Our lab system has access to

prescriptions (32-34) (Figure 1). Our proposed intervention partners with our province's single unified

criteria for reporting qualitative research (COREQ) as the reporting framework for this study (31).

cholesterol in those at high cardiovascular risk. In addition to generic thoughts on potential hypothetical

likely to achieve quality indicators than strategies which only target one aspect in isolation (21). One

1
2
3
4
4 5
6
0
/
8
9
10
11
12
13
14
12 13 14 15
16
17
16 17 18 19
10
19
20
21
20 21 22 23 24 25 26 27 28 29
23
24
25
26
20
27
20
29
30
31
32
33
34 35 36
35
36
37
38
38 39
40
41
42
43
44
45
46
47
48
40 49
49 50
50
51
52
53
54
55
56
57

58

59

Participant Recruitment

General Practitioners: We recruited general practitioners to participate in individual interviews, using a snowball sampling approach. First, we asked key stakeholders in areas of primary care, endocrinology, nephrology and cardiology affiliated with the university medical centre, to recommend community-based (non-academic) GPs to participate in the study. Individuals were then contacted by telephone and email with a formal invitation to participate. GPs who met the following criteria were enrolled: (1) currently practicing in community general practice settings; and, (2) at least one year of experience working as a GP in independent practice. We sampled participants purposively based on several key demographic characteristics in order to achieve representation across a range of ages, genders and practice types.

Patients: We recruited patients who would qualify as recipients of the proposed intervention. Specifically, we were interested in recruiting those at high risk of cardiovascular disease, who self-reported a prior history of high cholesterol, preferably with co-existing vascular disease (myocardial infarction, stroke or peripheral vascular disease), diabetes, or chronic kidney disease. Using a convenience sampling approach, we invited patients who were part of an established advisory panel and previously agreed to be contacted about research opportunities for study participation (37, 38). In addition, patients were recruited using poster advertisements placed throughout the academic health sciences centre and in various clinical care areas where care is provided to patients with diabetes, heart disease and kidney disease.

Data Collection

Data was collected from September 2018 to November 2018 using both qualitative semi-structured interviews (with GPs) and focus groups (with patients). We chose focus groups for patients as rich personal disclosures are more likely to occur in this setting than in individual interviews (39). However, we purposely used individually scheduled interviews to offset potential aversion to focus groups by community-based GPs due to their competing clinical demands. Furthermore, we wanted to recruit from both urban and rural locales which is more challenging to do in a focus group.

Question Guides: Both focus groups and interviews were guided by question guides (Appendix A & B) which were developed based on a review of the literature (40, 41) and discussion with the research team. These were designed so that they initially asked study participants what they thought would be effective strategies or interventions to improve statin uptake (i.e. prescribing, patient use and adherence). After they had given their unprompted views, participants were then given a brief explanation of facilitated relay, the specifics of the proposed intervention (Figure 1), and they were shown a copy of the proposed intervention letter for GPs (Appendix C). After briefing participants on the principles and practices of facilitated relay and showing them our preliminary documents for the intervention, we asked them to provide feedback on this proposed intervention.

Provider Interviews: All interviews were conducted in-person (in clinician offices) or via telephone, by a female trained research assistant (RCWL) with oversight by experienced study team members. Physician interviews were continued until the point of theoretical saturation when no new information emerged from the interviews (42). Because the research objective was relatively focused, interviews were brief and lasted approximately 30 to 45 minutes.

60

BMJ Open

1		
2 3		
4	177	Patient Focus Groups: None of the study team were acquainted with or involved in the clinical care of
5	178	the patients who participated. We convened two focus groups in our academic medical centre which
6	179	each lasted approximately 90 minutes. No one but researchers (including 1 facilitator and 2 field-note
7	180	takers) and participants were present. Focus group facilitators tried to ensure that there were no
8	181	dominant members and provide all participants with equal opportunity to voice their opinions.
9	182	
10	183	Interviews and focus group proceedings were digitally audio-recorded and transcribed verbatim by a
11	184	professional transcriptionist. Field notes were recorded to inform data analysis. All data were
12	185	anonymized and stored securely. Signed informed consent was received from each study participant.
13 14	186	Gift cards were provided to all participants. Ethics approval was granted from the University's Health
14	187	Research Ethics Board.
16	188	
17	189	Data Analysis
18	190	
19	191	Analysis was completed using conventional qualitative content analysis (43), a method of interpreting
20	192	interview data with the goal of describing the phenomenon of interest. Transcripts for the initial three
21	193	interviews were reviewed by three team members (DJTC, RCWL and SB), with the objective of
22	194	inductively establishing a preliminary coding template that was used for subsequent data analysis. All
23	195	transcripts were then analyzed by two reviewers (DJTC and RCWL). Codes were generated from the
24 25	196	interview data and systematically applied to identify themes and patterns. The process was iterative,
25 26	197	reflexive, and interactive as continual data collection and analysis shaped each other. For example, code
27	198	titles or definitions identified based on earlier interviews were modified according to the data collected
28	199	during subsequent interviews. The team met together to review the coding to elicit discussion about the
29	200	coding strategy and attempted to achieve consensus to resolve coding discrepancies. NVivo 12
30	201	(Doncaster, Australia) qualitative data analysis software was used to facilitate the coding process.
31	202	
32	203	Patient and public involvement
33	204	
34 35	205	Patient partners and family members from the Libin Cardiovascular Institute's established patient and
35 36	206	family member advisory group (44) voiced that <i>prevention</i> was one of their top research priorities for
37	207	cardiovascular health. This work is related to prevention of cardiovascular disease. Patients were
38	208	included in focus groups.
39	209	
40	210	RESULTS
41	211	
42	212	In total, we eventually reached out to 27 GPs to invite them to participate, 4 declined to participate, 4
43	213	didn't respond to the invitation, 19 were scheduled for interviews, with 2 cancelling. We reached
44 45	214	saturation after having completed 17 individual GP interviews (Table 1a). The majority were women
45 46	215	(88%) with 65% having graduated from medical school within the last ten years. All GPs spent more
40 47	216	than 50% of their time in clinical practice, most were in urban centers within Primary Care Networks
48	217	(PCNs). PCNs are networks of GPs that share interdisciplinary resources to enhance the delivery of
49	218	primary care within geographical regions (45); they are associated with improved chronic disease care
50	218	and outcomes(46).
51	219	מות סתנכוווכא(דטן.
52	220	Table 1a. Descriptive statistics for General Practitioners (n = 17).
53	<u>-</u> -1	Physician characteristics Total (%)
54		Age (years)
55 56		< 40 13 (76)
50 57		
58		6

1			
2			
3		40 - 60	4 (24)
4 5		Gender	
6		Man	2 (12)
7		Woman	15 (88)
8		Years of primary care practice	
9		< 10	14 (83)
10		10 – 20	3 (18)
11		Years since medical school graduation	
12		< 10	11 (65)
13		≥10	6 (35)
14 15		Primary Care Network membership	
16		Yes	15 (88)
17		No	2 (12)
18		Location of primary care practice	
19		Urban	13 (76)
20		Rural	4 (24)
21		Focused practice interest	
22		Yes*	9 (53)
23		No	8 (47)
24 25			. ,
25 26		Clinical practice last 12 months	
20		Estimated number of patients at high CVD risk	
28		< 20	1 (6)
29		20 to 99	7 (41)
30		≥100	9 (53)
31		Use of endocrinology consultation services	
32		Yes	5 (29)
33		No	12 (71)
34 25		Use of cardiology consultation services	()
35 36		Yes	10 (59)
37		No	7 (41)
38		Use of nephrology consultation services	
39		Yes	3 (18)
40		No	14 (82)
41			11 (02)
42		Proportion of patients in their practice who would be	Mean: 32%
43		considered high risk on the basis of cardiovascular risk	Range 10-75%
44 45		factors (n=14)	
45 46			
40 47		Proportion of high-risk patients in their practice who have a	Mean: 82%
48		current LDL-level on file (n=9)	Range 70-90%
49			Kange /0 50/0
50	222	* Focused practice, or special interest types: care of the elderly	(n-2) emergency medicine $(n-1)$
51	223	urgent care (n = 1), refugee medicine (n = 1), obstetrics (n = 2), i	
52	224	1).	
53	225	-).	
54 55	226		
55 56	220		
57			
58		7	
59			
60		For peer review only - http://bmjopen.bmj.com/sit	te/about/guidelines.xhtml

BMJ Open

Our patient focus groups had 8 and 6 participants, respectively (Table 1b). There was a range of ages

represented among patients, with a similar number of men and women. Nearly all had a general
practitioner and were also followed by medical specialist(s). The conditions represented in our patient
group were diabetes, history of myocardial infarction and elevated cholesterol level; none reported a
history of stroke, chronic kidney disease, or peripheral arterial disease.

10 233 **Table 1b.** Descriptive statistics for patient participants based on self-report (n = 14).

	Patient characteristics	Total (%)
	Age (years)	
	< 40	2 (15)
	40 - 60	5 (39)
	> 60	6 (46)
	Gender	
	Men	6 (46)
	Women	7 (54)
	Chronic condition qualifying as "high CVD risk"	
	High cholesterol only	3 (23)
	Diabetes only	6 (46)
	Myocardial infarct (MI) only	1 (8)
	Diabetes & MI	3 (23)
	Has a primary care provider	
	Yes	12 (92)
	No	1 (8)
	Followed by a medical specialist	
	Yes	10 (77)
	No	3 (23)
	Self-reported awareness of high cholesterol levels	
	Yes	11 (85)
	No	2 (15)
	Current use of statin medication	
	Yes	6 (46)
	If not, had spoken with physicians about statins	3 (23)
	If not, had not spoken with physicians about statins	4 (31)
	*Note one participant did not complete a demographic	_
	questionnaire	
234		
235		
236	General suggestions for potential interventions	
237		
238	Several themes arose regarding interventions to improve sta	tin initiation during
239	portion of the interviews (Table 2). GPs described that statin	-

e unprompted portion of the interviews (Table 2). GPs described that statin prescribing may be improved by: (1) enhancing aspects of physician education to promote appropriate statin prescribing; and, (2) implementation of support tools to help physicians in decision-making and identification of patients for whom statins are indicated. In addition, patients suggested that having access to their own laboratory results may enable them to be more effective self-advocates.

Table 2. General suggestions by general practitioners and patients to increase initiation of statins

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30 20 21 22 23 24 25 26 27 28 20 20 20 20 20 20 20 20 20 20	
$\begin{array}{c} 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ 60\\ \end{array}$	

Providers	Treatment of specific Sub- populations	Patients with chronic kidney disease: "I struggle with the GFRs [glomerular filtration rate] – knowing when it would be safe, when it wouldn't be safe. I do get confused as to the dosing based on GFR." (GP-05)
		Patients who previously experienced side effects with statin(s): <i>"I have one strategy but if somebody is still like 'no, it's completely not tolerable for me' then I don't know what the next step is after that."</i> (GP-13)
		Elderly patients: "getting some better understanding about the elderly. Are there any contraindications to starting on statin therapy? Is there one statin that may be more beneficial than another?" (GP-10)
		Patients with hypertriglyceridemia: <i>"I always find it hard to know what to do with triglycerides more education around how to manage those [patients]."</i> (GP-15)
	Treatment to Targets *	"Most people in my office are confused about what we are doing in terms of treating to the target of 2 mmol/L, because the cardiologist is still sending consults about that, but then we have these family medicine evidence-based groups saying that targets don't matter". (GP-02)
		<i>"I know the TOP [Towards Optimized Practice] guidelines don't necessarily correlate with CCS [Canadian Cardiovascular Society] guidelines, so there are several schools of thought". (GP-09)</i>
		"There's no real way to unify the guidelines, but to have an education session on why they're different and how to approach it so maybe you'll break down patient populations that fit better with one guideline versus another". (GP-08)
	Preferred modality of Education	"we have a lot of drug reps [representatives] coming to town, so it would be great to have more [education] that was not pharma, absolutely". (GP-04)
	EMR-based tools	"One thing that would be helpful for me is if there was some automatic flag that came when I saw a patient that would alert to the fact that their treatment is not optimized for their conditions". (GP-06)
Patients	Laboratory Results	<i>"I would like to get a copy, in addition to the doctor. I can do with it what I want"</i> (Pt-09)
		<i>"It gets you questioning things so that you can come back to your doctor and say 'I saw these numbers, what does that mean? What do I need to do?'"</i> (Pt-02)
	Enhanced education	"What if somebody was going regularly to a lab, and a clinician sort of goes: 'How are you doing on this?". (Pt-08)

2		
3	245	EMR: electronic medical record
4	243 246	* Specialist guidelines, the 2016 Canadian Cardiovascular Society guideline (47) advocates that patients
5	240 247	at high risk (based on risk calculators) or those with 'statin-indicated conditions' (defined as diabetes,
6		chronic kidney disease, or preexisting vascular disease be treated with statin therapy to achieve a target
7	248	
8	249	LDL-c level of < 2.0 mmol/L. GP Guidelines, the 2015 TOP Alberta Guideline (48) encourages GPs to treat
9	250	high risk patients with moderate-to-high intensity statins and should not repeat lipid levels, or attempt
10	251	to treat to a fixed target.
11	252	
12 13	253	
14	254	1) General practitioner <i>education:</i>
15	255	
16	256	Nearly all GPs highlighted that there are general areas of knowledge that could be bolstered in order to
17	257	enhance statin prescription. One of the main content areas in which they sought enhanced education
18	258	related to the treatment of specific patient sub-populations, in particular those with chronic kidney
19	259	disease, patients who have had prior statin intolerance/side-effects, elderly patients, and those with
20	260	other concurrent lipid disorders (i.e. hypertriglyceridemia).
21	261	
22	262	Whether providers should be treating patients to a specific cholesterol level was a major source of
23	263	confusion. They frequently referenced receiving conflicting advice, including a contradiction in clinical
24 25	264	practice guidelines(49), some of which advocate for a 'fire and forget' approach(8, 50), while
25 26	265	Canadian(7) and European(51) specialist guidelines recommend a 'treat-to-target' approach(7).
20	266	
28	267	Regarding the modality of education sessions, most preferred in-person education sessions delivered at
29	268	their clinics and delivered by someone who did not have clear conflicts of interest with pharmaceutical
30	269	companies. Many GPs also suggested the use of handouts, tools or algorithms to simplify their decision-
31	270	making process.
32	271	
33	272	2) General practitioner <i>tools</i>
34	273	
35	274	In addition to education, several GPs suggested that the use of automated tools would facilitate their
36 37	275	prescribing of statins. Most felt that they would benefit from optimizing the use of their electronic
38	276	medical records (EMR) to 'flag' individuals who were at high cardiovascular risk or had elevated
39	270	cholesterol levels. Other GPs spoke of wishing for a 'running list' of eligible patients, while some
40	277	mentioned using an employee or contractor designated as a panel manager to perform these tasks.
41	278	mentioned using an employee of contractor designated as a panel manager to perform these tasks.
42		3) Patient results and information
43	280	s) Putient results and injornation
44	281	Many patients independently indicated that they would like to have access to their livid test you de
45	282	Many patients independently indicated that they would like to have access to their lipid test results,
46	283	without needing to rely on this being conveyed to them by their general practitioner. Some patients also
47	284	suggested that providing them with their own results might reduce the frequency of unnecessary follow-
48	285	up visits; and as a result, alleviate related financial burden on the healthcare system. Doing so was also
49 50	286	thought to help foster patient engagement with their GP.
50	287	
52	288	Patients also felt that having greater access to information about cholesterol and treatment might
53	289	facilitate more patients being on statin therapy. Suggestions were made to deliver this through
54	290	enhanced patient-facing materials (i.e. brochures), as well as pharmacists or lab technicians who were
55	291	able to discuss results and treatment options. Further information about patient education, shared
56		
57		
58		10
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60		

3	292	decision-making, and clinical decision support tools are described in our other report from this work
4	293	(16).
5	294	
6 7	295	Feedback on the proposed facilitated relay intervention
8	296	
9	297	Emerging themes regarding our proposed intervention were organized into four major categories: (1)
10	298	general feedback and impression; (2) suggested changes; (3) intervention details; and, (4) workflow
11	299	processing considerations.
12	300	
13	301	1) General feedback and impression
14	302	1) General Jeedback and impression
15		Constral practitionary region dad to the proposed intervention with strengly positive feedback (Table 2)
16	303	General practitioners responded to the proposed intervention with strongly positive feedback (Table 3),
17	304	which included stating that they found the information to be helpful and direct. They generally felt that
18	305	the letter was written in a clear fashion and with a respectful tone. Several mentioned that the
19	306	information provided them with reassurance and credibility in making recommendations to their
20	307	patients.
21 22	308	
22	309	GPs also voiced some questions and potential concerns after hearing about our proposed intervention.
24	310	These concerns included whether the introduction of a facilitated relay intervention might increase their
25	311	workload, lead to possible disclosure to patients of new diagnoses of conditions that qualified them as
26	312	high risk (i.e. diabetes), and pose a threat to their therapeutic relationships with patients. In addition,
27	313	logistical issues around how the letter will be best delivered to ordering providers and patients were
28	314	raised as concerns.
29	315	
30	316	Patients generally felt that bringing their facilitated relay letter to a scheduled appointment would be
31	317	positive in their relationship by providing structure to the follow-up encounter, holding GPs to account,
32	318	and enhancing patient-provider communication. Even though most were generally positive, some
33	319	patients expressed concern about the facilitated relay intervention, including the possibility for privacy
34 35	320	breaches and increasing patient anxieties.
36	321	
37	322	2) Suggested information to remove or add
38	323	
39	324	We asked GPs specifically what they would like to see changed in the preliminary materials shown.
40	325	Almost unanimously, they suggested that the letter would be more appreciated if it the two-page
41	326	document were shortened to fit on one page. Several participants suggested removing the references,
42	327	mention of clinical studies, and guideline citations to make it more reader-friendly. There was also a
43	328	preference voiced for revising the introductory paragraphs to have direct relevance to individual
44	329	patient(s):
45 46	330	
46 47	331	"I'm going to read it for sure, but then when you start to read it, people might put it down and say
48	332	'oh this is a study intervention', [but] if you have the first thing at the very top: 'you know this person
49	333	has been identified as being at risk' – then it's about the patient rather than being about the
50	334	studies". (GP-16)
51		studies . (GP-10)
52	335 336	A few GPs voiced opinions that specific additions could be made to improve the letter's utility. These
53		
54	337	suggestions included adding: information about health behavior change (<i>"the whole picture, as opposed</i>
55	338	to just medication" (GP-04)); adding contact information for a specialist; and details about how/why a
56	339	particular individual was flagged as eligible for the facilitated relay intervention: "It would be helpful if I
57 59		4.4
58 59		11
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
58 59		12
57 58		10
56 57	201	Signed by another Gr.
55 56	387	signed by another GP.
54	386	letters come from a local specialist in cardiology or endocrinology would be preferable to having them
53	385	We also asked patients if they had a preference for who had signed the letter. Most felt that having
52	384	is not in nating . (Or 17)
51	383	it's not irritating". (GP-17)
50	381	enough that I vaguely remember that I meant to do something with that, but not a few weeks later, [so]
49	381	months, and possibly even as long as six months after the initial contact. One participant stated: "close
47 48	380	discussion amongst the groups, consensus was achieved that follow-up should not happen prior to four
46 47	379	Most patients felt that they would benefit from receiving a follow-up reminder. After considerable
45 46	378	
44 45	377	masses". (GP-13)
43	376	have a three-month wait list time, you may have to pick an interval more like six-months to appeal to the
42	375	sufficient to ascertain whether or not the patient would have started on therapy: "There are people that
41	374	Those who felt a reminder would be acceptable generally agreed that a 6 month window should be
40	373	
39	372	was split with roughly half of the general practitioners stating that a reminder would not be necessary.
38	371	study team, if patients had not filled the prescription as recommended in the initial letter. The response
30 37	370	We also asked pointedly about how providers would feel about receiving a follow-up reminder from the
35 36	369	
34 35	368	for it, if you have the means to do it, then why not?" (GP-10)
33 34	367	relay: "I can't even think of the amount of work it would take to do it patient-specific. I'd love it. Sure go
32	366	While the 'audit and feedback' approach was more popular, some GPs were clearly in favor of facilitated
31	365	
30	364	"[a list would] decrease paper burden, decrease the chance of it getting misplaced". (GP-13)
29	363	
28	362	"Am I going to get this letter 20 times? I'm probably just going to read it once" (GP-03)
27	361	<i>"</i>
26	360	"this is going to get tiresome very quickly" (GP-05)
25	359	
24	358	Regarding receiving letters for each patient, participants stated:
23	357	list or report (audit and feedback) was preferred by roughly 2/3 of the general practitioners interviewed.
22	356	identified) or 'audit and feedback' (summary report including a group of their patient panel). A summary
20 21	355	information about their patient in the form of facilitated relay (individual letter for each patient identified) or (audit and facely (common report including a group of their national action of the second
19 20	354 255	In addition to general feedback, we also explicitly asked GPs whether they would prefer to receive information about their patient in the form of facilitated relay (individual letter for each patient)
18 10		In addition to general feedback we also explicitly asked CBs whether they would prefer to receive
17	352 353	
16		3) Intervention details
15	351	
14	350	but also giving some basic education and an action plan to follow.
13	349	However, numerous patients also stressed the importance of not only providing results or diagnoses,
12	348	
11	347	means, I'm sorry, I don't have time for that" (Pt-07).
10	346	a strong preference for brevity: "If I have to go through 14 pages of information to figure out what that
9	345	somebody that doesn't know what the [results] mean" (Pt-10). Similar to physicians, patients expressed
8	344	case they have further questions about interpreting their results: <i>"back that up with a helpline for</i>
6 7	343	Patient feedback was notable for also suggesting that the intervention provide contact information, in
5	342	
4	341	from". (GP-01)
3	340	got a name, condition and then the statin-indicated condition, and where the condition was pulled
2		

4) Workflow processing considerations (General practitioners only)

To each GP we asked specific details about how our intervention letter would be received in their offices and what would happen upon receipt. The majority stated that such a letter would be opened and processed by their front-desk staff. One participant clarified that the information on the envelope would determine who opened it: "if it's addressed to me then it will come to me, if it has a patient name for me, then it goes through our document people [who file it]". (GP-09)

Once the letter has been opened, different offices employed a variety of different processes. In many practices, it would be given directly to the GP; while in others it would be scanned directly into a patient's file in an electronic medical record, yet in others, the hardcopy would be filed in a patient's chart.

In terms of the preferred delivery modality, most GPs felt that electronic delivery directly via the EMR platform would be the preferred method of receiving the intervention. However, a number still felt that conventional delivery via paper mail or fax would be preferable. Even those who expressed a preference for conventional delivery, many elaborated that such letters would often be scanned into a patient's electronic file: "if it was to come by mail or fax, then they have to scan it onto the computer" (GP-11). A few GPs described systems which can do this process automatically: "our office works with a new web system, so everything that comes in via the fax actually goes directly into the computer and they then allocate to the patient". (GP-11)

(General Practitioners		Patients
	Ро	sitive	
Composition	"Overall I thought it was worded quite well and was very clear" (GP- 08)	Provides structure to interaction	"My doctor would be okay with that It gives them a little checklist of things to talk about". (Pt-05)
	"I think it's appropriate, it didn't take me very long to get through" (GP-16)		2/
Tone	"it's written in a way that doesn't make you feel stupid, I guess" (GP- 11)	Enhances communication	"I think that's good 'cause these doctors, some guys don't communicate." (Pt-13)
	"it's good because [it's] not telling you to do this [start statin therapy], but telling you to have a conversation]." (GP-17)		
Credibility	"it gives family physicians more confidence to do those things and know the specialists are behind them in that recommendation" (GP-02)	Increases doctor accountability	"I think it keeps them [doctors] honest as well. They should actually be proactive in terms of having that information already, but that's not always the case. So I don't have a

Table 3. Positive and negative feedback on facilitated relay intervention from general practitioners and patients

	"there's so much information for people to sift through if you can get valid information that's corroborated and consistent, that's helpful" (GP-15)		problem with a patient having all their information at their disposal". (Pt-14)
Direct	 "it's a good idea it tells you what to do, which is great. You don't have to look up the guideline every time" (GP-04) "it's just one of those extra little reminders that takes the brain power out of the work you have to do day-to-day" (GP-06) 	Increases patient accountability	"If [patients] are encouraged to work with their doctor to monitor your numbers, you have a bit of control a well as the doctor like working together". (Pt-03)
Information	"[side effects] are what people hear about in the news a lot, so it's very helpful to have some numbers around it, and strategies to address that" (GP-09) "All the suggestions that you made are excellent. I'm reading through this and I'm like ' oh yeah, I didn't realize this' and ' this is something I can do for some of my patients'" (GP-12)	Provides peace of mind	"It gives me a little peace of mind in that we've talked about all of the things that are important and that should be covered that we haven't left anything out". (Pt-05)
	Neg	gative	
Increased workload	"I would caution against anything that causes more documents or more paperwork there's already so much" (GP-16)	Privacy concerns	"You know what, my doctor isn't going to send it out to me, anyway. It's going to go on to a receptionist, who might pass it on to somebody else in the office, so there's no guarantee of privacy there" (Pt-05) "Privacy is always an issue. I mean it' like, the less information that's out there about you, the better off you are, period. I don't care what it is" (Pt-07)
Disclosing new diagnoses	"my concern is that they get this information from a letter my preference would be that it came straight to me" (GP-01)	Difficulty interpreting results	"Some people might know all the numbers and everything else, I don't You give me a bunch of numbers, it means nothing to me. So unless the doctor explained it to me I'd rather talk to my doctor" (Pt-07)

Provoking

Anxieties

"There are people who are coming

down with every disease known to

man, so for someone like that, that

"If the patient gets a letter that's

like 'you need to be on a statin' and

we already had a conversation that

2 3	
4 5	
6 7	
8 9	
10	
11 12	
13 14	
15 16	
17	
18 19	
20 21	
22	
23 24	41
25 26	41 41
27	41
28 29	41 41
30 31	41
32 33	41 41
34	42
35 36	42 42
37 38	42 42
39	42 42
40 41	42
42 43	42 42
44	42 43
45 46	43 43
47 48	43
49	43 43
50 51	43
52 53	43 43
54	43 43
55 56	43 44
57 50	

58 59

60

1

Therapeutic relationship

		they didn't need a statin. That		kind of information would just send
		could cause some issues in the		them off the deep-end, right?" (Pt-
		therapeutic relationship." (GP-04)		05)
	Logistical	"What if a person gets a check from	Lack of	"You mentioned mail outs and things
	concerns	a walk-in clinic? My concern is then	engagement	like that have they proven to be
		is that walk-in clinic docs are just		effective, though, 'cause how many
		going to ignore this letter" (MD-05)		people read them? How many people
				understand them? I don't think there
		"If it goes to the patient,		would be a lot of point in it, 'cause I
		sometimes you get lots of mail and		don't think people pay that much
		they may just discard it" (MD-10)		attention" (Pt-09)
			Sense of	"Some will [say] 'I can't talk to my
			intimidation	doctor like that'. There will be some
				people who might be intimidated to
				initiate that conversation" (Pt-03)
411				
411				
412	DISCUSSION			
413	DISCOSSION			
414	While stating h	have a more limited role in certain popu	ulations (low risk a	nd those with limited life
415		52, 53), they are important for the prev	•	
410		vascular disease and in those with diak		•
417	•	patients acknowledged that there is the		
418		among those at high risk for cardiovas		
419		I that there was a need for improved pl		
420	-	and track patients would be helpful. Pat		•
421	• •	t results and information on treatment		
422		porting our hypothesis that facilitating s	•	
423		ition. When shown the proposed interv		
424		relay intervention. While there were cl		
425		re raised by both GPs and patients. In g		· · · · ·
		, , , ,		
427	· ·	ontain high yield information and provi		ation where clarification could be
428	sought.			
429	Manufatoria		the weeklows of sta	tio undomine. A number of
430	•	ntions have been attempted to address	•	
431	•	red approaches have been tried with va		
432		e cognitive education and behavioural c	-	
433		re often unsuccessful at changing beha		
434		tion, comprised of a mail and phone ed		
435	•	dication, had no impact on adherence		
436		focusing on enhancing care provision th	hrough team-based	l care may be effective at
437	increasing stat	tin adherence (56).		
438				
439		en trying to target the problem of low s		-
440	patients are no	ot likely to work. An alternate approach	h is to facilitate GPs	s ability to identify and prescribe
			-	
		15	5	

BMJ Open

statins, to those in whom they are appropriate (57), through audit and feedback or facilitated relay. An

- educational audit and feedback intervention regarding dyslipidemia treatment in Italian primary care practices was shown to increase adherence to statins by approximately 10% (58). Improved communication and shared decision making, which are explicit goals of facilitated relay interventions, can improve patient adherence (59). While these and other studies have reviewed the clinical efficacy of quality improvement strategies (21), few have used detailed qualitative methods as we have done. One large qualitative study interviewed audit and feedback experts to generate hypotheses about the various factors that may contribute to the efficacy of such interventions (60). Others have used qualitative methods to highlight the barriers physicians face in encouraging adherence (61), but ours is unique in using such methods to design and develop an intervention to address these challenges. Finally, we also appreciate that as much as there is underuse of statins, there is also overuse, for example, in people with short life expectancy. Perhaps interventions to increase initiation may also include a component that conveys statin benefits are measured in years rather than months. The fact that participants suggested elements of our facilitated relay intervention in the unprompted portion of the interviews lends credibility and face validity to the proposed intervention. However, it is notable that while GPs felt they would benefit from having internal systems to monitor patients' records, none independently suggested a strategy mediated by an independent third party (such as facilitated relay or audit and feedback), as we have proposed. Investigators who wish to implement facilitated relay interventions to enhance adherence to medical therapies can use the findings of this study to help develop interventions that are more likely to be acceptable to both GPs and patients. One of the main findings is to ensure that any information provided is brief and high yield, containing patient identifiers early to capture general practitioner's attention. Such interventions can be strengthened by incorporating education on controversial or little-known topics. Patients strongly preferred any correspondence to also contain direct suggestions or an action plan. Workflow and processing of these letters needs to be considered and interventions designed to be as minimally disruptive to clinical
- practice as possible - with most physicians preferring that it be embedded directly within the EMR; yet in healthcare settings (like ours) where there is marked heterogeneity in the use and type of EMRs, this may not be possible.
- There are limitations to this study. Firstly, as in most qualitative studies, the number of participants was relatively small. This concern over sample size is mitigated by the fact that physician interviews proceeded until the point of saturation. Patient data were not collected in this manner, and these themes may not be fully saturated and we appreciate this as a limitation. Furthermore, the patient sample we recruited may not be representative of the broader population, as many of them had previously stated an interest in quality improvement and research and therefore may be attuned to the importance of preventive therapies more than other members of the general public. Secondly, given the context-dependent nature of qualitative data, the applicability of these findings to other settings is not certain. Yet physicians in most settings face similar problems (i.e. time constraints, patient complexity and comorbidities and patient resistance to medical therapies) in numerous facets of medical care; therefore, it is conceivable that the findings of this study would apply to interactions between patients and GPs in other clinical settings. Due to time constraints of participants and researchers, member checking was not undertaken in this study. Finally, it is important to note that feedback was sought specifically about the proposed intervention. However, given the details reported, we feel that these findings are likely to be helpful to others proposing similar quality improvement interventions. One of the major strengths of this study is the depth and richness of the qualitative data that were collected. By asking questions in an open-ended manner, we were able to record detailed accounts and opinions.


 Statin therapy has been demonstrated to effectively lower cholesterol and reduce the risk of cardiovascular events and death in individuals at high risk of cardiovascular disease. Despite this, they remain undervued. There are patient, provider and system factors that contribute to statin undervues. Facilitated relay interventions hold promise as a potential method to address this important care gap. Our study sought perspectives of both healthcare providers and patients, which will be incorporated into intervention design to maximize acceptability. Insights gained from qualitative data will be used to improve the likelihood of success and achieve the desired clinical impact. The insights about these interventions are also likely to be of interest to many researchers and clinicians who are considering and designing provider- and/or patient-facing interventions to improve the uptake of preventive medications. Contributions DITC, RCWL, KAM, TIA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and methods. The study design was conceived by DITC and SB. DITC wrote the first draft of the study protocol. Data collection and analysis was completed by DITC, RCWL, ad SB. KAM, TIA, HQ, AACL, GC, ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DITC. RCWL, KAM, TIA, HQ, AACL, GC, ML, CN, and SB contributed substatively to further revisions of the manuscript and have consented to the publication of this version. Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB –	3 4 5	488 489	Another strength of this work is the fact that we also sought patient input into the development of this intervention, rather than relying on physician feedback alone.
 cardiovascular events and death in individuals at high risk of cardiovascular disease. Despite this, they remain underused. There are patient, provider and system factors that contribute to statin underuse. Facilitated relay interventions hold promise as a potential method to address this important care gap. Our study sought perspectives of both healthcare providers and patients, which will be used to improve the likelihood of success and achieve the desired clinical impact. The insights about these interventions are also likely to be of interest to many researchers and clinicians who are considering and designing provider- and/or patient-facing interventions to improve the uptake of preventive medications. Contributions Dirt, RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and methods. The study design was conceived by DITC and SB. DITC wrote the first draft of the study protocol. Data collection and analysis was completed by DITC, RCWL and SB. KAM, TJA, HQ, AACL, GC, SG ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DITC. RCWL, KAM, TA, HQ, AACL, GC, ML, CN, and SB contributed substantively to further revisions of the manuscript and have consented to the publication of this version. Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Figure 1: Laboratory-Based Facilitated-Relay intervention Soard. Soard. Soard. Soard. Soard. Soard. Soard. Soard. Soard.	6	490	
 remain underused. There are patient, provider and system factors that contribute to statin underuse. Facilitated relay interventions hold promise as a potential method to address this important care gap. Our study sought perspectives of both healthcare providers and patients, which will be incorporated into intervention design to maximize acceptability. Insights gained from qualitative data will be used to improve the likelihood of success and achieve the desired clinical impact. The insights about these interventions are also likely to be of interest to many researchers and clinicals who are considering and designing provider- and/or patient-facing interventions to improve the uptake of preventive medications. Contributions DJTC, RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and methods. The study design was conceived by DJTC and SB. DJTC wrote the first draft of the study protocol. Data collection and analysis was completed by DJTC, RCWL and SB. KAM, TJA, AQ, AACL, GC, ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB. contributed substantively to further revisions of the manuscript and have consented to the publication of this version. Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Ma Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement DC, CRI, KAM, AL, TA, HQ, GG, SB – none. CN is a director of a private laboratory that doe	7		
10 Facilitated relay interventions hold promise as a potential method to address this important care gap. 11 1000 Suit dy sought perspectives of both healthcare providers and patients, which will be incorporated 11 1100 Into intervention design to mainize acceptability. Insights gained from qualitative data will be used to 121 1100 representation of the second of success and achieve the desired clinical impact. The insights about these 121 1100 representations are also likely to be of interest to many researchers and clinicians who are considering and 121 1200 redictions. 122 1201 Contributions 123 011C, RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and 123 methods. The study design was conceived by DITC and SB. DITC wrote the first draft of the study 124 protocol. Data collection and analysis was completed by DITC, RCWL and SB. KAM, TJA, HQ, AACL, GC, 125 ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of 125 wersion. 126 Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. 126 Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. 127			
11 495 Our study sought perspectives of both healthcare providers and patients, which will be incorporated 13 496 into intervention design to maximize acceptability. Insights gained from qualitative data will be used to 14 496 interventions are also likely to be of interest to many researchers and clinicians who are considering and 14 496 designing provider- and/or patient-facing interventions to improve the uptake of preventive 15 Contributions 1017C, RCWL, KAM, TIA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and 1500 DDTC, RCWL, KAM, TIA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and 1501 DDTC, RCWL, KAM, TIA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and 1502 Data collection and analysis was completed by DITC and SB. DTC wrote the first draft of the study 1503 DITC, RCWL, KAM, TIA, HQ, AACL, GC, ML, CMA, TIA, HQ, AACL, GC, ML, CN, and SB contributed 1504 the manuscript was written by DITC. RCWL (AM, TIA, HQ, AACL, GC, ML, CN, and SB. Contributed 1505 the manuscript was written by DITC. RCWL (AM, TIA, HQ, AACL, GC, ML, CN, and SB contributed 1506 substantively to further revisions of the manuscript and have consented to the publication of this 1505 the manuscript and have consented to the publication of this <t< td=""><td></td><td></td><td></td></t<>			
12 496 into intervention design to maximize acceptability. Insights gained from qualitative data will be used to 13 10 improve the likelihood of success and achieve the desired clinical impact. The insights about these 14 10 interventions are also likely to be of interventions to improve the uptake of preventive 15 10 Contributions 15 10 10 15 10 10 15 10 10 15 10 10 15 10 10 15 10 10 15 10 10 15 10 10 16 10 10 10 17 10 10 10 15 10 10 10 16 10 10 10 17 10 10 10 10 18 10 10 10 10 10 18 10 10 10 10 10 10 10 19 10 10 10 10 <td></td> <td></td> <td></td>			
 improve the likelihood of success and achieve the desired clinical impact. The insights about these interventions are also likely to be of interest to many researchers and clinicians who are considering and designing provider- and/or patient-facing interventions to improve the uptake of preventive medications. Contributions DITC, RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and methods. The study design was cornelved by DJTC and SB. DJTC wrote the first draft of the study protocol. Data collection and analysis was completed by DJTC, RCWL and SB. KAM, TJA, HQ, AACL, GC, ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB. contributed substantively to further revisions of the manuscript and have consented to the publication of this version. Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay intervention Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering DLC C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowerin		495	Our study sought perspectives of both healthcare providers and patients, which will be incorporated
 interventions are also likely to be of intervent to many researchers and dilicians who are considering and designing provider- and/or patient-facing interventions to improve the uptake of preventive medications. Contributions DiTC, RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and methods. The study design was conceived by DJTC and SB. DJTC wrote the first draft of the study protocol. Data collection and analysis was completed by DJTC, RCWL and SB. KAM, TJA, HQ, AACL, GC, ML, AN, TJA, HQ, AACL, GC, ML, CN, and SE. KAM, TJA, HQ, AACL, GC, ML, CN, and SE. KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed substantively to further revisions of the manuscript and have consented to the publication of this version. Funding Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement Dc, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LD-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Revi		496	into intervention design to maximize acceptability. Insights gained from qualitative data will be used to
15 435 interventions are also likely to be of interest to many researchers and clinicians who are considering and designing provider- and/or patient-facing interventions to improve the uptake of preventive medications. 16 499 designing provider- and/or patient-facing interventions to improve the uptake of preventive medications. 17 500 Contributions 18 501 Contributions 19 DITC, RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and methods. The study design was conceived by DITC and SB. DITC wrote the first draft of the study protocol. Data collection and analysis was completed by DITC, RCWL and SB. KAM, TJA, HQ, AACL, GC, ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DJTC. RCWL KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed substantively to further revisions of the manuscript and have consented to the publication of this version. 16 Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. 17 No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. 18 Competing Interest Statement Octific testing in the jurisdiction under study. 19 Eigure 1: Laboratory-Based Facilitated-Relay Intervention Efferences 10 Iffer		497	improve the likelihood of success and achieve the desired clinical impact. The insights about these
designing provider and/or patient-facing interventions to improve the uptake of preventive medications. S00 Contributions DITC, RCWL, KAM, TIA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and methods. The study design was conceived by DITC and SB. DITC wrote the first draft of the study protocol. Data collection and analysis was completed by DITC, RCWL and SB. KAM, TJA, HQ, AACL, GC, ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DITC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed substantively to further revisions of the manuscript and have consented to the publication of this version. Prunding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. S12 Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. S13 Figure 1: Laboratory-Based Facilitated-Relay Intervention S14 S24		498	interventions are also likely to be of interest to many researchers and clinicians who are considering and
17 500 medications. 18 501 19 502 Contributions 19 503 DJTC, RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and 19 methods. The study design was conceived by DJTC and SB. DJTC wrote the first draft of the study 19 protocol. Data collection and analysis was completed by DJTC, RCWL and SB. KAM, TJA, HQ, AACL, GC, 100 ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of 101 the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed 102 substantively to further revisions of the manuscript and have consented to the publication of this 103 Funding 104 Funding 105 Funding 105 Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. 105 Data Availabile. Given that qualitative data are not deidentified and tell individuals' 103 Dersonal stories, data cannot be shared beyond the scope of this project, as per our research ethics 105 Dord. Soard. 105 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently		499	designing provider- and/or patient-facing interventions to improve the uptake of preventive
S01 Contributions DITC, RCWL, KAM, TIA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and methods. The study design was conceived by DJTC and SB. DJTC wrote the first draft of the study protocol. Data collection and analysis was completed by DJTC, RCWL and SB. KAM, TJA, HQ, AACL, GC, ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed substantively to further revisions of the manuscript and have consented to the publication of this version. S11 Funding S12 Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. S13 Data Availability Statement S14 Data Availability Statement S15 No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. S18 Competing Interest Statement S20 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. S21 Figure 1: Laboratory-Based Facilitated-Relay Intervention S22 References S23 References S24 Superman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association S21		500	medications.
19 502 Contributions 20 503 DJTC, RCVU, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and 20 methods. The study design was conceived by DJTC and SB. DJTC wrote the first draft of the study 20 protocol. Data collection and analysis was completed by DJTC, RCWL and SB. KAM, TJA, HQ, AACL, GC, 20 ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of 20 the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed 208 substantively to further revisions of the manuscript and have consented to the publication of this 209 substantively to further revisions of the manuscript and have consented to the publication of this 209 S11 Funding 201 Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. 203 Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' 205 personal stories, data cannot be shared beyond the scope of this project, as per our research ethics 203 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently 204 offer testing in the jurisdiction under study. 212 <td< td=""><td></td><td></td><td></td></td<>			
 DJTC, RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, SB collaborated to develop the research question and methods. The study design was conceived by DJTC and SB. DJTC wrote the first draft of the study protocol. Data collection and analysis was completed by DJTC, RCWL and SB. KAM, TJA, HQ, AACL, GC, ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed substantively to further revisions of the manuscript and have consented to the publication of this version. Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LD-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. Bory P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 			Contributions
21 504 methods. The study design was conceived by DJTC and SB. DJTC wrote the first draft of the study 25 protocol. Data collection and analysis was completed by DJTC, RCWL and SB. KAM, TJA, HQ, AACL, GC, 25 ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of 25 the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed 26 substantively to further revisions of the manuscript and have consented to the publication of this 27 Funding 28 Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. 29 511 20 Data Availability Statement 315 No additional data available. Given that qualitative data are not deidentified and tell individuals' 316 personal stories, data cannot be shared beyond the scope of this project, as per our research ethics 317 Doradlineterst Statement 320 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently 318 Figure 1: Laboratory-Based Facilitated-Relay Intervention 319 Funding in the jurisdiction under study. 321 KL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently			
 protocol. Data collection and analysis was completed by DITC, RCWL and SB. KAM, TJA, HQ, AACL, GC, ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DITC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed substantively to further revisions of the manuscript and have consented to the publication of this version. Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention State Statement World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. Brudin J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 			
 ML, and CN contributed to the interpretation and contextualization of study findings. The first draft of the manuscript was written by DJTC. RCWL, KAM, TIA, HQ, AACL, GC, ML, CN, and SB contributed substantively to further revisions of the manuscript and have consented to the publication of this version. Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Dat Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention Morid Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 			
 the manuscript was written by DJTC. RCWL, KAM, TJA, HQ, AACL, GC, ML, CN, and SB contributed substantively to further revisions of the manuscript and have consented to the publication of this version. Funding Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention Stepsonal MC, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 	23		
 substantively to further revisions of the manuscript and have consented to the publication of this version. substantively to further revisions of the manuscript and have consented to the publication of this version. Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention Pittps://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. Bord Association J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 	24		
 509 version. 510 Funding 511 Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. 513 514 Data Availability Statement 515 No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. 518 519 Competing Interest Statement 520 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. 522 Figure 1: Laboratory-Based Facilitated-Relay Intervention 524 525 References 526 527 1. World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. 529 2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular fisk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 			
 510 511 Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. 512 Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. 513 514 Data Availability Statement 515 No additional data available. Given that qualitative data are not deidentified and tell individuals' 516 personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. 518 519 Competing Interest Statement 520 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. 521 522 Figure 1: Laboratory-Based Facilitated-Relay Intervention 524 525 References 526 527 1. World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. 522 523 Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 531 A Systematic Review and Meta-analysis. JAMA. 2016;16(12):1289-97. 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 533 2019;367:15674. 			
 Funding Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Fild Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Fild Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. fild Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention Figure 1: Laboratory-Based Facilitated-Relay Intervention Figure 1: Laboratory-Based Facilitated-Relay Intervention S25 References S26 S27 World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-cause-of-death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-cause-of-death. S29 S10 Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. S32 Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 			version.
 Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada. Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention Figure 1: Laboratory-Based Facilitated-Relay Intervention S22 S23 Figure 1: Laboratory-Based Facilitated-Relay Intervention S24 S25 References S26 S17 S18 S27 World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. S23 S14 S24 S25 S14 S25 S17 S18 S26 S18 S27 S18 S28 S19 S19 S10 S29 S10 S20 S10 S20 S11 S21 S12 S14 S23 S14 S24 S25 S14 S25 S14 S26 S17 S27 S28 S27 S28 S29 S18 S29 S18 S29 S18 S20 S18 S20 S20 S21 S21 S22 S22 S23 S23 S24 S24 S25 S25			
31 513 32 514 33 515 34 515 35 No additional data available. Given that qualitative data are not deidentified and tell individuals' 35 personal stories, data cannot be shared beyond the scope of this project, as per our research ethics 36 board. 37 518 38 519 Competing Interest Statement Operating in the jurisdiction under study. 31 520 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. 41 522 323 Figure 1: Laboratory-Based Facilitated-Relay Intervention 34 525 351 References 36 526 37 1. 38 S19 39 2. 30 Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 31 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 32 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 33 3. <			
31 Data Availability Statement 33 515 No additional data available. Given that qualitative data are not deidentified and tell individuals' 34 515 No additional data available. Given that qualitative data are not deidentified and tell individuals' 34 516 personal stories, data cannot be shared beyond the scope of this project, as per our research ethics 36 517 board. 37 518 38 519 Competing Interest Statement 30 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently 40 521 offer testing in the jurisdiction under study. 41 522 Figure 1: Laboratory-Based Facilitated-Relay Intervention 42 525 References 44 526 References 45 527 1. World Health Organization. The top 10 causes of death 2018 [Available from: 44 522 Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 532 3. Byrne P, Cull			Funding for this project was provided by a research grant to Sonia Butalia from Diabetes Canada.
 S14 Data Availability Statement No additional data available. Given that qualitative data are not deidentified and tell individuals' personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention Figure 1: Laboratory-Based Facilitated-Relay Intervention Keferences S25 References S26 S17 S27 World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. S29 S10 S20 S10 S21 S11 S22 S12 S12 S12 S12 S13 S13 S14 S24 S25 S14 S25 S15 S26 S27 S18 S28 S29 S18 S29 S18 S29 S18 S20 S18 S20 S20 S20 S21 S21 S22 S12 S23 S24 S25 S25 S26 S26 S27 S27 S28 S28 S29 S29 S20 S20 S20 S20 S20 S21 S21 S21 S22 S22 S22 S23 S23 S25 S24 S25 S25 S26 S26 S26 S27 S28 S28 S29 S29 S29 S29 S20 S20 S20 S21 S21 S21 S22 S23 S23 S24 S24 S25 <l< td=""><td></td><td></td><td></td></l<>			
 S15 No additional data available. Given that qualitative data are not deidentified and tell individuals personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. S18 S19 Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention Figure 1: Laboratory-Based Facilitated-Relay Intervention Figure 1: Laboratory-Based Facilitated-Relay Intervention S26 Figure 1: Laboratory-Based Facilitated-Relay Intervention S27 World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. S28 S19 S29 Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. S33 Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 		514	Data Availability Statement
 personal stories, data cannot be shared beyond the scope of this project, as per our research ethics board. board. Competing Interest Statement DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. Figure 1: Laboratory-Based Facilitated-Relay Intervention Figure 1: Laboratory-Based Facilitated-Relay Intervention S24 S25 References S26 S27 World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. S28 S19 S20 Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. S33 S019;367:15674. 		515	No additional data available. Given that qualitative data are not deidentified and tell individuals'
 517 board. 518 519 Competing Interest Statement 520 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. 521 522 Figure 1: Laboratory-Based Facilitated-Relay Intervention 524 525 References 526 527 1. World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. 2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 332 Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 		516	personal stories, data cannot be shared beyond the scope of this project, as per our research ethics
 518 519 520 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. 521 522 523 Figure 1: Laboratory-Based Facilitated-Relay Intervention 524 525 526 757 1. World Health Organization. The top 10 causes of death 2018 [Available from: 6 526 7527 1. World Health Organization. The top 10 causes of death 2018 [Available from: 6 526 7 527 1. World Health Organization. The top 10 causes of death 2018 [Available from: 6 528 6 529 530 540 531 541 552 551 552 552 552 553 553 554 555 555 556 556 557 558 559 550 550 551 551 551 551 552 552 553 553 554 555 555 556 556 557 558 559 550 550 551 551 551 552 552 552 553 552 553 554 555 555 555 556 556 557 557 557 558 558 559 559 559 550 551 551 551 552 552 552 552 552 552 553 552 553 554 555 555 555<td></td><td>517</td><td>board.</td>		517	board.
 519 Competing Interest Statement 520 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. 522 523 Figure 1: Laboratory-Based Facilitated-Relay Intervention 524 525 References 526 7 527 1. World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. 529 2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 533 2019;367:15674. 		518	
 520 DC, RL, KAM, AL, TA, HQ, GC, SB – none. CN is a director of a private laboratory that does not currently offer testing in the jurisdiction under study. 522 523 Figure 1: Laboratory-Based Facilitated-Relay Intervention 524 525 References 526 7527 1. World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. 529 2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 5019;367:15674. 		519	Competing Interest Statement
 40 521 offer testing in the jurisdiction under study. 41 522 42 523 Figure 1: Laboratory-Based Facilitated-Relay Intervention 524 525 References 526 47 527 1. World Health Organization. The top 10 causes of death 2018 [Available from: 48 528 <u>https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.</u> 529 2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 533 2019;367:15674. 	39	520	
 Figure 1: Laboratory-Based Facilitated-Relay Intervention Figure 2: Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. Silverman P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 	40		· · · ·
 Figure 1: Laboratory-Based Facilitated-Relay Intervention References Figure 1: Laboratory-Based Facilitated-Relay Intervention Figure 1: Laboratory-Based Facilitated-Relay Intervention References Silver 1: World Health Organization. The top 10 causes of death 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. Between P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:15674. 			
 Figure 1 Figure 1 Figure 2 Fig			Figure 1: Laboratory-Based Facilitated-Relay Intervention
444 525 References 45 526 47 527 1. World Health Organization. The top 10 causes of death 2018 [Available from: 48 528 https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. 49 529 2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 50 529 2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 51 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 52 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 53 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 54 533 2019;367:15674. 56 17 58 17			
 526 527 1. World Health Organization. The top 10 causes of death 2018 [Available from: 528 https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. 529 52. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 533 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 533 2019;367:15674. 			References
 47 527 1. World Health Organization. The top 10 causes of death 2018 [Available from: 48 528 <u>https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.</u> 49 529 2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 533 2019;367:15674. 			herefelles
 48 528 <u>https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.</u> 49 529 2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 50 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 54 533 2019;367:15674. 			
 Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:I5674. 			· · · · ·
 529 2. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 54 533 2019;367:15674. 			
 530 Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 533 2019;367:15674. 56 56 57 58 17 59 		529	
 531 A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97. 532 3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 533 2019;367:15674. 55 56 57 58 17 59 		530	
54 533 2019;367:l5674. 55 56 57 58 17 59		531	A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-97.
55 56 57 58 17 59	53	532	3. Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ.
56 57 58 17 59	54	533	2019;367:I5674.
57 58 17 59			
58 17 59			
59			
			17
			For peer review only - http://bmjopen.bmj.com/site/about/auidelines.xhtml

1		
2		
3 4	534	4. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary
5	535	prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative
6	536	Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet.
7	537	2004;364(9435):685-96.
8	538	5. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of
9	539	lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study
10 11	540	of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92.
12	541	6. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative G. MRC/BHF
13	542 543	Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a
14	543 544	randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-16. 7. Anderson TJ. Grégoire J. Pearson GJ. Barry AR. Couture P. Dawes M. et al. 2016 Canadian
15	544 545	7. Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of
16	545 546	Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2016;32(11):1263-82.
17	540 547	8. Grundy SM, Stone NJ. 2018 American Heart Association/American College of
18 19	548	Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention.
20	549	JAMA Cardiol. 2019;4(6):589-91.
21	550	9. Butalia S, Lewin A, Simpson S, Dasgupta K, Khan N, Pilote L, et al. Sex-based disparities in
22	551	cardioprotective medication use in adults with diabetes. Diabetol Metab Syndr. 2014;5(6):117.
23	552	10. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R, et al. 2012 Update of
24	553	the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the
25	554	Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2013;29(2):151-67.
26 27	555	11. Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular Risk and Statin Use in
28	556	the United States. The Annals of Family Medicine. 2014;12(3):215-23.
29	557	12. Gamble JM, Butalia S. Medical Practice Variations in Diabetes Mellitus. In: Johnson A, Stukel T,
30	558	editors. Medical Practice Variations. Health Services Research: Springer US; 2015. p. 1-40.
31	559	13. Tu JV, Chu A, Maclagan L, Austin PC, Johnston S, Ko DT, et al. Regional variations in ambulatory
32	560	care and incidence of cardiovascular events. Canadian Medical Association Journal. 2017;189(13):E494-
33 34	561	E501.
35	562	14. Hennessy DA, Tanuseputro P, Tuna M, Bennett C, Perez R, Shields M, et al. Population health
36	563	impact of statin treatment in Canada. Health Rep. 2016;27(1):20-8.
37	564	15. Yang Q, Zhong Y, Gillespie C, Merritt R, Bowman B, George MG, et al. Assessing potential
38	565	population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases
39	566	in the USA: population-based modelling study. BMJ Open. 2017;7(1):e011684.
40	567	16. Butalia S, Lee-Krueger R, McBrien K, Leung A, Anderson T, Quan H, et al. Barriers and Facilitators
41 42	568	to Using Statins: A Qualitative Study with Patients and Family Physicians Canadian Journal of Cardiology
43	569	Open. 2020;Online ahead of print.
44	570	17. Schroff P, Gamboa CM, Durant RW, Oikeh A, Richman JS, Safford MM. Vulnerabilities to Health
45	571	Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke)
46	572	Study. J Am Heart Assoc. 2017;6(9).
47	573	18. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in
48 49	574	Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin
49 50	575	Lipidol. 2012;6(3):208-15.
51	576	19. Jacobson TA, Khan A, Maki KC, Brinton EA, Cohen JD. Provider recommendations for patient-
52	577	reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America
53	578 570	and Gaps in Patient Education survey. J Clin Lipidol. 2018;12(1):78-88. 20. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in
54	579	
55	580	primary care: a systematic review. CMAJ. 1997;156(12):1705-12.
56 57		
58		18
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

21. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012;379(9833):2252-61. 22. Rash JA, Campbell DJ, Tonelli M, Campbell TS. A systematic review of interventions to improve adherence to statin medication: What do we know about what works? Prev Med. 2016;90:155-69. 23. Walsh J, McDonald KM, Shojania KG, Sundaram V, Nayak S, Davies S, et al. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies (Vol 3: Hypertension Care). AHRQ Technical Reviews. Rockville (MD)2005. Zhang Y, Moran AE. Trends in the Prevalence, Awareness, Treatment, and Control of 24. Hypertension Among Young Adults in the United States, 1999 to 2014. Hypertension. 2017;70(4):736-42. 25. Jardine MJ, Kasiske B, Adu D, Alrukhaimi M, Ashuntantang GE, Basnet S, et al. Closing the gap between evidence and practice in chronic kidney disease. Kidney Int Suppl (2011). 2017;7(2):114-21. 26. Walsh JM, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, et al. Quality improvement strategies for hypertension management: a systematic review. Med Care. 2006;44(7):646-57. 27. Campbell DJ, Sargious P, Lewanczuk R, McBrien K, Tonelli M, Hemmelgarn B, et al. Use of chronic disease management programs for diabetes: in Alberta's primary care networks. Can Fam Physician. 2013;59(2):e86-92. 28. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):7. 29. Pope C, van Royen P, Baker R. Qualitative methods in research on healthcare quality. Qual Saf Health Care. 2002;11(2):148-52. 30. Ayala GX, Elder JP. Qualitative methods to ensure acceptability of behavioral and social interventions to the target population. J Public Health Dent. 2011;71 Suppl 1:S69-79. 31. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-57. 32. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. 33. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7:37. 34. Michie S, Johnston M, Francis J, Hardeman W, Eccles M. From Theory to Intervention: Mapping Theoretically Derived Behavioural Determinants to Behaviour Change Techniques. Applied Psychology. 2008;57(4):660-80. 35. Barrett B, Ricco J, Wallace M, Kiefer D, Rakel D. Communicating statin evidence to support shared decision-making. BMC Fam Pract. 2016;17:41. 36. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, et al. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167(10):1076-82. 37. Santana M, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Working Together with Patients and Clinician Researchers to Improve Cardiovascular Health. 2018 SPOR Summit; Ottawa, ON. 38. Santana M, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Working Together: Co-designing Priorities for Patient-Oriented Cardiovascular Research by Patients, Clinicians, and Researchers. Canadian Association for Health Services and Policy Research (CAHSPR); Halifax, NS2019. Guest G, Namey E, Taylor J, Eley N, McKenna K. Comparing focus groups and individual 39. interviews: findings from a randomized study. Int J Soc Res Methodol. 2017;20(6):693-708. 40. Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care. Br J Gen Pract. 2003;53(494):684-9. 41. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291.

1		
2		
3	629	42. Walker JL. The use of saturation in qualitative research. Can J Cardiovasc Nurs. 2012;22(2):37-
4	630	46.
5	631	43. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res.
6 7	632	2005;15(9):1277-88.
7 8	633	44. Santana MJ, Zelinsky S, Ahmed S, Doktorchik C, James M, Wilton S, et al. Patients, clinicians and
9	634	researchers working together to improve cardiovascular health: a qualitative study of barriers and
10	635	priorities for patient-oriented research. BMJ Open. 2020;10(2):e031187.
11	636	45. Drew P, Jones B, Norton D. Team effectiveness in primary care networks in Alberta. Healthc Q.
12	637	2010;13(3):33-8.
13	638	46. Manns BJ, Tonelli M, Zhang J, Campbell DJT, Sargious P, Ayyalasomayajula B, et al. Enrolment in
14	639	primary care networks: impact on outcomes and processes of care for patients with diabetes. Canadian
15	640	Medical Association Journal. 2012;184(2):E144-E52.
16	641	47. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian
17	642	Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of
18 19	643	Cardiovascular Disease in the Adult. Can J Cardiol. 2016;32(11):1263-82.
20	644 644	48. Toward Optimized Practice Cardiovascular Disease Risk Working Group. Prevention and
20	645	
22		management of cardiovascular disease risk in primary care clinical practice guideline Edmonton, AB:
23	646	Toward Optimized Practice; 2015 [Available from:
24	647	https://top.albertadoctors.org/CPGs/Lists/CPGDocumentList/CVD-Risk-CPG.pdf.
25	648	49. Tibrewala A, Jivan A, Oetgen WJ, Stone NJ. A Comparative Analysis of Current Lipid Treatment
26	649	Guidelines: Nothing Stands Still. J Am Coll Cardiol. 2018;71(7):794-9.
27	650	50. Toward Optimized Practice (TOP) Cardiovascular Disease Risk Working Group. Prevention and
28	651	management of cardiovascular disease risk in primary care clinical practice
29	652	guideline 2015 [Available from:
30 31	653	http://www.topalbertadoctors.org/download/1655/Lipid%20Pathway%20CPG.pdf? 20150916105016.
32	654	51. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS
33	655	Guidelines for the Management of Dyslipidaemias. Rev Esp Cardiol (Engl Ed). 2017;70(2):115.
34		
35	656 657	52. Kristensen M, Christensen PM, Hallas J. The effect of statins on average survival in randomised
36	657 (58	trials, an analysis of end point postponement. BMJ Open. 2014;5(007118).
37	658	53. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular
38	659	disease take a statin? BMJ. 2013;347:f6123.
39	660	54. Jornten-Karlsson M, Pintat S, Molloy-Bland M, Berg S, Ahlqvist M. Patient-Centered
40	661	Interventions to Improve Adherence to Statins: A Narrative Synthesis of Systematically Identified
41	662	Studies. Drugs. 2016;76(15):1447-65.
42 43	663	55. Ivers NM, Schwalm JD, Bouck Z, McCready T, Taljaard M, Grace SL, et al. Interventions
43 44	664	supporting long term adherence and decreasing cardiovascular events after myocardial infarction
45	665	(ISLAND): pragmatic randomised controlled trial. BMJ. 2020;369:m1731.
46	666	56. van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R. Interventions to improve
47	667	adherence to lipid-lowering medication. Cochrane Database Syst Rev. 2016;12:CD004371.
48	668	57. Kaya H, Beton O, Yilmaz M. How to increase level of patients' awareness regarding the
49	669	importance of statins despite the influence of the media? International Journal of Cardiology.
50	670	2016;207:164.
51	671	58. Casula M, Tragni E, Piccinelli R, Zambon A, De Fendi L, Scotti L, et al. A simple informative
52	672	intervention in primary care increases statin adherence. Eur J Clin Pharmacol. 2016;72(2):227-34.
53 54	673	59. Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, et al. Shared treatment decision
54 55	674	making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med.
56	675	2010;181(6):566-77.
57		
58		20
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3 4 5 6 7 8	676 677 678 679 680	 Colquhoun HL, Carroll K, Eva KW, Grimshaw JM, Ivers N, Michie S, et al. Advancing the literature on designing audit and feedback interventions: identifying theory-informed hypotheses. Implement Sci. 2017;12(1):117. Kvarnström K, Airaksinen M, Liira H. Barriers and facilitators to medication adherence: a qualitative study with general practitioners. BMJ Open. 2018;8(1):e015332.
9 10 11 12 13 14 15 16 17 18 9 20 21 22 32 22 22 22 22 22 22 22 22 22 22 22	681 682	
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml






Figure 1: Laboratory-Based Facilitated-Relay Intervention Dashed lines: traditional interface between lab and ordering provider

Appendix A: Interview Guide for health care professional

Thank you for agreeing to participate in our interview today. We wish to discuss your experience in managing dyslipidemia (or high cholesterol) in order to better understand how we might help family physicians treat dyslipidemia (or high cholesterol). We have a proposed intervention and would like your assistance in how to enrich it.

1. Experience managing dyslipidemia

Please describe any challenges or difficulties that you experience in identifying and managing patients with dyslipidemia?

- Do you use any resources to guide you in the management of these patients?
 - Canadian Cardiovascular Society Guidelines
 - Diabetes Canada Guidelines
 - TOP guidelines

In addition to measuring a patient's lipids, what are some other parameters that you consider when assessing a patient for dyslipidemia, and how to optimally manage this condition?

2. Dyslipidemia-related practices

In your practice, do you find it helpful to quantify a patient's LDL-cholesterol or get a lipid panel?

If yes,

- Are there certain populations in whom you find this test most helpful?
- What is your chosen method/diagnostic test to do so?
 - Fasting or random lipid profile
 - Total cholesterol
 - HDL-cholesterol
 - LDL-cholesterol
 - ApoB
- How does this information change your clinical practice?
- How often do you repeat cholesterol testing for patients with with conditions that puts them at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease)?

If no,

- Why is it not particularly helpful?
 - Don't know which test to do
 - Don't know how to order it
 - Don't know in whom it is indicated

Don't know what to do with the results

In thinking about your practice, what proportion of your patients with conditions that put them at high risk for cardiovascular disease (i.e. previous myocardial infarction, stroke, diabetes, and/or chronic kidney disease) have had their lipid profile assessed in the past 12 months?

What are some of the reasons this does not happen (in your practice and in others')?

- Didn't think it was indicated/for whom it is indicated
- Too many things to attend to
- Not perceived to be an important issue amongst all other disease/conditions that FPs manage
- Patient factors (doesn't go for test)

3. Intervention

If we wanted to increase the use of statins among people at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease), what might be done? What tools, resources, prompts may help facilitate increased treatment of dyslipidemia?

In your opinion, what type of educational intervention is most effective in disseminating clinical practice guidelines to family physicians? (i.e. conferences, local lectures, treatment recommendations on lab results).

We are considering the use of a facilitated relay strategy, where patient's information from Calgary Laboratory Services is used to identify those who have indications for statin therapy. Those who are not currently filling statin prescriptions at the pharmacy would receive a letter from the lab indicating that they may benefit from statins. They will be encouraged to bring this letter in to discuss this with you.

How would family physicians respond to receiving a letter from the lab prompting them to consider starting their patient on statin treatment?

- What would be the characteristics of such a letter that would make it more likely to succeed?
 - Short/Pictorial/Colorful

Would it be more helpful to have this information specific about one named patient, or rather have an audit of your entire practice that would indicate what proportion of eligible patients with statin-indicated conditions are currently being treated with statins? (i.e. Audit and Feedback)

How should such an intervention either on a specific patient or about your entire practice be received?

• Mail/Fax/EMR/combo

How would such an intervention be processed in your office?

- Who would open the envelope?
- What would they do with it? (give it to you, put it in the patient's chart)
- How likely would you be to see this information?

Who should this letter be coming from in order to have it received in the most positive way possible?

- A non-clinical academic researcher (Dr. XXXX)
- Head of the Calgary Laboratory Services (Dr. Christopher Naugler)
- A lipid specialist (Dr. Sonia Butalia, Alex Leung)
- An academic family doctor (Dr. Kerry McBrien)
- A respected community family doctor
- The lead of Dyslipidemia Guidelines (Dr. Todd Anderson)
- Dr. Cello Tonelli, Associate Vice-President (Research) at the University of Calgary
- Dr. Richard Lewanczuk, Senior Medical Director for Primary Care, Chronic Disease Management, Community and Rural for Alberta Health Services
- Someone else

Would it be helpful to receive a reminder or follow-up letter?

• How much later should this be sent, so as to be useful and not annoying?

If the intervention provided you with patient-oriented material about this subject, and asked you to share it with your patients, how would you feel about doing so?

- What content should be included in this patient-oriented material to enhance statin use?
- What format should this material be in? Electronic, hard-copy? How should it be delivered? Mail, email?
- Would you share it in a clinical setting?
- Would you be willing to mail it to patients directly?

Do you have any additional comments or suggestions for developing an intervention to increase the use statins in people at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease) in primary care?

Thank you for participating in today's interview. Using the information you provided, we will work on developing an intervention to improve the treatment of dyslipidemia in patients who are at high risk for cardiovascular disease (i.e. previous clinical cardiovascular disease, diabetes, chronic kidney disease)?

Appendix B: Focus Group Guide for patients

Thank you for agreeing to participate in our focus group today. There are many risk factors for heart attacks and stroke. Today we want to focus on one risk factor being high cholesterol. High cholesterol is a major risk factor for heart attacks, strokes and circulatory problems. There are no symptoms of high cholesterol and it is diagnosed by a lab test that your doctor would order. Importantly, we work for the University of Calgary and have no relationship with any medication companies.

We wish to discuss your experience in managing *cholesterol* with medications in order to better understand how we might help family physicians (*doctors*) treat high cholesterol.

1. Experience with high cholesterol

Think about the last time your doctor has sent you for a cholesterol test. Did your doctor talk to you about the results? Treatment? What kind of treatment was discussed (diet, exercise, a medication)?

Put yourself in the position of being told that you need to take a medication for your cholesterol. What factors would make you more likely to take it? What factors would make you not want to take it? Reasons, side effects, costs

- Would you use any resources to help you decide?
 - o Doctor
 - \circ Dietician
 - o Internet
 - Family, friends

What would you think if your doctor told you that your cholesterol wasn't all that high, but because of your other health conditions she wanted to start you on a cholesterol lowering medication to reduce your risk of heart attack and stroke?

Do you think it would be helpful to get the actual result of your cholesterol level sent directly from the lab to you?

Currently, cancer screening programs send letters to patients about their results and next steps. What are your thoughts for something similar for high cholesterol?

What about information about recommended treatments and potential side effects? Would you find this to be invasive of your privacy (i.e. info from the lab about treatment and not your doctor)?

How would you feel about taking a letter with these recommendations to your doctor to discuss about a medication for high cholesterol?

How do you feel your doctor would respond to you bringing this information?

What things on the letter would make it helpful?

-length, colour, graphics,

Who should this letter be coming from in order to have it received in the most positive way possible?

- A non-clinical academic researcher (Dr. XXXX)
- Head of the Calgary Laboratory Services (Dr. Christopher Naugler)
- A lipid specialist (Dr. Sonia Butalia, Alex Leung)
- An academic family doctor (Dr. Kerry McBrien)
- A respected community family doctor
- The lead of Dyslipidemia Guidelines (Dr. Todd Anderson)
- Dr. Richard Lewanczuk, Senior Medical Director for Primary Care, Chronic Disease Management, Community and Rural for Alberta Health Services
- Someone else

Would it be helpful to receive a reminder or follow-up letter?

• How much later should this be sent, so as to be useful and not annoying?

Do you have any additional comments or suggestions for developing an way to increase the use the treatment of people with high cholesterol?

Appendix C: Facilitated Relay Letter



Date: XXXX-XX-XX

Dear Dr. [Physician Last Name],

RE: [Patient Name]

As you may recall, your Primary Care Network is involved in a study with the University of Calgary. This is an investigator-initiated study with public funding from the [*Canadian Institutes of Health Research*].

Dyslipidemia is a major risk factor for myocardial infarction and stroke¹⁻². As you know, in patients like [name], statins are indicated for their dyslipidemia because they are proven to reduce cardiovascular outcomes and mortality³⁻⁴. Because of numerous randomized controlled trials, guidelines recommend statin use in individuals with history of previous cardiovascular disease, diabetes, or chronic renal failure⁵.

We are writing to you to consider initiating a statin in your patient. We know the importance of the therapeutic relationship that you have with your patients and know that we do not know your patient like you do. The purpose of this letter is to assist in you in your discussion with [name], about using a statin medication.

[Name] may not be taking a statin because of underestimation of their personal risk of cardiovascular disease, fear of side-effects, previous side-effects, or cost. If cost is a concern, compassionate programs are available for several statin medications. Please kindly call our study telephone number to assist in facilitating this.

The most common side effect from statins is muscle aches, and the frequency of statin-induced rhabdomyolysis is very rare (i.e. < 1 in 10,000 patients per year on statins)⁶. Studies suggest that there are several proven methods for managing people who have experienced muscle aches. For those unable to tolerate daily high intensity statins, some statin is still better than none, and the following strategies can be considered:

- 1. *Reducing the dose of statin*. i.e. Atorvastatin 10-20mg or Rosuvastatin 2.5-5mg⁷.
- Trying a low potency statin medication. Lower potency statins seem to be less strongly associated with muscle aches. Fluvastatin and Pravastatin were much less likely than Simvastatin and Atorvastatin to cause myalgia⁸. For your reference, maximum doses of these low potency statins, and their equivalencies are:

 Pravastatin 80mg = Atorvastatin 20mg = Rosuvastatin 10mg Fluvastatin XL 80mg = Atorvastatin 10mg = Rosuvastatin 5mg

3. Reducing dose or lengthening administration interval. Studies have demonstrated that greater than 70% of patients affected by myalgias were able to tolerate every other day administration with no recurrence of muscle symptoms⁹.

There is a small chance that your patient may have been misclassified with a statin indicated condition. We sincerely apologize for this and would be most appreciative if you can call or fax us to let us know.

We welcome any questions or comments so please kindly contact us at 403-955-8327 (or fax 403-955-8249), for more information.

Sincerely, Sonia Butalia MD, FRCPC, MSc and the study team See telle

References

- 1. Yusuf S, Hawken S, Ôunpuu S, et al. The Lancet. 2004;364(9438):937-952.
- O'Donnell MJ, Xavier D, Liu L, et al. The Lancet. 2010;376(9735):112-123. 2.
- Cholesterol Treatment Trialists Collaboration. The Lancet. 2010;376(9753):1670-1681. 3.
- Cholesterol Treatment Trialists Collaborators. The Lancet. 2012;380(9841):581-590. 4.
- Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines 5. for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2016;32(11):1263-1282.
- Graham DJ, Staffa JA, Shatin D, et al. JAMA. 2004;292(21):2585-2590. 6.
- Arca M, Pigna G. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2011;4:155-7. 166.
- 8. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Cardiovascular Drugs and Therapy. December 01 2005;19(6):403-414.
- 9. Bellosta S, Paoletti R, Corsini A. Circulation. June 15, 2004 2004;109(23 suppl 1):III-50-III-57.

<u>Strategies for Enhancing Cholesterol Lowering Medication Use</u> <u>Among Patients at High Cardiovascular Disease Risk: Patient and</u> <u>General Practitioners' Perspectives on a Facilitated Relay</u> <u>Intervention</u>

Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

No	Item	Guide questions/ description	Response
Domain 1: Research			
team and reflexivity			
Personal Characteristics	Ċ,		
		Which author/s conducted the interview or focus	Line 137
1.	Interviewer/facilitator	group?	
2.	Credentials	What were the researcher's credentials? <i>E.g. PhD</i> , <i>MD</i>	Author information
		What was their occupation	Line 137
3.	Occupation	at the time of the study?	
		Was the researcher male	Line 137
4.	Gender	or female?	
	Experience and	What experience or training did the researcher	Line 137
5.	training	have?	

Item	Guide questions/ description	Response
Relationship established	Was a relationship established prior to study commencement?	Line 138-139
Participant knowledge of the interviewer	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	Not discussed
Interviewer	What characteristics were reported about the interviewer/facilitator? e.g. <i>Bias, assumptions,</i> <i>reasons and interests in</i>	Not discussed
characteristics	the research topic	
		5
Methodological orientation and	What methodological orientation was stated to underpin the study? <i>e.g.</i> grounded theory, discourse analysis, ethnography, phenomenology, content	Qualitative Description – Line 98
	Relationship established Participant knowledge of the interviewer lInterviewer characteristics	ItemdescriptionRelationship establishedWas a relationship established prior to study commencement?Participant knowledge of the interviewerWhat did the participants know about the researcher? e.g. personal goals, reasons for doing the researchParticipant knowledge of the interviewerWhat characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topicInterviewerWhat characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topicMethodological orientation andWhat methodological orientation was stated to underpin the study? e.g. grounded theory, discourse analysis, ethnography, phenomenology, content

Page 33 of 35

No	Item	Guide questions/ description	Response
Participant selection			
10.	Sampling	How were participants selected? e.g. purposive, convenience, consecutive, snowball	GP – Snowball (line 106-107) Patients – Convenience (line 116)
11.	Method of approach	How were participants approached? e.g. face-to- face, telephone, mail, email	Line 106-120
		How many participants	Line 173
12.	Sample size	were in the study?	Line 186
13.	Non-participation	How many people refused to participate or dropped out? Reasons?	Line 176-177
Setting		2	
	Setting of data	Where was the data collected? e.g. home,	Line 137 Line 142
14.	collection	clinic, workplace	
15.	Presence of non- participants	Was anyone else present besides the participants and researchers?	Line 143
16.	Description of sample	What are the important characteristics of the sample? <i>e.g. demographic data, date</i>	Line 174-195

No	Item	Guide questions/ description	Response
Data collection			
17.	Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	Appendix A& B
18.	Repeat interviews	Were repeat interviews carried out? If yes, how many?	No
19.	Audio/visual recording	Did the research use audio or visual recording to collect the data?	Line 146
20.	Field notes	Were field notes made during and/or after the interview or focus group?	Line 143-144
21.	Duration	What was the duration of the interviews or focus group?	Line 142-143
22.	Data saturation	Was data saturation discussed?	Line 140 + limitations section
23.	Transcripts returned	Were transcripts returned to participants for comment and/or correction?	No
Domain 3: analysis and findings			

No	Item	Guide questions/ description	Response
Data analysis			
24.	Number of data coders	How many data coders coded the data?	Line 156-160
25.	Description of the coding tree	Did authors provide a description of the coding tree?	Line 157
26.	Derivation of themes	Were themes identified in advance or derived from the data?	Line 157-158 (inductive)
27.	Software	What software, if applicable, was used to manage the data?	Line 164-165
28.	Participant checking	Did participants provide feedback on the findings?	Line 414-415
Reporting		7	
29.	Quotations presented	Were participant quotations presented to illustrate the themes / findings? Was each quotation identified? e.g. participant number	In-text and Table 3
30.	Data and findings consistent	Was there consistency between the data presented and the findings?	Yes

No	Item	Guide questions/ description	Response
	Clarity of major	Were major themes clearly	Results section
31.	themes	presented in the findings?	
		Is there a description of	Table 2 & 3
	Clarity of minor	diverse cases or discussion	
32.	themes	of minor themes?	